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Immunotherapies harness the power of the immune system, broadly, to identify, suppress, or otherwise
control disease progression. Potent immune checkpoints, such as PD-1/PD-L1, CTLA4, and here,
CD47-SIRPα restrain immunity in normal regulation to protect healthy ‘self’ cells, yet can become
dysregulated in the progression of diseases. Antibody-based blockade of such checkpoints has emerged
as a powerful tool to retrain and re-energize immune surveillance, but significant barriers to efficacy and
safety remain. CD47-SIRPα is the macrophage immune checkpoint that enables macrophages, a first line
of defense in innate cellular immunity, to discriminate ‘self’ vs. ‘foreign’, which many cancers utilize to
evade clearance. Consequently, CD47 is now a clinical target for antibody-based blockade in early and
late phase clinical trials in many liquid tumors and some solid tumors. However, clinically targeting a
ubiquitously expressed surface marker presents numerous challenges, including a large antigen sink, ontarget but off-tumor clearance, and mass permeation of solid tissues that are yet to be answered (Chapter
1 and Chapter 4). Here, we demonstrate that efficacy of molecular and cell-based therapies targeting
CD47-SIRPα requires complete ablation of signaling and a pro-phagocytic signal to drive tumor-specific
macrophage phagocytosis in solid tumors (Chapter 2). We further delineate and provide evidence for a
novel phenomenon of “cooperative phagocytosis” in these tumors, whereby macrophages that are
maximally activated along the CD47-SIRPα paradigm, work together to disrupt solid tumor adhesions and
durably eliminate tumoroids in vitro and tumors in vivo (Chapter 3). Finally, we highlight a significant role
for macrophages as potent immune effectors to clear tumors and induce a de novo, endogenous
antibody response that strengthens macrophage phagocytosis and cooperativity with high tumor antigenbinding and -specificity (Chapter 3). These results position macrophages as potent immune effectors in
solid tumors with the potential to overcome long-standing challenges in immuno-oncology (Chapter 5).
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ABSTRACT

LEVERAGING MACROPHAGE IMMUNE CHECKPOINT BLOCKADE TO LINK INNATE
AND ADAPTIVE IMMUNITY AGAINST SOLID TUMORS
Jason Christopher Andrechak
Dennis E. Discher

Immunotherapies harness the power of the immune system, broadly, to identify, suppress,
or otherwise control disease progression. Potent immune checkpoints, such as PD-1/PDL1, CTLA4, and here, CD47-SIRPα restrain immunity in normal regulation to protect
healthy ‘self’ cells, yet can become dysregulated in the progression of diseases. Antibodybased blockade of such checkpoints has emerged as a powerful tool to retrain and reenergize immune surveillance, but significant barriers to efficacy and safety remain. CD47SIRPα is the macrophage immune checkpoint that enables macrophages, a first line of
defense in innate cellular immunity, to discriminate ‘self’ vs. ‘foreign’, which many cancers
utilize to evade clearance. Consequently, CD47 is now a clinical target for antibody-based
blockade in early and late phase clinical trials in many liquid tumors and some solid
tumors. However, clinically targeting a ubiquitously expressed surface marker presents
numerous challenges, including a large antigen sink, on-target but off-tumor clearance,
and mass permeation of solid tissues that are yet to be answered (Chapter 1 and Chapter
4). Here, we demonstrate that efficacy of molecular and cell-based therapies targeting
CD47-SIRPα requires complete ablation of signaling and a pro-phagocytic signal to drive
tumor-specific macrophage phagocytosis in solid tumors (Chapter 2). We further delineate
and provide evidence for a novel phenomenon of “cooperative phagocytosis” in these
tumors, whereby macrophages that are maximally activated along the CD47-SIRPα
iv

paradigm, work together to disrupt solid tumor adhesions and durably eliminate tumoroids
in vitro and tumors in vivo (Chapter 3). Finally, we highlight a significant role for
macrophages as potent immune effectors to clear tumors and induce a de novo,
endogenous antibody response that strengthens macrophage phagocytosis and
cooperativity with high tumor antigen-binding and -specificity (Chapter 3). These results
position macrophages as potent immune effectors in solid tumors with the potential to
overcome long-standing challenges in immuno-oncology (Chapter 5).
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CHAPTER 1: THE MACROPHAGE CHECKPOINT CD47:SIRPα
FOR RECOGNITION OF ‘SELF’ CELLS: FROM CLINICAL TRIALS
OF BLOCKING ANTIBODIES TO MECHANOBIOLOGICAL
FUNDAMENTALS

1.0 Contributions and copyright
The contents of this chapter appear in Philosophical Transactions of the Royal Society
B:
Andrechak, J. C.*, Dooling, L. J.* & Discher, D. E. The macrophage checkpoint CD47 :
SIRPα for recognition of ‘self’ cells: from clinical trials of blocking antibodies to
mechanobiological fundamentals. Philos. Trans. R. Soc. B Biol. Sci. 374, 20180217
(2019).
Lawrence J. Dooling is a co-equal author* and contributed significant ideas, writing, and
revision to this work, especially Sections 1.5-1.8.

1.1 Abstract
Immunotherapies against some solid tumor types have recently shown unprecedented,
durable cures in the clinic, and the most successful thus far involves blocking inhibitory
receptor ‘checkpoints’ on T cells. A similar approach with macrophages is emerging by
blocking the ubiquitously expressed ‘marker of self’ CD47 from binding the inhibitory
receptor SIRPα on macrophages. Here, we first summarize available information on the
safety and efficacy of CD47 blockade, which raises some safety concerns with the
clearance of ‘self’ cells but also suggests some success against hematological (liquid)
and solid cancers. Checkpoint blockade generally benefits from parallel activation of the
immune cell, which can occur for macrophages in multiple ways such as by combination
with a second, tumor-opsonizing antibody and perhaps also via rigidity sensing.
1

Cytoskeletal forces in phagocytosis and inhibitory ‘self’-signaling are thus reviewed
together with macrophage mechanosensing, which extends to regulating levels of SIRPα
and the nuclear protein, lamin A, that affects phenotype and cell trafficking.
Considerations of such physical factors in cancer and the immune system can inform the
design of new immunotherapies and help to refine existing therapies to improve safety
and efficacy.

1.2 Introduction
Specific molecular interactions between two cells or a cell and extracellular matrix are
often viewed as pro-adhesive and ultimately favoring attachment. However, specific
interactions can also be inhibitory, as is the case for several targets for cancer therapy in
the clinic. Both pro-adhesive and inhibitory interactions can also involve important
mechanobiological factors. Immune cells provide particularly illustrative examples as they
frequently contact cells that either belong to ‘self’ (the same organism) or that are ‘foreign’
(e.g. microbes that breach epithelia). Specific molecular interactions at immune cell
surfaces lead to recognition of ‘self’ or else result in forceful attack and elimination of
‘foreign’. An important example with T cells is the protein PD-1 that interacts with PD-L1
on multiple ‘self’ cells in parallel with T cell receptor interactions; if the latter activates the
T cell to attack, the former can effectively passivate it. In cancer, blocking this PD-1:PDL1 checkpoint by systemic injections of antibodies to either of these two proteins leads to
T cell elimination of tumors in a minor fraction (~10-30%) of otherwise untreatable patients,
and the patients that respond best are those with the most mutated (i.e. ‘foreign’) tumors
1–4

. In simplest molecular terms the T cell receptor activates kinases that signal activation

while PD-1:PD-L1 activates a phosphatase (e.g. SHP isoform) that dominates in its
inhibition – although there remains much to learn. Mechanobiology enters in at least via
the kinases and/or phosphatases that regulate local membrane mechanics on the small
scale and/or cytoskeletal function at a larger scale

5,6

. Importantly, this paradigm of

activation-dominated-by-inhibition applies not only to other lymphocytes (e.g. Natural
Killer (NK) cells7) but also to macrophages that are the focus of this review.
2

1.3 CD47:SIRPα as a macrophage checkpoint in cancer
‘Marker of self’ membrane protein CD47 is normally expressed on all cells and binds with
weak, sub-micromolar affinity to ‘signal regulatory protein’ SIRPα on macrophages,
including precursor monocytes. CD47:SIRPα binding leads to local accumulation of SIRPα
at phagocytic synapses and ultimately to inhibition of engulfment of ‘self’ cells (Figure 1.1)
8,9

. This inhibitory interaction occurs in parallel with various activating interactions, only

some of which are well characterized. The clearest example of activation is through
immunoglobulin G (IgG) antibodies that bind to a target cell and that also engage
activating Fc receptors (FcRs) on macrophages. Some of the key FcRs signal via kinases
in very similar ways to integrins activated by extracellular matrix, with downstream
accumulation of focal adhesion proteins such as phospho-paxillin and talin as well as
sensitivity to whether the adhesive substrate – i.e. target for phagocytosis – is soft or stiff
10,11

. However, adhesion and phagocytosis of stiff targets more than soft is just one aspect

of the mechanosensitivity of macrophages.
CD47:SIRPα blockade strategies have revitalized decades of interest in macrophages as
effector cells for cancer therapy. CD47 is expressed on cancer cells 12,13 and was originally
described as the OA3 antigen that is highly upregulated on ovarian cancer cells

14

; CD47

should in principle shield cancer cells from immune surveillance and removal by
phagocytic cells. However, solid tumors possess mechanical properties that can influence
cancer phenotypes 15 and that might also influence immune cells, including macrophages.
Studies in mice, for example, suggest high collagen microenvironments (associated with
stiffness) cause macrophages to upregulate SIRP expression and also cause
macrophages to switch off a pro-phagocytic phenotype

16

. These factors motivate a

renewed focus on the mechanobiology of phagocytic cells that certainly include
macrophages but also neutrophils 17 and dendritic cells 18, which both express SIRPα.
Patient safety is always a concern in therapy, and the main goal of any Phase 1 clinical
trial in the US is to establish a safety window for dosing. Because CD47 is expressed on
all cells, anti-CD47 antibodies injected intravenously are readily predicted to bind blood
cells. Indeed, the pioneering studies that first described ‘marker of self’ function showed
3

that CD47-deficient mouse red blood cells (RBCs) are engulfed within hours of injection
into normal mice by macrophages in the spleen 9, with CD47-deficient platelets exhibiting
similar clearance

19

. CD47 knockout in at least one strain of mouse (non-obese diabetic,

NOD) leads not only to anemia (RBC loss) but also to premature death of mice with
autoimmunity against RBCs

20

. None of these mouse studies clearly determined what

factors on a CD47-deficient RBC or platelet activate the engulfment by normal splenic
macrophages, but anti-CD47 IgG will engage FcRs and tend to activate phagocytosis. As
with integrin-based adhesion, however, a high density of adhesive ligands (IgG in this
case) favors focal adhesion complex formation and activated adhesion, and CD47 is more
of a low density signaling molecule on RBCs 8. Regardless, the various findings in mice
underscore the importance of safety studies, and the report of autoimmunity also has
intriguing implications for development of anti-cancer immunity.

1.4 Clinical blockade of the anti-adhesive CD47-SIRP interaction
– a current snapshot
According to the National Institutes of Health (NIH) database of clinical trials
(clinicaltrials.gov), there are presently 15 ongoing anti-CD47 interventional clinical trials,
with all but two in Phase 1

21–35

. Although tumor cells are unlikely to display sufficiently

strong ‘eat me’ factors to activate macrophages
tumors (e.g. ovarian cancer

14

16

, and modest upregulation of CD47 on

) is unlikely to present sufficient anti-CD47 to activate

phagocytosis, clinical trials all must start with injections of just anti-CD47 to test safety
without interference. All current clinical trials targeting CD47 consist of monoclonal
antibodies or engineered fusion proteins and are being driven by companies – no doubt
because of the costs involved. Designations for these agents are Hu5F9-G4 (Forty-Seven
Inc., Menlo Park, CA), CC-90002 (Celgene Corporation, Summit, NJ), TTI-621 and TTI622 (Trillium Therapeutics Inc., Mississauga, Ontario, Canada), SRF231 (Surface
Oncology, Cambridge, MA), ALX148 (ALX Oncology Inc., Burlingame, CA), and IBI188
(Innovent Biologics, Suzhou, China). Clinical trial details are summarized in Table 1.1
(complemented by a thorough review of preclinical information in
4

36

). Reporting on these

trials remains sparse, but details are emerging in meeting abstracts and on company
websites. Such information is public but should be treated with caution as it is not clear
that companies will publish in peer reviewed forums, though publications are now
beginning to appear. Nonetheless, the information provides some initial insight into the
potential safety and efficacy of CD47 blockade therapies in humans.
Hu5F9-G4 is a humanized anti-CD47 monoclonal IgG4 antibody and is the most advanced
therapeutic in this class to progress through the clinic 37,38. The Fc end of an IgG4 engages
FcRs only weakly; one might therefore expect minimal interactions with FcRs on splenic
macrophages and perhaps other macrophages. In one of the most advanced trials of
Hu5F9-G4, the Phase 1b/2 study for relapsed/refractory non-Hodgkin lymphoma (r/r NHL)
patients combined anti-CD47 with rituximab (anti-CD20) to provide an ‘eat me’ signal to
activate macrophages; the reported objective response rate (ORR) was 50% and the
complete response rate (CRR) was 32%

39

. These numbers were revised in late 2018 to

40% ORR and 33% CRR in 15 diffuse large B-cell lymphoma patients and 71% ORR and
43% CRR in 7 follicular lymphoma

40

. The investigators also noted that they were able to

limit anemia by administration of a priming dose to clear older RBCs prior to maintenance
doses, though to what extent is unclear.
In Phase 1a of the trial for relapsed/refractory acute myeloid leukemia (r/r AML), 15
patients tolerated Hu5F9-G4 well with no max tolerated dose (MTD) reported. However,
just two patients exhibited biologic activity in response, which the authors defined as
“significant reduction in marrow cellularity observed similarly in pre-clinical models.” The
majority of the studied patients (79%) showed grade 3 anemia prior to dosing in the study
and also received transfusions of RBCs
42

41

. In prior reported safety results of 13 patients

, the maximum observed hemoglobin (Hb) drop was 5.2 g/dL, representing a loss of

about 40% of RBCs, though the median decrease was 1.2 g/dL. Antibodies are of course
bivalent, and some anti-RBC antibodies have long been known to drive crosslinking of
RBCs (hemagglutination); such adhesive clusters of cells can be expected to have
impaired circulation, especially through the narrow slits of the spleen – which would tend
to favor macrophage interactions and anemia. Forty-Seven, Inc. has also initiated
additional trials against other malignancies to test Hu5F9-G4 in combination with the
5

chemotherapeutic azacitidine, the anti-epidermal growth factor receptor (EGFR)
monoclonal antibody cetuximab, and the PD-L1 targeting antibody, avelumab 22,25,28. Later
reports in the first-in-human trial with advanced solid tumors indicated a priming dosing
led to 57% and 36% of patients showing transient anemia and hemagglutination
respectively, mostly grade 2

43,44

. Whether the loss of RBCs can ever contribute to

autoimmune response to RBCs or other cell types has not been addressed.
TTI-621 is a fully human recombinant SIRP-Fc fusion protein developed by Trillium
Therapeutics, Inc. with preclinical evidence for enhanced phagocytosis in AML and B
lymphoma xenograft models

45

. It consists of the N-terminal V-type immunoglobulin-like

domain of human SIRP as a fusion with the Fc portion of human IgG1. IgG1 is expected
to bind FcRs more strongly than IgG4 and may increase both antibody-dependent cellmediated cytotoxicity and complement-dependent cytotoxicity effects. It is being
administered intravenously for hematologic malignancies and intratumorally for solid
tumors and mycosis fungoides

46

. Early reports in late 2016 showed two patients with

dose-limiting toxicities in grade 3 elevated liver enzymes and grade 4 thrombocytopenia
(loss of platelets). This result raises questions of the drug safety profile, although later the
company stated that this thrombocytopenia was transient and reduced after multiple
infusions. The company also reported that 9 out of 10 patients in the intratumorallyadministered trial saw reduction of lesions

46

and later, that 15 out of 17 r/r mycosis

fungoides and Sézary syndrome patients were described as having measurable
improvement in lesion severity

47

. They have expanded their study to new cohorts

receiving TTI-621 in combination with approaches such as a PD-1:PD-L1 inhibitor or
radiation therapy. A second candidate linked to an IgG4 domain instead of IgG1, TTI-622,
was initiated in a Phase 1a/1b clinical trial in mid-2018 33.
SRF231 is a fully human anti-CD47 antibody being evaluated against advanced solid
tumors and lymphoma/chronic lymphocytic leukemia

48

. CC-90002 is a humanized anti-

CD47 monoclonal antibody of the IgG4 subclass in early clinical development, with
preclinical work presented at the 2017 ASCO Annual Meeting

49

. Both CC-90002 and

SRF231 seem to avoid hemagglutination, but how this is achieved is unclear

50

. Notably,

despite the expansion of anti-CD47 efforts by pharmaceutical companies, Celgene
6

terminated its monotherapy trial of CC-90002 in October 2018 while continuing to recruit
in its combination trial with rituximab

34,35

. This further highlights the importance of

combining an activating signal for phagocytosis with blockade of the macrophage
checkpoint.
ALX148 is a fusion protein with two CD47 binding domains derived from the SIRP Nterminal D1 domain and an inactive Fc region designed to mitigate hemagglutination and
anemia

51

. The presence of an inert Fc region also indicates its design as a combination

therapeutic with tumor-opsonizing antibodies, unlike agents discussed thus far which can
directly engage FcRs on the macrophage surface to mediate effector function 52. Reports
at the 2018 ASCO Annual Meeting showed data from the first 30 patients enrolled, 25 of
whom received only ALX148, with the remaining five patients receiving combination
regimens with pembrolizumab (3 patients), trastuzumab (1 patient), or rituximab (1
patient). ALX148 was generally tolerated with four combination patients achieving stable
diseases, though two patients exhibited grade 3 thrombocytopenia

53

.

IBI188 is a fully human anti-CD47 monoclonal IgG4 antibody and is the most recent drug
to move from the preclinical phase to Phase 1 trials, where it is currently being evaluated
against advanced malignancies as a monotherapy and in combination with rituximab

26,27

.

The trials dosed their first patients in late February 2019. Blockade of CD47:SIRP in
patients is thus being pursued by a growing list of companies even though single agent
efficacy is not especially compelling. Safety issues that are most easily measured and that
are widely reported include significant anemia, thrombocytopenia, and hemagglutination,
which must be balanced in turn with establishing efficacy – most often by combining with
an IgG that binds to abundant antigens on a tumor cell and thereby strongly activates
adhesion-initiated phagocytosis. Consequently, the drug space aimed at CD47:SIRP has
expanded dramatically with significant investment in new antibodies, small molecules, and
peptides.

1.5 Macrophage checkpoint blockade plus opsonizing antibodies
– initial success with liquid tumors, but are solid tumors next?
7

Targeting the SIRP side of the CD47:SIRP interaction

54,55

rather than CD47 has not

yet been attempted in the clinic but could prove analogous to blocking PD-1 (on the T cell)
that shows clinical efficacy, and certainly, preclinical anti-SIRP development efforts are
encouraging

50

. What is appearing clinically is the utility of combination therapies with

tumor-specific opsonizing antibodies that seek to strongly shift from anti-phagocytic
signals to pro-phagocytic activity. This is especially interesting for patients refractory to
tumor-specific monotherapies such as rituximab. The combination approach is now seen
in virtually all of the trials discussed above: Hu5F9-G4 with rituximab, cetuximab, and
avelumab, CC-90002 with rituximab, and ALX148 with trastuzumab (anti-HER2) and
rituximab, to name a few (complete list in Table 1.1). It is increasingly clear that elimination
of non-‘self’ requires an ‘eat me’ cue, often by IgG opsonization and subsequent
engagement of macrophage FcRs, in addition to the ‘don’t eat me’ signal of CD47:SIRP.
In further recognition of the merits of this phenomenon, bispecific antibodies containing
CD47-specifc and tumor-specific (e.g. mesothilin, CD20, or CD33) domains are in
preclinical development (reviewed in-depth in

56

), while anti-SIRP antibodies may also

provide opsonization on the tumor cell surface.
Effective clearance by innate immune effector cells relies on much more than one or two
cell surface interactions. Some immunotherapies have shown unprecedented success in
generating durable cures to blood cancers, but have faltered in treatment of solid, stiff
tumors. Macrophages engulf foreign material in all types of native tissues and thus seem
tailor-made to enter and eat solid tumors; it will therefore be very interesting to see whether
the success with anti-CD47 and rituximab against liquid tumors translates to solid tumors.
CD47:SIRP’s regulatory role in phagocytosis and physical differences in the tumor
microenvironment between hematological and solid malignancies motivate a deeper
understanding of the mechanobiological underpinnings of phagocytosis in healthy and
pathological processes. Cells in solid tumors generally adhere strongly to each other
and/or to extracellular matrix – which is not true of liquid tumors and which makes it
physically more challenging for a macrophage to completely engulf a cancer cell
integrated in a solid tumor. Knowledge of mechanosensing by phagocytes is likely to help
maximize the utility of macrophage checkpoint therapies and macrophage functions more
broadly. The following sections describe some of the physical factors to consider in
8

macrophage biology (Figure 1.2a) and how that information might be used to inform
therapeutic design.

1.6 Forces in phagocytosis and ‘self’-signaling
Phagocytosis is an ancient process that proceeds by extensive reorganization of the actin
cytoskeleton and (often) via contractions mediated by myosin motors. Myosins bind,
cross-link, and pull on actin filaments, and myosins are well-known to be load-sensitive
(i.e. contractile velocity decays with force), which provides a basis for mechanosensitive
interactions. As with integrin mediated adhesion, target particle or cell binding to surface
receptors frequently leads to receptor clustering and activates signaling pathways that
drive maturation of adhesions via actomyosin activity: for macrophages, this involves the
formation of pseudopod protrusions around the target, with actin polymerization and
branching generating forces of protrusion

57

. Although the pro-phagocytic signals

mediating cancer cell engulfment in the presence of CD47:SIRPα blocking agents have
not been fully elucidated, it is clear that phagocytosis is improved with an opsonizing
antibody, suggesting an FcR-mediated mechanism 55,58. Other pro-phagocytic signals may
also be involved depending on the target. Phagocytosis of hematopoietic cancer cells by
macrophages is reported to depend on Mac-1 (complement receptor-3, CR3, or αMβ2
integrin), which binds to an unknown receptor on its target, along with a homotypic
SLAMF7 interaction and signaling through ITAM-containing co-receptors 59. Calreticulin is
also proposed to be a pro-phagocytic signal recognized by scavenger receptor LRP-1 on
macrophages

60

. These pro-phagocytic cues are an emerging theme in CD47:SIRPα

blockade trials and may be especially critical for the success of these agents in shrinking
solid tumors.
Several myosin motor proteins localize at phagocytic synapses (Figure 1.2b)

61–64

. The

role of myosin in FcR- and complement receptor-mediated phagocytosis has been
investigated by pharmacological inhibitors as well as overexpression and knockdown of
nonmuscle myosin IIa (NMIIA). Target engulfment is deficient in mouse bone marrowderived macrophages and macrophage cell lines treated with inhibitors of myosin light
9

chain kinase (ie. ML7) or myosin (ie. 2,3-butanedione monoxime and blebbistatin) 8,62,65,66.
Similarly, the human monocytic cell line THP-1 internalizes ‘non-self’ sheep red blood cells
less efficiently when transfected with siRNA against NMIIA and more efficiently when
NMIIA is overexpressed 8. Scanning electron microscopy revealed that ML7-treated cells
still form phagocytic cups bound to IgG-opsonized sheep RBCs, but the membrane
protrusions are not as closely associated with the target as in the untreated control

67

.

Thus, it appears that actin assembly and membrane protrusion occur independently of
myosin IIA in FcR-mediated phagocytosis, but mature or stable adhesions might require
contractility through NMIIA. In contrast, in complement receptor-mediated phagocytosis,
NMIIA is implicated even earlier in the process and mediates actin organization with a
requirement for Rho-ROCK signaling

65

. Other myosins including class I myosins and

myosin X have been observed to participate in various stages of phagocytosis and have
potential roles in phagosome formation and closure 62–64.
Cell spreading on matrix-coated substrates uses many of the same cellular components
as phagocytosis, and cells typically exhibit greater spreading on stiff substrates than on
soft ones. Similarly, the efficiency of phagocytosis is determined in part by the stiffness of
the target, with softer targets regarded as more difficult to phagocytose than stiff targets,
a factor to consider in cancer cell engulfment. This has been demonstrated with
engineered hydrogel microbeads

10,68

and chemically stiffened red blood cells

11

. In light

of this effect, control of particle stiffness has risen as a strategy to increase the circulation
time of drug-loaded nanocarriers through delaying phagocytic clearance by splenic and
liver macrophages

68,69

. Prolonging clearance has also be accomplished by decorating

particles or viruses with recombinant CD47 or small ‘self’-peptide mimetics 70,71.
When CD47 on a target cell (or engineered particle or virus) engages SIRPα on
macrophages, the cytoplasmic immunoreceptor tyrosine inhibitory motif (ITIM) of SIRPα
is phosphorylated and recruits the phosphatase SHP-1 (Figure 1.2b)

72

. Nonmuscle

myosin IIA is a direct target of SHP-1, which inhibits NMIIA accumulation at the phagocytic
synapse and prevents the macrophage from efficiently engulfing the target 8. For very stiff
opsonized targets, however, such as dialdehyde-crosslinked RBCs, NMIIA becomes
hyperactivated at the phagocytic synapse in macrophages and inhibitory signaling is
10

unable to prevent target engulfment

11

. This could have implications for phagocytosis of

cancer cells and for cancer treatment. Cancer cells can be softer than normal cells
which together with increased expression of CD47

12,13

73

,

could allow transformed cells to

evade phagocytosis. Alternatively, stiffening of cancer cells following chemotherapy could
make pre-treated tumors more susceptible to phagocytosis and macrophage checkpoint
therapies 74. Future progress on this subject could identify biophysical signatures of cancer
cells that relate to response to anti-CD47 therapy for predictive or prognostic purposes.
The interaction of CD47 and SIRPα on juxtaposed membranes is also governed by
physical forces including fluctuations of the flexible plasma membrane. In cell-derived
giant vesicles displaying human CD47, vesicle spreading and CD47 accumulation was
observed on SIRPα-coated coverslips 75. The apparent binding affinity increased with the
concentration of CD47:SIRPα complexes, indicating a cooperative interaction that arises
from a decrease in out-of-plane membrane fluctuations. As a result, even low expression
levels of CD47 or SIRPα alleles with low binding affinity may be able to achieve sufficient
levels of ‘self’-signaling to limit phagocytosis. Decreasing the pH to mimic acidosis that is
frequently observed in tumors rigidifies the vesicle membrane and decreases
cooperativity. It is speculated that such a loss of cooperativity could permit macrophages
to phagocytose cells expressing low levels of CD47, and in doing so select for cancer cells
expressing high levels of CD47 75.

1.7 Macrophage mechanosensing from matrix to nucleus and
SIRPα
In cancer clearance, monocytes and macrophages face a number of challenges presented
by the tumor microenvironment; they must be able to extravasate through small or large
pores, differentiate to a phagocytic phenotype, resist re-programming to an antiphagocytic state, and ultimately, eat their targets. This process requires the ability to probe
and respond to the mechanical forces surrounding the cells. Macrophages lack focal
adhesions and stress fibers but form podosome adhesions with the extracellular matrix
that are capable of sensing the environment
11

76

. These structures contain a protruding

branched actin core and peripheral actomyosin cables attached to integrins through
adapter proteins, and multiple podosomes can be connected into higher order structures.
Force generation in podosomes involves actin polymerization in the core and myosin
contractility that allows cells to probe substrate stiffness

76

. Human monocyte-derived

macrophages form more podosomes on stiff substrates than on soft substrates, and
phosphorylation of myosin light chain and force generation are also correlated with
substrate stiffness 77,78. How the mechanical stimuli sensed at podosomes are transduced
to alter gene expression remains unclear but is likely to be critical in understanding
macrophage behavior and how the tumor microenvironment can directly or indirectly affect
the cells’ ability to clear ‘foreign’ targets.
Mechanosensing macrophages exhibit differential spreading, migration, and polarization
depending on the physical properties of the matrix. Alveolar macrophages from rats are
rounded when cultured on soft epithelial monolayers but flatten and spread on
polyacrylamide gels of intermediate compliance and stiff glass substrates

79

. Similarly,

human monocyte-derived macrophages are more spread on stiff polyacrylamide gels
coated with fibronectin than on soft ones 80. A biphasic relationship between cell area and
substrate stiffness has also been reported for human macrophages with a maximal area
reached at an intermediate stiffness

81

. Both studies observed stiffness effects on

macrophage migration in two dimensions. In three-dimensions, human monocyte-derived
macrophages exhibit different migration modes depending on the structure of the matrix,
but seem to be less sensitive to matrix stiffness than to matrix organization

82

. In Matrigel

or a dense collagen gel, macrophages underwent mesenchymal migration that was slow
and dependent on protease activity. In a fibrillar collagen matrix, macrophages underwent
amoeboid migration, which was faster and protease-independent. Podosome-like
protrusions with collagen-degrading activity were observed during mesenchymal
migration through collagen gel but not during amoeboid migration through fibrillar collagen.

Macrophages exhibit considerable plasticity with respect to their polarization or activation
states

83

. Very broadly, macrophages can be polarized to a classical, inflammatory state

or to alternatively-activated states with anti-inflammatory or wound healing properties.
12

Biophysical cues including matrix stiffness, topography, and external forces can potentially
influence macrophage polarization (reviewed

84,85

), although further research into their

effects is still needed. In particular, investigations of the effects of matrix stiffness on
macrophage polarization have reached very different conclusions as to whether stiffness
promotes an inflammatory or alternatively-activated phenotype

86–91

. This may be due in

part to different sources of macrophages (primary cells vs. cell lines), different substrates
(synthetic polymer scaffolds, collagen gels, etc.) and adhesive ligands (fibronectin,
collagen), and to simultaneous activation with different cytokines (e.g. IFNγ, IL-4/IL-13) or
inflammatory signals (e.g. LPS). Alternatively, differences could be due to the inadequacy
of current classification methods to describe the full range of macrophage polarization or
to the relatively weak effect of substrate stiffness on this phenotype. Given the altered
matrix and different physical cues potentially present in solid tumors, the efficacy of
macrophage checkpoint blockade may be strongly influenced by the macrophages’ ability
to sense and respond to this matrix while maintaining a pro-phagocytic phenotype.
Several studies have noted a relationship between macrophage shape and polarization
92,93

.

Polarization

of

macrophages

toward

an

inflammatory

phenotype

with

lipopolysaccharide (LPS) and interferon-γ (IFNγ) produces round cells while alternative
activation with interleukin-4 and interleukin-13 produces elongated cells 92. The converse
also appears to be true. When mouse bone marrow-derived macrophages are cultured on
micropatterned lines of fibronectin, they become elongated and upregulate expression of
anti-inflammatory markers Arg-1 (arginase-1) and CD206 while downregulating
inflammatory markers iNOS (inducible nitric oxide synthase) and IFNγ 92. Pharmacological
inhibition of the actin cytoskeleton with cytochalasin D or cellular contractility with
blebbistatin, ML-9, or Y27632 attenuates this polarization. Perhaps consistent with the
effects of shape on macrophage polarization, moderate cyclic strain of macrophages on
polymeric scaffolds

94

and interstitial flow shear forces

95

seem to promote alternative

activation.

With some exceptions, tissue-resident macrophages originate from yolk sac- or fetal liverderived hematopoietic cells during embryonic development
13

96

. In response to injury or

inflammation, monocytes can also be recruited to tissues from circulation and differentiate
into macrophages. Transcriptomic and epigenetic analyses have revealed that
macrophage phenotype is tailored by the local microenvironment

97,98

. Whether

biophysical cues including matrix stiffness contribute to tissue-specific phenotypes in
macrophages remains unclear but plausible.
Macrophages reside in tissues that span a wide range of stiffnesses. For example,
microglia are the resident macrophages in brain tissue, which is very soft with an elastic
modulus of ~0.3 kPa. Osteoclasts are the resident macrophages on bone tissue, which is
much stiffer with an elastic modulus of >30 kPa (non-calcified, and far higher for calcified).
Using mass spectrometry-based proteomics, it was demonstrated that the nuclear
intermediate filament protein lamin A, but not lamin B, is mechanosensitive 99. Specifically,
lamin A protein levels measured in mouse tissue lysates exhibit a power-law scaling with
tissue elasticity E while lamin B levels remain nearly constant. In a meta-analysis of
transcriptomic data from different mouse tissue-resident macrophages, the ratio of lamin
A to lamin B mRNA (LMNA:LMNB) also exhibited power-law scaling with E 100. Consistent
with this finding, immunofluorescence staining of lamin A was greater in phorbol myristate
acetate (PMA)-differentiated THP-1 cells when cultured on stiff polyacrylamide gels than
when cultured on soft gels 16.
The increased stiffness of collagenous tumors relative to normal tissue has implications
for lamin A expression in tumor-associated macrophages and for macrophage adoptive
transfer therapies. For example, the LMNA:LMNB transcript ratio in macrophages isolated
from subcutaneous A549 lung cancer xenografts conformed to the power law scaling
relationship with the measured tumor stiffness

16

. This suggests that tumor-associated

macrophages (TAMs) are mechanosensitive, and that increased stiffness in tumors could
in principle contribute to the reprogramming of monocytes recruited from circulation or
tissue-resident macrophages to TAMs. In the macrophage checkpoint context, high
collagen microenvironments in vivo (associated with stiffness) and stiff gels in vitro cause
macrophages to upregulate SIRP expression and also cause macrophages to switch off
a pro-phagocytic phenotype 16. For therapy, this likely means that more blockade antibody
will be required and perhaps more opsonizing antibody to activate a macrophage.
14

1.8 Macrophage infiltration and differentiation
Within dense, fibrotic tissues including collagenous tumors, extracellular matrix fibers
create constrictions that are generic barriers to 3D migration. As the largest organelle in
the cell, the nucleus limits migration through narrow constrictions and must be deformed
to pass through pores smaller than the nuclear diameter. Thus, by controlling the
deformability and mechanical integrity of the nucleus, lamin expression and scaling with
tissue elasticity has implications for tumor infiltration and macrophage migration as well
as egress from marrow. Lamin levels in hematopoietic cells are indeed relevant to
migration through small pores such as those encountered while trafficking from bone
marrow into circulation or from circulation into tissue 99,101.
Three-dimensional migration through Transwell filters with 3-8 μm diameter pores has
served as an in vitro model of constricted migration
the nucleus but can also limit migration

102

102,103

. High levels of lamin A protect

. Nuclear rupture and cell death has been

observed in human monocyte-derived dendritic cells migrating through 2 μm constrictions
in microfluidic channels 104. Whether nuclear rupture occurs frequently during macrophage
migration in vivo is unknown, but leakage of DNA into the cytoplasm or formation of
micronuclei could have significant inflammatory effects by activating cGAS/STING
pathway of interferon activation

104,105

. Infiltration is thus physically modulated but has

implications for cell fate and inflammation – which are likely to impact success of
checkpoint blockade.
Lamin A has also been described as a differentiation marker in the monocyte lineage.
Early studies showed lamin A and the alternative splicing product lamin C are
undetectable in rat bone marrow-derived precursor cells but increase significantly
following in vitro differentiation to monocytes and macrophages 106. A similar increase was
observed during the in vitro differentiation of human peripheral blood monocytes to
macrophages. Differentiation of the HL-60 cell line to monocyte- and macrophage-like
cells by PMA increases levels of both lamin A and B 107. Lamin A and B expression and
the A:B ratio vary greatly during hematopoietic maturation in vivo as measured by mass
15

spectrometry-calibrated, intracellular flow cytometry of freshly isolated human marrow and
blood cells

108

. While the total lamin levels decrease slightly or remain approximately

constant between human marrow progenitor cells (CD34+ CD38+, CD34+ CD38-) and
peripheral blood or marrow monocytes and granulocytes, the lamin A:B ratio increases
due to downregulation of lamin B and upregulation of lamin A. Flow cytometry
measurements also revealed that the total amount of lamin A and

B is lower in

hematopoietic cells that traffic into circulation (e.g. lymphocytes and peripheral blood
granulocytes and monocytes) than cells residing primarily in the bone marrow
compartment (e.g. CD34+ progenitor cells, erythroblasts, megakaryocyte lineages, and
mesenchymal stem cells). Like cancer cells, the constricted migration of hematopoietic
cells through Transwell pores approximating marrow sinusoidal capillaries is strongly
influenced by lamins

108

. Through such processes and others lamin A levels can also

change during macrophage activation in vivo. Mouse peritoneal macrophages collected
five days after stimulation with thioglycollate stain strongly for lamin A/C whereas
unstimulated macrophages do not

106

. Together, these results indicate that the nuclear

lamins, which are key components of the matrix to nuclear mechanosensing pathway,
exhibit different expression during lineage maturation and across different tissues. It will
be important to determine whether such changes are accompanied by changes in levels
of SIRPα.

1.9 Conclusions
The CD47:SIRPα axis is an intriguing, rapidly emerging therapeutic target involving
innate immune macrophages. It is likely dependent not only on strongly opsonizing
antibodies (such as rituximab) but also on other processes and factors including
mechanical ones. Safety issues include clearance of red blood cells and platelets, and
these mechanically related processes and factors could play a role. Phagocytic effector
cells are well-known to be sensitive to their microenvironment, which motivates careful
study of the physical forces involved in phagocytosis and the broader mechanobiology of
macrophages including precursor monocytes. Matrix mechanics in solid tumors affects
cancer cells and likely immune cells as well, and physical forces also govern the level of
16

SIRPα as well as the engagement of CD47:SIRPα which inhibits phagocytosis.
Moreover, the inflammatory state of a macrophage depends on biophysical cues
including local matrix stiffness and external forces such as fluid shear, which also
influence the ability of these cells to infiltrate tumors and phagocytose cancer cells.
Therapeutic designs that utilize macrophages and other phagocytes as effector cells are
likely to be advanced by recognition and careful consideration of the relevant forces and
related physical factors.
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1.10 Main Figures & Tables

Figure 1.1 ‘Self’-signalling and opsonization in phagocytosis.
Binding of CD47 expressed by a target cancer cell to SIRPα on the macrophage surface
signals ‘self’ to the immune cell and inhibits phagocytic clearance (a). Inhibition of ‘self’signalling with an anti-CD47 antibody (Ab) in combination with a tumor-opsonizing Ab
that engages macrophage Fc receptors leads to phagocytosis of the target (b).
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Figure 1.2: Summary of macrophage mechanobiology and forces in phagocytosis.
(a) Many factors play roles in macrophage interactions and the immune cells’ ability to
clear ‘foreign’ matter. In solid tumors, macrophages must contend with cell–matrix and
cell–cell adhesions that can influence their ability to engage and eat cancer cells.
Macrophages sense matrix properties through podosome adhesions and exhibit lamin A
levels that scale with matrix stiffness. Such matrix to nucleus mechanosensing might
influence macrophage polarization characterized by different cytokine secretions and
surface marker expression. (b) Engagement of CD47 by SIRPa recruits the phosphatase
SHP-1 to the phagocytic synapse in the macrophage where it inhibits myosin IIa
assembly (top). In blockade therapy, activating signals from the clustering of Fc
receptors drive cytoskeletal reorganization and myosin IIa assembly which promote
phagocytosis.
19

Table 1.1: Summary of ongoing anti-CD47 clinical trials.
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2.1 Abstract
The macrophage checkpoint interaction CD47-SIRPα is an emerging target for cancer
therapy, but clinical trials of monoclonal anti-CD47 show efficacy only in liquid tumors
when combined with tumor-opsonizing IgG. Here, in metastatic solid tumors, CD47
deletion shows no effect on tumor growth or survival unless combined with otherwise
ineffective tumor-opsonization, and wild-type metastases are likewise suppressed by
SIRPα-blocked macrophages with tumor-opsonization. Lung tumor nodules of syngeneic
B16F10 melanoma cells with CD47 deletion show opsonization drives macrophage
phagocytosis of B16F10s, consistent with growth-vs-phagocytosis calculus for
exponential suppression of cancer. Wild-type CD47 levels on metastases in lungs of
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immunocompetent mice and on human metastases in livers of immunodeficient mice show
systemic injection of engineered macrophages also suppress growth. Such in vivo
functionality is also modulated by particle pre-loading of the macrophages. Thus, even
though CD47-SIRPα disruption and tumor-opsonizing IgG are separately ineffective
against established metastatic solid tumors, their combination in molecular and cellular
therapies prolongs survival.

2.2 Introduction
The CD47-SIRPα ligand-receptor interaction between myeloid and ‘self’ cells serves as a
ubiquitous immune checkpoint to regulate the phagocytic clearance of ‘foreign’ pathogens,
materials, and debris relative to healthy ‘self’ cells 1. CD47 signals “don’t eat me” to
macrophages by passivating phagocytic activation of the cytoskeleton 2. Recent interest in
CD47 as a cancer therapeutic target has led to rapid expansion of preclinical and clinical
efforts to physically block its inhibitory signaling in liquid and solid tumors that express
CD47 at normal or elevated levels3,4. CD47-blocking antibodies in human trials have
demonstrated promising early results in lymphoma that indicate a requirement for
combination therapy with a tumor-opsonizing IgG (e.g. anti-CD20, rituximab)5,6. Efficacy
of anti-CD47 antibodies in solid tumors remains uncertain, however, with a pre-clinical
replication study of a syngeneic, immunocompetent mouse model casting doubt on past
reports of success in mouse models with anti-CD47 monotherapy5,6. More generally, some
immunotherapies (e.g. engineered T cells) show impressive success against liquid tumors
with durable long-term responses7–9, but solid tumors remain a general challenge –
especially with poorly immunogenic tumors that are particularly clinically relevant.
Infusions of species-relevant anti-CD47 IgG (e.g. mouse IgG into mouse, or humanized
IgG into human) cause loss of blood cells, which confirms biological activity but raises
concerns over safety5,6. Such on-target, off-tumor effects underscore the limited efficacy
of monotherapy and motivate an increasing focus on combination therapies (Figure
2.1Ai)3–5,10–14. Trials are now beginning with anti-SIRPα, but SIRPα is expressed on many
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cell types and clinical advantages remain unclear15–17. Transport of antibodies and effector
cells into solid tumors including metastatic lesions can also be problematic.
Here, we focus first on poorly immunogenic, syngeneic B16F10 melanoma cells in lung 18
to model solid tumor metastasis within immunocompetent C57BL/6 mice. Deletion of
CD47 on opsonized B16F10s increases the engulfment of cell suspensions in vitro by
bone marrow-derived macrophages in our recent studies 19. We now find in vivo efficacy
against established B16F10 metastatic nodules requires both CD47 deletion and a prophagocytic, melanocyte-specific IgG. Our quantitative analyses of tumor growth with CD47
deletion together with high-resolution imaging indicates on-target phagocytosis with IgG
opsonization in B16F10 tumor suppression. In a second approach, we modify marrow
macrophages for an adoptive cell therapy by pre-blocking SIRPα and pre-loading Fcreceptors with tumor-opsonizing IgG prior to infusion. Human lung carcinoma A549 liver
metastases in immunodeficient mice confirm the effects of this cell therapy and thus
confirm the benefits of the combination approach.

2.3 Results
2.3.1 Tumor-opsonizing antibodies drive regression of metastases only when CD47
is disrupted
We used CRISPR/Cas9 to eliminate CD47 from the surface of B16F10 cells without
affecting surface levels of another relevant protein, tyrosinase-related protein 1 (Tyrp1;
Extended Data Figure 2.1)19. Tyrp1 is targetable in vivo with a mouse monoclonal IgG2a/c
antibody (anti-Tyrp1 clone TA99) that activates Fc-receptors20,21 and can suppress wildtype (WT) B16F10 tumors if injected within ~1 day of B16F10 inoculation 20,22. TA99
monotherapy is generally ineffective in established WT B16F10 tumors (Figure 2.1Aii;
Extended Data Figure 2.2A, B), which concurs with recent clinical trial results of antiTYRP1 monotherapy against human melanoma that demonstrated safety but no antitumor efficacy23. Our dosage range for TA99 is similar to that in the clinical trial: 1-10
mg/kg here compared to safety dose testing of 5, 10, 20, and 30 mg/kg in the trial.
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For all in vivo B16F10 experiments, metastases are allowed to establish in the lungs prior
to tail-vein injections of anti-Tyrp1 (Figure 2.1Bi: treatment from days 4 to 15). Tumor
burden was quantified from melanized area and/or nodules on the surfaces of mouse lung
lobes post-sacrifice (Extended Data Figure 2.2C,D); we avoid live-animal imaging
methods such as those using luciferase because they add immunogenicity. For WT
B16F10 metastases expressing wild-type levels of CD47, high TA99 doses (250 µg: ~10
mg/kg) show no significant effect on lung tumors compared to untreated or isotype IgG2atreated controls 14 days after tumor inoculation (Figure 2.1Aii, S2B). Yet, when CD47 is
deleted from the tumors, even moderate doses (75 µg, ~3 mg/kg) suppress growth even
at days 16 and 20 (Figure 2.1Bi-iii). Whereas untreated lungs show melanoma covering
nearly the entire lung surface, anti-Tyrp1-treated lung lobes exhibit relatively few, smaller
nodules.
At the anti-Tyrp1 doses that we show are effective against established CD47 KO tumors,
WT metastatic tumors show no significant change (Extended Data Figure 2.2A), even with
systemic injections of murine anti-CD47 combined with the anti-Tyrp1 (Extended Data
Figure 2.3). The latter result might be explained in part by previous observations that
systemic anti-CD47 can only access and bind a fraction of CD47 on the surface of these
tumor cells24,25. Thus, in contrast to WT tumors, complete disruption of CD47’s inhibitory
“don’t eat me” signal enables FcR-mediated phagocytosis to suppress in vivo growth of
CD47 KO metastatic tumors. Most past studies of WT that show efficacy of TA99 began
treatment on days 0 to 1 after tumor inoculation 22,24,25, affecting initial cell engraftment
rather than treating the more clinically relevant, established tumors. Even in one early
study where TA99 was done later22, mAb doses were ~8-fold higher than here.
CD47-deleted lung metastases across a cohort measured at different time points exhibit
exponential (or power law) growth, and growth is identical to WT tumors (Figure 2.1Biii,
iv).

These results align with current clinical results that generally show anti-CD47

monotherapy does not affect tumor growth. Our studies show tumor variance increases
with time, which is consistent with the exponential-type growth that is typical of unhindered
proliferation, including B16 tumors at subcutaneous sites 26. Longitudinal measurements
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of B16 lung metastasis growth are challenging without modified cells (e.g. without
immunogenic reporters), but one study that showed similar exponential-type B16 growth
used computed tomography (CT) 27. Our own CT imaging of tumor margins (Extended
Data Figure 2.4) suggested higher resolution and higher confidence in the mean kinetics
when measured by optical imaging of a cohort at sacrifice (Extended Data Figure 2.2).
Overall, the doubling of CD47 KO metastases is suppressed ~4-5-fold by anti-Tyrp1
(Figure 2.1Biii), suggesting that anti-Tyrp1 drives tumor cell phagocytosis.

2.3.2 Macrophages infiltrate and phagocytose CD47-depleted, IgG-opsonized
B16F10 nodules
To assess phagocytosis in the melanized tumor nodules, late-stage lung sections were
immunostained for macrophage marker F4/80 (Extended Data Figure 2.5). We also noted
that the DAPI-stained nuclei in nodules are large and consistent with B16’s high-modal
karyotype28. Importantly, CD47 KO tumor nodules treated with anti-Tyrp1 show many
F4/80-positive cells that are round in morphology and that contain a single large nucleus
plus some melanization (Figure 2.2Ai, ii). Such features indicate in vivo phagocytosis of a
B16F10 cell. Lymphatics-localized F4/80+ macrophages are distinct and always appear
more spread. Bone marrow-derived macrophages in culture are similarly spread on plastic
unless they have phagocytosed an anti-Tyrp1-opsonized B16F10 cell, in which case they
are round and melanized (Figure 2.2Aiii). Increased tumor infiltration by immune cells is
further suggested by a marker-free analysis of nuclear size and intensity (small and bright)
(Extended Data Figure 2.6).
Untreated tumor nodules show the same low density of phagocytic F4/80+ macrophages
at days 16 and 20, and 2.6-fold more on day 16, with 2.1-fold more on day 20 (Figure
2.2Bi). The modest decrease is consistent with rapid B16 proliferation and tumor growth
(Figure 2.1Biii) progressively dominating clearance by these effector immune cells. We
model the net growth rate of metastatic tumors as an exponential growth solution to a
differential equation where tumor growth rate increases with tumor cell proliferation and
decreases as a function of macrophage phagocytosis (Figure 2.2Bii, eqns). This
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exponential fits well to total tumor burden versus number of phagocytic macrophages
(Figure 2.2Bii, plot), and illustrates the disproportionate potency of tumor clearance
possible when CD47 disruption is combined with IgG opsonization.

2.3.3 Tumor clearance induced by opsonization and CD47 deletion prolongs
survival, but some tumors escape
To directly assess survival, we followed small cohorts of untreated and treated mice over
time.

All untreated mice with CD47 KO lung metastases exhibited numerous clinical

symptoms that required euthanasia (hunched posture, slow movement, labored
breathing), whereas mice treated with anti-Tyrp1 showed a median survival ~30% longer
(Figure 2.3A). Furthermore, untreated controls all required sacrifice within a narrow
window of 2-3 days (at ~23 days), whereas all mice in the treatment group survived longer,
with a large variation and 20% surviving up to 2-fold longer.
Applying our exponential-type analyses (Figure 2.1B, 2.2B) to single snapshot
measurements on sacrificed mice at early timepoints (e.g. day-16), we estimated cohort
survival curves (Figure 2.3B) that agree with our direct measurements of survival (Figure
2.3A). More specifically, we use our exponential-type fits to fit a similar curve to each
sacrificed mouse, and then we identify when the curve crosses a critical tumor burden
(see Methods). The Kaplan-Meier curves shows the projected long-term survival is nearly
the same as measured survival, with 20% again living twice as long or longer than the
controls (~20 days). Although these experiments used different anti-Tyrp1 doses in the
treated cohorts (3 mg/kg vs. 10 mg/kg), the overall agreement suggests the higher antiTyrp1 dose in the symptoms-based cohort is in therapeutic excess.
Strikingly, despite the similar clinical symptoms between treated and untreated mice, lower
lung tumor burden was present on the long-surviving, treated mice (Figure 2.3C, D). Mice
with the lowest lung tumor burden measured at sacrifice survived the longest. Clinical
symptoms leading to rapid decompensation were consistent with compression of airways,
blood vessels, and surrounding lung tissues leading to hypoxia, and post-mortem
dissection indeed showed a few large tumor masses (Extended Data Figure 2.7). We
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confirmed the identity of these melanized masses as B16F10 tumors by disaggregating
and growing the cells in culture. Thus, a small number of metastases can outpace
clearance by macrophages and cause death in this fast-growing model. Regardless,
complete CD47 disruption combined with tumor-opsonizing antibody significantly
suppresses metastatic-type tumor growth and prolongs survival.

2.3.4 Engineered marrow macrophages eliminate lung tumor nodules in WT
metastases, while anti-Tyrp1 treatment alone does not
WT metastases that express CD47 are more clinically relevant than CD47 KO tumors,
and so we sought a translatable approach to the treatment of WT B16F10 lung
metastases. To do this, we extended an adoptive cell therapy we had developed 29 in which
an anti-SIRPα blocking antibody is added to fresh marrow macrophages and monocytes
together with anti-Tyrp1 loaded onto Fc receptors (Figure 2.4A). Tail-vein injections of
these Antibody-primed Plus SIRPα-Blocked (A’PB) engineered macrophages previously
proved safe and effective against subcutaneous human tumor lines in immunodeficient
mice but had not been tested on metastases in syngeneic, immunocompetent models.
A’PB cells were tail-vein injected into mice with established lung metastases (2 x 107 A’PB
at day 4 post-inoculation). To continue to drive phagocytosis via tumor opsonization, antiTyrp1 was administered per above (Figure 2.1Bi). WT metastases are clearly suppressed
by A’PB (Figure 2.4B, Extended Data Figure 2.8), whereas anti-Tyrp1 does not show
significant effects relative to controls including isotype IgG2a (in agreement with Figure
2.1Aii and Extended Data Figure 2.2A, B). Survival estimations for these day 14 timepoints
show prolonged survival with A’PB, giving a projected median survival that is almost 2fold longer than the control cohort (again showing ~23 day median survival) (Figure 2.4C).
To further enhance anti-tumor efficacy, a second dose of A’PB at day 6 (“2xA’PB”) was
administered, which confirmed significant suppression of tumor growth (Figure 2.4B). and
prolonged the projected survival. Compared to the median survival of the control cohort in
this separate study (~25 days), all of the treated cohort survived longer (Figure 2.4C), and
20% were projected to survive 3-4-fold longer (82 days) - which is the longest survival in
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any of our studies. Multiple doses of our engineered macrophage therapy can thus offer
further opportunity to enhance suppression of WT metastases.
Mathematically, any given cohort within an experiment shows higher variation for larger
mean tumor size (Figure 2.4D), as expected with exponential or power law growth curves
that are highly nonlinear (e.g. Figure 2.1Biii). Moreover, the variation in lung metastasis
size scales with mean tumor size, as is also the case for measured subcutaneous B16F10
tumors. However, lung metastases show more variation, consistent with individual tumor
nodules growing in the lungs (Figure 2.1Bi). Using our exponential-type growth fits (Figure
2.1B) for WT allows estimation from day 14 data of both the average size and s.e.m. for
day 16 and day 20, where WT versus (WT + anti-Tyrp1) conditions still do not differ
significantly. Thus, these results in the WT CD47 model agree with the CD47 ablation
results achieved earlier, suggesting a promising therapeutic strategy to suppress toughto-treat metastases.

2.3.5 WT human lung cancer metastases in liver suppressed by engineered
macrophages
To assess the A’PB engineered macrophages in a second metastatic model and to assess
relevance to human, liver metastases of human lung cancer A549 tumors were first
established in immunocompromised NSG mice (Figure 2.5A, B) as previously described
by our group30. A549 expression of tdTomato enables imaging of infiltrative nodules after
engraftment in liver via surgical implantation (Figure 2.5Bi, ii). Macrophages in NSG mice
express a SIRPα variant that favors engraftment of human cells due to its high affinity with
human CD47, but NSG mice lack antibodies and functional T cells, B cells, and NK
cells31,32. Compared to B16F10 tumors that show exponential phase growth from 100 to
200 mm2 in 2-3 days (Figure 2.1Biv), A549 tumors grow more slowly with linear growth to
the same extent in ~2 weeks (Figure 2.5Biii).
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A’PB treatment of these liver metastatic A549 tumors combined with a tumor-opsonizing
antibody regimen (polyclonal anti-human IgG) led to exponential tumor shrinkage of ~50%
within days, consistent with our model for growth vs. phagocytic clearance (Figure 2.5Bii).
Regression is transient but aligns with our previous results for A549 subcutaneous tumors
that had shown (i) opsonizing antibody alone has no significant effect and that (ii) injected
macrophages show progressively less evidence of phagocytosis over time as they
differentiate toward a tumor-associated macrophage phenotype 33. These results further
illustrate that for slow-growing solid tumors, macrophage phagocytosis can be engineered
or otherwise controlled to dominate tumor growth, in agreement with the proposed
mathematical model (Figure 2.2Bii). B16F10 melanoma tumors grow so rapidly that
phagocytosis can only slow the tumor doubling time, but human melanomas grow slowly
at rates of <1 mm per month34. A549 tumors grow significantly faster at >10 mm per month.
Hence, engineered macrophages with SIRPα-blockade and clinically relevant anti-Tyrp123
can in principle out-compete and thereby repress human metastatic melanoma.

2.3.6 Engineered macrophages are less effective when pre-loaded with
microparticles
We hypothesized that pre-loading the A’PB macrophages with micron-sized particles will
impact their tumor access and/or activity, further modulating their phagocytic ability.
Engulfment of polystyrene particles reportedly enhances subsequent phagocytosis of
particles and bacteria in vivo35, but pre-engulfment might also undermine motility including
anti-cancer phagocytic activity.29 To test this possibility, A’PB cells were incubated with
IgG-opsonized polystyrene microparticles, with ~40% of cells associating with ~1-10
microparticles (Figure 2.6A). Microparticle pre-loaded A’PB preparations were injected at
day 4 (per Figure 2.4C) and at day 6 per the ‘2xA’PB’ dosing therapy (plus anti-Tyrp1 per
Figure 2.4B) in the B16F10 lung metastasis model. Mice sacrificed on day 14 showed the
2xA’PB+microparticles had no significant effect on tumor area relative to untreated
controls (Figure 2.6B). The result nonetheless shows that A’PB activity can be effectively
modulated.
41

2.4 Discussion
Here, we show that CD47 ablation is insufficient on its own to affect tumor progression in
a poorly immunogenic, metastatic model that is widely used as a pre-clinical model. Our
KO and WT control tumors across various B16F10 lung metastases indicate a consistent
median survival of ~20-25 days that reflects exponential-like growth (Figures 2.3A, B for
CD47 KO and Figure 2.4C, 2.6B for WT B16). Clinical trials also show CD47 monotherapy
is rarely, if ever, effective against human cancer 5. Anti-CD47 blockade in combination with
a second opsonizing mAb can show efficacy in the clinic against liquid cancer, but solid
tumors likely present larger barriers and limits to anti-CD47-based blockade even in
combination treatments. Similarly, subcutaneous B16F10 tumors treated with anti-Tyrp1
show little to no effect of anti-CD4724,25. Our CD47 knockout is 100% (rather than
incomplete per earlier studies), and combination with the tumor-opsonizing IgG TA99
proves effective against established lung metastases of B16F10s. The effect is consistent
and significant, with survival extended 2-3-fold across the different studies (Figure 2.7).
Our anti-SIRPα blocked macrophages also prove effective in combination with tumor
opsonization.
Heterogeneity of lung tumor nodules and explosive growth can be difficult to suppress.
Anti-Tyrp1 therapy of mice bearing CD47-deleted metastases nonetheless resulted in
lower overall tumor burden even though mice succumbed with similar clinical symptoms
as untreated controls. These observations point to a small number of escaping tumors
causing moribundity, but otherwise exceptional tumor control by tissue-resident
macrophages36. The model of phagocytic suppression of rapidly growing B16F10
metastases is extended to slow-growing A549 liver metastases that are effectively
repressed by treatment. The A549/NSG model lacks other effector immune cells,
consistent with a key role for macrophages and phagocytic function. Overall, our analyses
of tumor growth, variability, and phagocytosis provide insight into immune cell-tumor
relationships that might translate to a patient’s response to such therapy.
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Our results with a standard pre-clinical cancer model contrast with many early reports that
anti-CD47 monotherapy can suppresses tumor growth in various mouse models (often
xenogeneic in immunodeficient mice). The only “monotherapy” to succeed to date against
patient tumors is an intratumorally administered SIRPα-IgG1 chimera in fungoides
mycosis (a type of lymphoma), with evidence that the IgG1 serves to opsonize while
SIRPα binds CD4737,38. However, even low levels of CD47 can block phagocytosis19,39,
and recent studies with subcutaneous tumors of B16F10s engineered to locally secrete
anti-CD47 nanobody failed to achieve 100% blockade and extended survival only
modestly even with anti-Tyrp125. The combination of complete CD47 disruption and tumor
opsonization is thus not only synergistic, but required for tumor control.
Our engineered macrophage strategy effectively suppresses growth in two solid tumor
models of physically distributed metastases, and it motivates a quantitative understanding
of macrophage infiltration and activity. SIRPα blockade is restricted in our approach to
myeloid cells, unlike blockade of CD47 on all healthy ‘self’ cells. Additionally, a complex
interplay of cell biophysics (e.g. membrane fluidity and cellular compliance 35) and
catabolism-metabolism is suggested by our finding that phagocytosed micro-particles
modulate the in vivo efficacy of engineered macrophages. We did find that pre-feeding
bone marrow-derived macrophages in vitro with red blood cells could inhibit subsequent
B16F10 eating, but the in vivo consequences need more study (Figure S9). Pre-loading
with fewer, smaller, and/or degradable particles, including viruses, might usefully enhance
macrophage phenotype.

2.5 Conclusion
CD47 is a promising, emerging target for clinical cancer therapeutics but has significant
safety issues and efficacy remains a challenge. Pro-phagocytic signals are required in
combination, rather than acting in synergy, with blockade of CD47 inhibitory signaling to
drive tumor clearance. The clinical success of CD47-based therapeutics depends on
macrophage activation, not just inhibition of “don’t eat me” signals. We demonstrate this
strategy in two different models of metastasis by CD47 deletion and by adoptive transfer
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of SIRPα-blocked marrow cells in combination with tumor-opsonizing IgG. While
advancing our understanding of phagocytosis and CD47’s role in solid tumors, further
efforts might seek to: (i) maximize CD47 disruption, (ii) increase the numbers of phagocytic
effector cells, and (iii) provide additional pro-phagocytic signals (e.g. another tumorspecific monoclonal antibody, bispecific antibodies, some chemotherapeutics, etc.) that
are suppressed by CD47-SIRPα.
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2.6 Materials and Methods
Mice
6-14-week-old C57BL/6J mice were procured from The Jackson Laboratory (Bar Harbor,
ME). 6-10-week-old NOD-scid IL2Rγnul (NSG) mice were procured from the Stem Cell &
Xenograft Core at the University of Pennsylvania. To induce lung tumor metastases, 2 x
105 wild-type (WT) or CD47 KO B16F10 cells were injected intravenously in 100 µl of
sterile PBS. Initial studies with anti-CD47 were similar but subcutaneous. To induce liver
metastases, A549 cells were surgically implanted in the livers of NSG mice and monitored
with fluorescence imaging (IVIS Lumina). Donor bone marrow for marrow treatments was
isolated from age-matched C57BL/6 or NSG mice using well-established protocols (see
Marrow harvest & engineering). All animal studies were performed according to approved
Institutional Animal Care and Use Committee (IACUC) protocols at the University of
Pennsylvania.

Quantification of tumor burden
Mouse lungs were excised and dissected into the five individual murine lung lobes.
Harvested lobes were imaged with Nikon D7500 or D3000 DSLR cameras on an
SMZ1500 dissecting microscope with an AmScope camera adapter against a 5x5 mm 2
printed grid. Images were loaded into ImageJ and a selection was drawn around each
lung lobe. Red, green, and blue color channels were split to reduce false signal from blood,
bruising, and other tissue discoloration, and only the red channel was used for
quantification. The image was then thresholded with the auto-thresholding algorithm
‘MaxEntropy’. Relative contribution of white pixels (putative B16F10 nodules) and black
pixels (normal lung tissue) was calculated for an estimate of total lung tumor area. The
5x5 mm2 grid enabled conversion from pixel sensor to absolute area. Nodules were
counted in experiments with pre-determined sacrifice time points.
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Quantitative analyses for estimation of tumor growth & projected survival
To predict long-term survival from single timepoint measurements, nonlinear models
(exponential, Area = A0*ek*t; power law Area = A0*tB) were fit to multiple timepoint data (Fig
1Biii, iv) to choose respective growth exponent values for WT and CD47 KO B16F10
tumors. The measured tumor burden at sacrifice for each individual mouse was then fit
with an exponential with the determined exponent value. A0 for each individual mouse was
allowed to vary for best fit, reflecting individual engraftment environments. The critical
survival tumor area threshold of 300 mm2 was then used to calculate projected survival
time (t, in days) for each mouse with the calculated individual A0 and B parameters. Inset
plots show representative estimated growth curves for 3 individual mice within each
experiment using this method.

Marrow harvest & engineering
Donor mice were sacrificed by CO2 inhalation and subsequent confirmatory cervical
dislocation. Hind legs were gently dislocated before excision of surrounding fat, muscle,
and skin. Femurs and tibiae were separated, cut open at the ends, and centrifuged for up
to 25 seconds at 12,000 x g to remove marrow from the bones. Pellets were then resuspended in 1 mL ACK Lysing Buffer for 12 min before centrifugation for 5 min at 300 x
g to aspirate lysed RBCs. Marrow cells were counted with a hemocytometer, adjusted to
8 x 107 cells/mL (2x107 cells/250 µl cell injection), and incubated with anti-SIRPα blocking
antibody (P84, 4.5 µg/2 x 107 marrow cell injection) at RT for 45 min. Cells were then
centrifuged for 5 min at 300 x g to remove excess anti-SIRPα, then re-suspended again
at 8 x 107 cells/mL in 2% fetal bovine serum (FBS) and 1 x 103 µg/mL TA99. For
microparticle-loaded experiments, 2.1-µm streptavidin-coated polystyrene microparticles
(Spherotech #SVP-20-5, 0.5% w/v) were centrifuged at 16,300 x g for 20 min and resuspended in 5% FBS/PBS containing 5 µg/mL anti-streptavidin (BioLegend #410501,
clone 3.A20.2). Particles were then incubated on rotator for 15 min at RT, then centrifuged
again 16,300 x g for 10 min. Marrow cells after the removal of anti-SIRPα (concentration:
8 x 107 cells/mL) were then incubated with the opsonized microparticles for 1 h on rotator
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at RT in 5% FBS prior to being washed twice with 5% FBS/PBS at 300 x g for 5 min and
re-suspended in the final cell solution as above. 250 µl of these cell solutions were then
administered intravenously to strain-matched mice bearing tumors. A second engineered
cell dose in “2xA’PB” conditions was administered i.v. on day 6 post inoculation. 600 µg
doses of anti-human (Rockland #209-4139) were similarly injected to opsonize in A549
tumor experiments instead of TA99.

Cell culture
B16F10 melanoma cells were obtained from ATCC (Manassas, VA). Cells were cultured
at low passage number in RPMI-1640 until at least one passage before a planned tumor
inoculation or phagocytosis assay, when the media was switched to DMEM. B16F10 cells
melanize and exhibit slower growth rates in DMEM compared to RPMI. Isolated primary
bone marrow cells are differentiated for 7 days in Iscove’s Modified Dulbecco’s Medium
(IMDM) supplemented with 10% (vol/vol) FBS, 1% penicillin-streptomycin (P/S), and 20
ng/mL M-CSF to produce bone-marrow derived macrophages (BMDMs) for in vitro assays
(Biolegend). A549 lung carcinoma cells were cultured in F-12 media supplemented as
above. For B16F10 tumor disaggregation, mouse lungs were excised and disaggregated
with dispase (Corning #354235) supplemented with 3 mg/mL collagenase and DNaseI
prior to cell culture in DMEM.

CRISPR-Cas9 deletion of CD47
CRISPR/Cas9-mediated knockouts of Cd47 were generated using LentiV_Cas9_puro
(Addgene #108100) and Lenti_sgRNA_EFS_GFP plasmids (Addgene #65656), which
were gifts from Christopher Vakoc.

The following single guide RNA (sgRNA)

oligonucleotides was used: Cd47, 5′-TCCCCGTAGAGATTACAATG. All sgRNA
oligonucleotides were designed using the Broad Institute’s GPP sgRNA Design tool and
purchased from Integrated DNA Technologies. sgRNA targeting sequences were
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annealed and ligated into the Lenti_sgRNA_EFS_GFP expression vector with Esp3I
(Thermo Fisher Scientific).

Lentivirus was generated in individual wells of a 6-well plate (Corning) by transfecting
HEK293T cells with 165 ng pVSVg, 1.35 ug psPAX2, and 1.5 ug lentiviral transfer plasmid
using 7.5 ul TransIT-LT1 Transfection Reagent (Mirus Bio) per well following the
manufacturer’s protocol. Viral supernatants were collected 48 h after transfection,
centrifuged at 300 x g for 5 min to remove cell debris, and then added to targets cells at a
1:1 volumetric ratio of viral supernatant to culture media. To generate a stable Cas9expressing B16F10 line, cells successfully transduced with LentiV_Cas9_puro were
selected using puromycin (Invitrogen) at 2 ug/mL for one week. Stable Cas9-expressing
B16F10 cells were then again transduced with lentivirus for sgRNA expression vectors
with targeting sequences against Cd47. Individual clones were generated by serial dilution
and selecting only GFP-positive clones. Clonal knockout was confirmed by flow cytometry
using anti-mouse CD47 (clone MIAP301).

Phagocytosis assays
C57BL/6J bone marrow was harvested as described above, plated in 100 mm untreated
Petri dishes in IMDM (supplemented 10% FBS, 1%P/S, 20 ng/mL M-CSF), and allowed
to differentiate into macrophages for 7 days. On day 7 of differentiation, macrophages
were washed with 1x PBS, lifted with 0.25% Trypsin for 10 min at 37 °C, and plated in 24or 6-well plates in the same supplemented IMDM for phagocytosis assays the following
day. Targets for phagocytosis were opsonized for up to 30 minutes at RT or on ice at the
following concentrations and antibodies: 10 µg/mL TA99 (BioXCell) for B16F10 variants,
and 10 µg/mL anti-streptavidin for polystyrene microparticles. Where applicable against
WT targets, mouse targets were CD47-blocked with 10 µg/mL MIAP301 (BioXCell). Prior
to adding targets to the wells for phagocytosis, macrophages were labeled with 0.5 µM
CellTracker DeepRed in PBS for 15 min and B16F10 cells with 10 µM Vybrant CFDA SE
Cell Tracer Kit in PBS for 15 min at RT. Wells were washed with serum-free IMDM (IMDM
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supplemented with 0.1% BSA, 1% P/S, no M-CSF or FBS) after 2 h. For imaging, wells
were fixed for 20 min in 4% paraformaldehyde at RT, then washed with PBS and stored
at 4 °C in PBS prior to imaging.

Immunohistochemistry
Lungs harvested from mice were fixed in 4% paraformaldehyde overnight at 4 °C and
stored in 70% ethanol. Lungs embedded in paraffin and sectioned by the Molecular
Pathology & Imaging Core or the Comparative Pathology Core at the University of
Pennsylvania. Staining for immune markers followed established core protocols.

Statistical analyses and equation fitting
Results were analyzed for statistical significance, and equations were fit both with built-in
analyses in Prism 9.0.1.
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2.11 Main Figures and Figure Legends

Figure 2.1: Tumor-opsonizing antibodies can drive regression of metastases only
when CD47 is disrupted.
A (i) Human clinical CD47 blockade in solid tumors compared to our main design of a
suitable preclinical model (mouse). Anti-CD47 monotherapies show no efficacy,
motivating combination with tumor-opsonizing antibodies (e.g. Cetuximab in colorectal
cancer). Anti-Tyrp1 monotherapy also showed no efficacy against Melanoma. Two
distinct approaches are taken in our model.
(ii) Anti-Tyrp1 opsonization of established wild-type (WT) B16F10 melanoma
metastases does not significantly affect lung tumor burden on day 14 post inoculation
with 2 x 105 B16F10 cells i.v. Tumors are allowed to establish, and mice are then
intravenously injected with 250 µg of anti-Tyrp1 intravenously on days 4, 5, 7, 9, 11, and
13 post-inoculation. Mice are sacrificed and organs are surveyed for B16 metastases.
Results are illustrative of 3 independent experiments (n = 5 per group, mean ± s.e.m.,
n.s. p > 0.05, Ordinary one-way ANOVA).

55

B CD47-deleted lung metastases are suppressed only with anti-Tyrp1. (i) Mice are tailvein injected with 2 x 105 CD47 KO B16F10 cells on day 0 and later treated by tail-vein
injections of anti-Tyrp1 (75 µg or 250 µg, doses specified in Legends). Mice are
sacrificed and organs are surveyed for metastases, but only lung shows nodules.
Representative images from untreated controls or anti-Tyrp1 treatment. (ii) Tumor area
on both sides of lung lobes were quantified, showing suppression by anti-Tyrp1
treatment (75 µg dosing regimen from B-i) (n = 5 per group, mean ± s.e.m.; * p < 0.05, **
p < 0.01, **** p < 0.0001, n.s. not significant, one-way ANOVA). (iii) Exponential-type
growth (Area = A0 tB : A0,ctrl = 0.0019, A0,tx = 0.0087, B,ctrl = 4.1, B,tx = 3.0). (iv) CD47
deletion does not affect tumor growth relative to WT (Area = A0 ek*t, where A0 = 0.05, k =
0.45).
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Figure 2.2: Tumor-opsonizing antibodies increase macrophage infiltration in
tumors.
A Phagocytic macrophages in treated CD47 KO lung tumor nodules. (i) Confocal images
of anti-Tyrp1-treated CD47 KO tumors show F4/80+ macrophages that are rounded in
morphology and contain melanin and large DAPI+ nuclei, indicating phagocytosis of
B16F10 cells. F4/80+ macrophages in control lymph tissue (lymphatics-localized) show
diffuse, non-phagocytic morphology. (ii) Treated lung nodules show more phagocytic
macrophages than untreated control lungs. (iii) Rounded macrophage in vitro after
engulfing an opsonized B16F10 cell. Scale: 50 µm.
B (i) Phagocytic macrophages per tumor area increase with anti-Tyrp1 treatment in
CD47 KO lung tumor nodules. Mean ± s.e.m. (* p < 0.05, ** p < 0.01, Student’s t-test, n
= 3 representative samples per group, closed circles indicate day 16 samples and open
circles indicate day 20 samples). (ii) Relationship between lung tumor area and density
of phagocytic macrophages: exponential-type growth versus phagocytic suppression.
Tumor burden, B, is modelled by an ordinary differential equation in which growth is
suppressed by phagocytic interactors, P. P0 refers to inactivated macrophages.
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Figure 2.3: Tumor clearance induced by opsonization AND CD47 deletion
prolongs survival, but a few large tumor masses still cause death.
A Survival of anti-Tyrp1-treated mice induced with 2 x 10 5 CD47 KO B16F10 cells
intravenously. 250 µg anti-Tyrp1 doses beginning on Day 4 post inoculation prolong
survival of mice by about 30%, but mice are unable to be cured completely (n = 5 per
group, ** p < 0.01, Log-rank test). Right: mice are healthy and exploratory, then rapidly
deteriorate in health in less than 24 h, showing clinical symptoms of hunched posture,
labored breathing, slow reactivity, and weight loss.
B Projected survival of anti-Tyrp1-treated mice induced with 2 x 10 5 CD47 KO B16F10
intravenously modeled with a power law fit based on single timepoint estimates of
growth. 75 µg of anti-Tyrp1 on the same dosing timeline leads to an estimated projected
survival advantage of ~6-7 days (n = 10 per group, **** p < 0.0001, Log-rank test). Inset:
exponential-type growth projections of six representative mice.
C CD47 KO B16F10 tumor burden on lung lobes at sacrifice. Anti-Tyrp1-treated mice
have lungs with markedly reduced tumor burden relative to untreated mice, yet
demonstrate similar clinical symptoms requiring sacrifice.
D Survival of mice in days versus lung surface tumor area at sacrifice. Exponential
model shows that survival is inhibited by lung tumor burden
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Figure 2.4: SIRPα-blocked, Tyrp1-targeted marrow cells suppress wild-type
metastases, while anti-Tyrp1 treatment alone does not.
A Schematic of SIRPα-blocked, Tyrp1-targeted (A’PB) marrow cell production and
treatment of WT B16F10 lung metastasis tumor-bearing recipients. CD47 signaling on
freshly harvested bone marrow that contains monocytes and macrophage pre-cursors is
blocked with anti-SIRPα, and marrow Fc receptors are pre-loaded with anti-Tyrp1 prior
to infusion back into mice bearing lung metastases. Mice receive 2 x 10 7 engineered
marrow cells intravenously on day 4 (1xA’PB) and 6 (2x A’PB) post inoculation.
Additional 250 µg anti-Tyrp1 was administered i.v. on days 4, 5, 7, 9, 11, and 13.
B WT B16F10 tumor burden in mice treated with engineered marrow. Left: Control mice
were treated with either isotype IgG2a antibody (gray, 250 µg dosing regimen) or
received no treatment (black), while treated mice received either anti-Tyrp1 (250 µg
dosing regimen) or A’PB marrow with anti-Tyrp1 (250 µg dosing regimen). Right: Tumor
burden in a separate experiment comparing control (untreated) or 2x A’PB groups. Lung
tumor burden was assessed on day 14 post inoculation. Mean and s.e.m. (* p < 0.05,
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n.s. not significant, Ordinary one-way ANOVA, n = 5 per group, except isotype control n
= 4)
C Projected survival advantages in A’PB-treated lung tumors.
D Variance of tumor areas scales with average tumor area of lung nodules, consistent
with power law growth kinetics. This inter-tumor heterogeneity for lung metastases
exceeds that of subcutaneous tumors, and might limit the ability to eliminate tumors
completely.
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Figure 2.5: A’PB therapy represses growth in human metastatic WT CD47 tumors.
A (i) Table of human xenograft mouse model details. Human lung A549 carcinoma is
surgically implanted at an orthotopic metastatic site in the livers of NSG mice. AntiSIRPα is used to block CD47 signaling on adoptively transferred marrow cells and antihuman is the source of tumor-opsonizing antibody (A’PB). (ii) Schematic of tumor
induction and treatment. NSG mice were surgically implanted with liver metastases.
Mice were treated with A’PB marrow on the indicated day 0 and 3 times weekly for 2
weeks with anti-human i.v.
B (i) Representative whole-body fluorescence image of tdTomato signal in surgically
implanted liver metastases (left). Images of explanted liver with liver metastasis (middle
top, A549 tumor circled, scale: 1 cm) and tdTomato signal of A549s infiltrating stroma
(middle bottom). (ii) Sectioned liver tissue images showing tdTomato, αSMA, DNA, and
collagen of A549 metastases relative to normal liver tissue (top right) and H&E staining
(bottom right). (ii) In vivo growth curve of liver metastatic human lung adenocarcinoma
A549 tumors. A’PB and tumor-opsonizing antibody repress tumor growth by 50% over
several days relative to untreated control. Tumor burden is monitored by fluorescent
imaging with an IVIS Lumina II (fluorophore: tdTomato). Without additional treatment to
continue tumor cell clearance, metastases begin to expand again after about 10 days.
Error bars represent s.e.m. Exponential growth fit for regressing treated tumor: Area =
exp(-t/1.554)) for 0 < t < 8.
61

Figure 2.6: Pre-loading A’PB with microparticle cargo hinders tumor suppression.
A Engineered macrophages pre-loaded with cargo prior to treatment. (i) Schematic of in
vivo marrow pre-load therapy to assess off-target effects on phagocytosis. Freshly
harvested marrow cells phagocytose IgG-opsonized polystyrene microparticles for 1 h
prior to tail-vein injections. (ii) Representative mages of marrow cells with polystyrene
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microparticles, with excess particles removed by centrifugation prior to injection. (iii)
Quantification of microparticles engulfed per marrow cell in a field of view (FOV). About
40% of marrow cells engulfed up to ~10 particles.
B In vivo phagocytosis of WT B16F10 cells in A’PB marrow treatments. (i) Lung tumor
burdens in control (untreated) and 2xA’PB+microparticle pre-loaded groups. Mice were
treated with engineered marrow on days 4 and 6 in addition to tail-vein injections of 250
µg anti-Tyrp1 per Fig. 1B through day 13. Mean and s.e.m. (* p < 0.05, n.s. not
significant, Ordinary one-way ANOVA, n = 5 per group). (ii) Projected survival curves.
A’PB pre-incubated with polystyrene microparticles show no significant reduction in
tumor burden versus untreated. Mean and s.e.m. (n.s. not significant, unpaired t-test, n =
5 per group)
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Figure 2.7: Summary of lung metastases results shows need for combination
therapy.
Schematic of survival results, with CD47-SIRPα disruption and tumor opsonization
extending survival in combination, but not separately based on statistical significance.
Each point is representative of median (square – 50% survival) or 80th percentile
(triangle – 20% survival) survival time for the indicated group and is normalized to
survival of untreated.
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2.12 Extended Data Figures & Legends

Extended Data Figure 2.1. Cell surface marker expression levels in B16F10 lines.
A CD47 surface expression is completely abolished via CRISPR/Cas9 editing. AntiCD47 (clone: MIAP301) was used as the primary antibody and AlexaFluor647 as the
secondary antibody prior to measurement by flow cytometry.
B Tyrp1 is expressed on the surface of the B16F10 cell surface and is thus a target for
IgG opsonization and Fc receptor-mediated phagocytosis. Anti-Tyrp1 (clone: TA99) was
used as the primary antibody and AlexaFluor546 as the secondary antibody prior to
measurement by flow cytometry.
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Extended Data Figure 2.2: Wild-type B16F10 metastases do not respond to low
and high doses of anti-Tyrp1.
A Representative micrographs of lungs from mice bearing metastases at day 14 post
inoculation of 1.5 x 105 wild-type B16F10s i.v. Tumors are allowed to establish, and mice
are then intravenously injected with 250 µg of anti-Tyrp1 intravenously on days 4, 5, 7, 9,
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11, and 13 post inoculation. Mice are sacrificed and organs are surveyed for B16F10
metastases. Same statistical analyses as Fig.1A-i.
B Quantification of tumor burden. WT B16F10 nodules were counted manually. No
significant differences were detected at day 14 (see Figure 1A and 4B for 2 x 10 5 WT
B16F10s i.v.). Results shown are from 3 independent experiments (n = 5 per group
within each experiment, open circles indicate results from groups in concurrent
experiments, gray symbols indicate isotype IgG2a control treated (250 µg i.v. on the
same timeline)), black symbols indicate untreated/non-injected, mean ± s.e.m., n.s. p >
0.05, Ordinary one-way ANOVA with Sidak’s multiple comparisons).
C Workflow for quantification of tumor burden on lung lobe surfaces. B16F10 tumor
burden was quantified in FIJI by analyzing black/melanized tumor area relative to normal
lung tissue area. Excised lungs were imaged with a dissecting microscope and a DLSR.
ROIs were drawn around each lung lobe and color channels were split in to RGB. The R
channel shows the highest signal-to-noise for tumor area. To reduce bias from manual
thresholding, all images were auto-thresholded with the ‘MaxEntropy’ method in FIJI,
then the relative contribution of white (tumor) pixels and black (normal lung tissue) pixels
was measured.
D Scaling relationship between nodule count and tumor area on day 14 as estimates of
tumor burden (2 x 105 i.v. cell inoculation number for all groups). Different B16F10
variants are shown, including a wild-type CD47-expressing variant, CD47 KO, CD47 KO
plus anti-Tyrp1 (TA99), and a nuclear lamin (LMNA) KO clone. Each solid point
represents lung tumor burden on one mouse, and each open point represents the
average value (mean ± s.e.m., n.s. p > 0.05, Ordinary one-way ANOVA with Sidak’s
multiple comparisons, indicated statistical comparison is for the x parameter relative to
CD47 KO). Gray shaded boxes show estimate of regimes for 1.5 x 105 and 2 x 105 i.v.
cell inoculation numbers, respectively as indicated, on day 14 post inoculation.
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Extended Data Figure 2.3: Combination anti-CD47 and anti-Tyrp1 fails to affect
tumor area of primary wild-type B16F10 tumors.
Tumor area comparing untreated and combination treated with anti-CD47 anti-Tyrp1 i.v.
on Days 4, 5, 7, 8, 11, 13, and 15 post inoculation of 2 x 105 cell WT B16F10 cells1. AntiCD47 + anti-Tyrp1 fails to affect tumor area on day 15 relative to untreated controls (n =
6 per group, n.s. p > 0.05 Welch’s t-test with Welch’s correction).
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Extended Data Figure 2.4: Computed tomography (CT) imaging of B16F10 lung
metastases (CD47 KO).
A Representative microCT images of mice bearing CD47 KO lung metastases on day –2
and day 25 post inoculation. Mice were inoculated with tumor cells and treated with antiTyrp1 or left untreated as described in Figure 1Bi. Anti-Tyrp1-treated mice (left) exhibit
low tumor burden at Day 25 relative to untreated (right) mice.
B Power law and exponential fits to previously reported microCT data of B16 lung
metastases2.
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Extended Data Figure 2.5: Melanin and nuclei of tumor and lung tissue in
embedded lung sections.
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Top panel: Brightfield images (4x and 40x) and DNA-stained/UV channel images (40x)
of anti-Tyrp1-treated lungs. Tumor nodules are present and disturb the surrounding
tissue as dense, solid masses co-localized with melanin (black) granule deposition.
B16F10 nuclei are large and densely packed relative to small, bright nuclei of the
surrounding normal tissue.
Bottom panel: Brightfield images (4x and 40x) and DNA-stained/UV channel images
(40x) of control (untreated) lungs. B16F10 tumors are widespread in size and melanin
deposition. Normal alveoli in the absence of tumor are shown in comparison.
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Extended Data Figure 2.6: Marker-free analysis of immune infiltrate in treated
CD47 KO lung tumor nodules.
A (i) Inverted contrast of DAPI-stained nuclei in a nodule (red outline) or brightfield
(yellow), with nuclear outlines to quantify size and intensity in tumors and adjacent
tissue. (ii) Fractions of normal nuclei with high intensity and small areas in tumors and
adjacent tissues (mean ± s.e.m.)

72

Extended Data Figure 2.7: Tumor masses on lungs (related to Main Figure 2.2).
Representative images of dissected mice with large tumor (CD47 KO B16F10) masses
compressing the lungs and chest cavity, despite reduced tumor burden on the lungs.
These masses were disaggregated with Dispase supplemented with collagenase and
DNaseI and plated for 3 days in DMEM to confirm their identity as B16F10 tumor cells
(GFP+, 488 nm Ex.).
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Extended Data Figure 2.8: Tumor growth in A’PB-treated mice.
A (i) Lung tumor burden as assessed on day 14 post inoculation. Representative
photographs of lung tumor nodules in A’PB-treated lungs and untreated control lungs.
(ii) Power law (Area = A0*tB) fits growth (A0,ctrl = 0.00088, A0,A’PB = 0.0039, Bctrl = 4.1, BA’PB
= 3.0). Inset: projected power law growth curves of representative individual control and
1xA’PB-treated mice (n = 3 each).
B (i) Projected power law growth curves of representative individual control and 2xA’PBtreated mice (n = 3 each).
(ii) Projected power law growth curves of representative individual control and
microparticle-preloaded 2xA’PB-treated mice (n = 3 each).
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Extended Data Figure 2.9: Pre-feeding bone marrow-derived macrophages with
non-tumor targets can affect on-target tumor cell phagocytosis.
A Schematic of in vitro pre-feed phagocytosis assay to assess off-target effects on
phagocytosis. Macrophages are allowed to phagocytose IgG-opsonized, CD47-blocked
human/mouse red blood cells (RBCs) 24 h prior to phagocytosis of TA99-opsonized,
CD47-deleted B16F10s. Bone marrow-derived macrophages are plated for 7 days in
IMDM supplemented with 20 ng/mL M-CSF prior to assay start.
B (i) Representative fluorescence image (40x magnification) of macrophage engulfment
of CD467 KO B16F10s in phagocytosis assays. Macrophages engulf B16s without prefeed (main image), while RBC-pre-fed macrophages fail to phagocytose target B16s
(inset). (ii) Quantification of fraction of phagocytic macrophages pre-fed with either
RBCs or microparticles. Macrophages engulf anti-Tyrp1-opsonized CD47 KO B16F10s
readily without pre-feeding (0:1 ratio input target:macrophage). High RBC phagocytosis
blocked B16F10 phagocytosis completely.
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CHAPTER 3: COOPERATIVE PHAGOCYTOSIS UNDERLIES
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3.1 Abstract
Macrophages are abundant in solid tumors and typically associate with poor prognosis,
but macrophage clusters in tumor nests have also been reported as beneficial even
though dispersed macrophages would have more contacts with cancer cells. Here, by
maximizing both phagocytic activity and macrophage numbers, we discover cooperative
phagocytosis by low entropy clusters in rapidly growing engineered immuno-tumoroids.
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The results fit the calculus of proliferation-versus-engulfment, and rheological
measurements and molecular perturbations provide a basis for understanding phagocytic
disruption of a tumor’s cohesive forces in soft cellular phases. The perturbations
underscore the utility of suppressing a macrophage checkpoint in combination with an
otherwise ineffective tumor-opsonizing monoclonal antibody, and the approach translates
in vivo to tumor elimination that durably cures mice from re-challenge and metastasis.
Adoptive transfer of engineered macrophages increases the fraction of mice that eliminate
tumors and potentially overcomes checkpoint blockade challenges in solid tumors like
insufficient permeation of blocking antibodies and on-target, off-tumor binding. Finally,
anti-cancer IgG induced in vivo are tumor-specific but multi-epitope and contribute to a
phagocytic feedback that drives macrophage clustering in vitro. Given that solid tumors
remain challenging for immunotherapies, durable cures here illustrate unexpected
advantages in maximizing net phagocytic activity.

3.2 Introduction
The ability of a macrophage (Mφ) to engulf another cell or microbe in a tissue maintains
homeostasis and potentially provides a first line of immune defense 1,2. However, within a
solid tumor, if a Mφ is to physically engulf a cancer cell, then phagocytic forces3 must
exceed the mechanical strength of the cohesion between solid tumor cells 4. A large
imbalance of such cell-cell interactions in mixtures of diverse tissue cell systems has long
been seen to drive phase separation 5, but segregation of immune cells is understudied.
Clusters of Mφ’s in tumor nests have been reported to correlate with patient survival for at
least two solid tumor types6,7, and Mφ aggregation in the contexts of tissue injury has been
compared to platelet clots8 that suggests a collective mechanical mechanism. On the other
hand, tumor-associated Mφ’s more typically correlate with poor clinical prognoses 9, and
such Mφ’s not only promote growth and invasion in some cancers10 but also often lack
phagocytic function11.
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Phagocytosis of ‘self’ cells is generally inhibited by a key Mφ checkpoint interaction
between SIRPα on the Mφ and CD47 on all cells including cancer cells 11–13. Tumor cell
engulfment can nonetheless be driven by anti-tumor monoclonal antibodies (mAb) that
bind Fc-receptors on Mφ’s14, (e.g. anti-CD20 in lymphoma). Importantly, more of these
patients benefit when the mAb is combined with Ab-based blockade of CD4715. However,
response rates with similar combinations in solid tumors are significantly lower 16,17. Many
phagocytosis signaling pathways are well-studied for Mφ’s attached to a culture dish18–20,
but understanding of biophysical factors that influence phagocytosis in tumors is lacking.
We hypothesized that a high number of maximally phagocytic Mφ’s could somehow work
together – perhaps as clusters – to overcome both the cohesive forces and the
proliferation of solid tumors.
Further challenges for Mφ checkpoint blockade in solid tumors include low permeation of
anti-CD4721 relative to the potency of inhibitory signaling22,23 as well as on-target, off-tumor
binding of Ab’s to ubiquitously expressed CD47. Adoptive transfer of engineered Mφ’s that
traffic to tumors could potentially overcome both challenges to improve efficacy and safety
of checkpoint blockade, especially if dosing maximizes the number of phagocytic Mφ’s
and any cooperative effects. Unknown is whether these cells that constitute a first line of
immune defense in vivo but lack antigen specific immune receptors could also contribute
to any form of anti-cancer immunity24,25. Given the requirement for combination of
checkpoint disruption with tumor-opsonizing IgG mAb's, we hypothesized de novo
generation of anti-cancer IgG could be an effective form of acquired immunity. Our results
provide the first evidence for cooperative phagocytosis by Mφ's engulfing solid tumor
targets and for an immune memory from macrophage checkpoint blockade that includes
cancer-opsonizing IgG’s that drive Mφ clustering and tumor cell engulfment.

3.3 Results
3.3.1 Mφ’s cluster when eradicating tumoroids
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To determine the requirements for Mφ’s to eliminate a proliferating, cohesive mass of
cancer cells, we engineered ‘tumoroids’ of B16 mouse melanoma cells in non-adhesive
culture plates (Figure 3.1A). This widely used tumor for cancer immunotherapy
development does not respond in vivo to T cell checkpoint blockade nor to CD47
disruption26 (and therefore represents a large number of patients thus far unresponsive to
immunotherapy27). B16 cells adhere to each other and grow as thin dark tumoroids with
irregular borders (Extended Data Figure 3.1A), akin to early-stage melanoma in the upper
layer of human skin28. Tumoroids resist deformation as a single cohesive mass when
pulled into a micropipette (Figure 3.1B), with a softness consistent with other neurolineage tissues such as brain that also relies for cohesion more on cell-cell adhesion than
matrix adhesion.29 Sustainable stresses of ~0.5-1 kPa are much higher than those exerted
by a Mφ engulfing a microparticle3, but tumoroids flow after a few minutes as the stress
favors disruption of adhesions – thus illustrating a means by which added Mφ's can over
time extract B16s from the tumoroid. Such viscoelastic behavior is typical of cultureaggregated spheroids, including cell mixtures that sort based on differential adhesion and
cortical tension30,31. Indeed, disrupting either Ca2+-dependent cell adhesions or actin
polymerization relaxed tumoroids as evidenced by a rapid (< 1 h) increase in projected
area (Extended Data Figure 3.1B). Subcutaneous tumors of B16s from mice exhibit similar
softness (Extended Data Figure 3.1C-F), despite the presence of various other cell types
including Mφ's.
We hypothesized that cancer phagocytosis could be maximized for targets lacking CD47,
and we therefore generated tumoroids from CRISPR/Cas9-engineered B16 cells with
either Cd47 knockout (KO) or wild-type (WT) levels of CD47 (Extended Data Figure 3.2A).
Bone marrow-derived Mφ’s were added to pre-assembled tumoroids together with antiTyrp1 mAb that binds and opsonizes B16 cells (Extended Figure 3.2A-B). Tyrp1 aids in
melanin granule synthesis, so that anti-Tyrp1 is relatively specific to melanocytes in
contrast to the ubiquitous phagocytosis checkpoint ligand CD47 (Extended Data Figure
3.2C). Despite the specificity, anti-Tyrp1 was recently found ineffective in the clinic against
melanoma32 and shows little to no effect on B16 tumors established in mice 26. Growth of
WT tumoroids is likewise unaffected by anti-Tyrp1 with or without added Mφ’s, but we do
find opsonization of CD47 KO ‘immuno-tumoroids’ maximizes phagocytic Mφ’s quantified
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~1-day after addition (Figure 3.1C) (Extended Data Figure 3.2D). Conventional assays
with cancer cell suspensions added to immobilized Mφ for 1-2 h show similar phagocytosis
trends (Extended Data Figure 3.2E) – all of which suggests Mφ’s in tumoroids can extract
and engulf individual B16s, as clearly visualized for opsonized CD47 KO’s (Figure 3.1Di). Importantly, only for this maximal phagocytosis condition is the exponential growth of
the tumoroid reversed and tumoroids eradicated (Figure 3.1D-ii) (Extended Data Figure
3.3A).

3.3.2 Mφ’s cooperatively phagocytose targets
Surprisingly, Mφ’s segregate under maximal phagocytosis conditions (Fig 1D-i). Such a
cluster will have few Mφ’s next to cancer cells and will physically impede interactions with
cancer cells compared to the dispersed Mφ’s under the other conditions. Despite the Mφ
clustering, adding more Mφ’s suppresses growth and fits the calculus of cell proliferation
suppressed on a stoichiometric basis by n phagocytes (Figure 3.1E) (Extended Data Fig.
3B). The rate constant keff exhibits a Hill slope n = -1.8 for KOs that indicates cooperative
phagocytosis as a function of Mφ number (Extended Data Figure 3.3C, D). WT tumoroids
could be eliminated by high concentrations of anti-CD47 + anti-Tyrp1 plus high Mφ
numbers, and tumoroid area again indicated cooperativity as a function of added Mφ’s
(Figure 3.1F-i) but not as a function of anti-CD47 (Figure 3.1F-ii and Extended Data Figure
3.3D-E). High dose anti-CD47 blockade can be difficult to achieve clinically given the low
permeation of solid tumors4, and the results also underscore a cell-level cooperativity that
reflects a cell-level structure such as a Mφ cluster. Indeed, although anti-CD47 + antiTyrp1 enhanced engulfment of WT B16 suspensions in standard 2D phagocytosis assays
relative to controls, high-density regions of the immobilized Mφ’s showed fewer phagocytic
Mφ’s than low-density regions – contrary to cooperativity (Extended Data Figure 3.3F).
Tumoroid cohesion might be needed for Mφ cooperativity, with Mφ clusters providing a
structural basis for this functional cooperativity – in a hypothetical “tug-of-war” on cohesive
tumoroids by Mφ's before successful phagocytosis of the targets (Figure 3.1G).
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To assess whether Mφ clustering consistently associates with tumoroid suppression, an
information entropy approach by Chaikin & coworkers 33 was applied to our many images
obtained under a wide range of time points and perturbations. Image files of clustered
Mφ’s are digitally compressed more than images of dispersed Mφ’s (i.e. more disordered)
(Figure 3.2A-i), and tumoroid area measurements at the same timepoint show the same
trend. Cell density profiles further show a central cluster of Mφ’s displaces B16 cells in
tumoroids only under maximum engulfment conditions (Figure 3.2A-ii), and kinetic studies
indicate clustering takes more than 3 h but is clear by 24 h (Figure 3.2A-i). Tumoroid
elimination and tight Mφ clusters are also promoted by pre-treating cultured Mφ’s with
interferon-γ (IFNγ) (Figure 3.2A-i), which increases Mφ surface receptors and results in a
low contractility mechanobiological state 11 consistent with soft tumoroid engulfment (e.g.
Myosin-II inhibition has no effect); interleukin-4 (IL-4) has the opposite effects and
disperses Mφ (Extended Data Figure 3.4). The Mφ priming approach notably avoids direct
cytokine effects on B16 growth34. Further studies show Mφ clusters are not sufficient for
efficient phagocytosis and tumoroid elimination, but the various analyses do indicate that:
when Mφ’s engulf maximally, they cluster.

3.3.3 Phagocytic Mφ numbers eliminate tumors
To assess whether conditions of maximum phagocytosis – including high numbers of Mφ
– are effective in vivo, CD47 KO tumors were established in mice (for 4 days) and then
given one intravenous (i.v.) injection of anti-Tyrp1 (Figure 3.2B-i). Mice were sacrificed 24
h later, and compared to control, the mAb caused 3-fold smaller tumors and 3-fold more
Mφ's (F4/80+ cells) in the tumor (Figure 3.2B-ii-iv). The remaining immune cells (CD45+,
F4/80-) did not differ between conditions. Mφ's also segregated within treated tumors and
co-localized with B16-produced melanin (Figure 3.2B-ii,v), which is consistent with
observations of tumoroids (Extended Data Figure 3.2F).
Longer duration experiments showed anti-Tyrp1 i.v. injections eliminated CD47 KO tumors
in ~40% of mice, whereas various control tumors, including untreated CD47 KO and both
treated or untreated WT tumors all showed the expected exponential growth (Figure 3.3A82

i,ii). The WT results are consistent with recent studies 26, and control IgG2a Ab or vehicle
injections also showed no effect (Extended Data Figure 3.5). To begin to assess the effect
of increased Mφ numbers, fresh bone marrow cells (with 5-10% monocytes (Mo.)/Mφ's)
were also i.v. injected together with anti-Tyrp1. The combination eliminated CD47 KO
tumors in ~80% of mice (Figure 3.3A-ii).
Given that WT tumors are unaffected by i.v. injections of anti-CD47 and anti-Tyrp1, we
hypothesized that we could eliminate WT tumors by adding i.v. injections of marrow
engineered by addition of anti-SIRPα to block CD47 interactions (A’PB cells in Figure
3.3B). This strategy enabled high levels of phagocytosis of WT B16s and eliminated
tumoroids in vitro at high Mφ:B16 ratios (Figure 3.3C-i, Extended Data Figure 3.6A), and
even in vivo without anti-CD47 we found WT cures in ~10% of mice (Extended Data Figure
3.6B) – which increased to ~17% with anti-CD47 injections and to ~38% with a subsequent
second i.v. injection of the marrow (Figure 3.3C-ii) (Extended Data Figure 3.6B). RNAsequencing of such marrow Mφ’s isolated from tumors have been found to exhibit markers
consistent with phagocytic activity11. To confirm Mφ’s are the effector cells and potentially
improve upon Ab-based blockade with additional genetic engineering approaches, we
deleted the SIRPα gene in conditionally immortalized Mφ (CIM) progenitors that retain
Mo./Mφ differentiation ability and phenotypes35,36(Extended Data Figure 3.7). These
engineered Mφ’s also phagocytosed target WT B16s highly with anti-Tyrp1 opsonization
in vitro (Figure 3.3D-i). Tumor-bearing mice i.v. injected with these cells and with antiTyrp1 (but no added anti-CD47) gave cures of WT tumors in ~60% of mice (Figure 3.3Dii). Thus, as we observed with the immuno-tumoroid results, a succinct summary of many
experiments shows that maximizing phagocytosis is necessary for tumor elimination and
high numbers of phagocytic Mφ maximize efficacy (Figure 3.3E, Extended Data Figure
3.6C).
Mφ’s and related phagocytic immune cells provide just a first line of defense with
possibilities of acquired immunity24,25. We therefore challenged surviving mice with a
second injection of CD47 KO cells 80 days after the initial challenge and again treated
with anti-Tyrp1 (a prime-boost strategy for an anti-cancer vaccine). From the initial cohort
of 40% (Figure 3.3A-ii), about 80% of the re-challenged mice survived (Figure 3.4A). Age83

matched naïve mice receiving their first challenge with or without treatment responded
similarly to the younger cohorts. A third challenge was left untreated (i.e. no anti-Tyrp1),
and 75% again resisted tumor growth, which indicates a durable immunological memory.
Whitening of the melanized fur was evident across all three challenges of treated mice in
the KO cohorts, consistent with an immune response against normal melanocytes that
occurs over time with anti-Tyrp1 as mediated by complement or Fc-receptors37. A second
model of B16s involving metastasis to lung with CD47 KO cells showed anti-Tyrp1
prolongs survival of naïve mice until all mice succumb with clinical symptoms (Figure
3.4B). Importantly, for mice cured of subcutaneous tumors, challenging with these
circulating tumor cells and then injecting anti-Tyrp1 allowed for long-term survival of ~35%
of mice.

3.3.4 Cured serum IgG drives tumor phagocytosis & Mφ clustering
Despite the importance of anti-Tyrp1 to initiate cures, this mAb was not used in a third
challenge of CD47 KO tumors cells that showed 75% of mice resisted the tumor (Figure
3.4A). We hypothesized therefore that acquired immune response is generated that might
also extend beyond Tyrp1. We thus knocked out Tyrp1 in the CD47 KO cells (double
knockout, DKO) and engrafted cured mice with DKO B16s, finding that without treatment,
50% of mice survived (Figure 3.4C-i,ii). Although this result provided initial evidence of
acquired immunity unrelated to Tyrp1, we tested the need for an acquired immune system
by assessing tumor growth in NSG mice that lack all adaptive immunity (no Ab’s or T, B,
or NK cells). Growth of B16 CD47 KO tumors proves similar in NSG mice to growth in C57
mice, and although i.v. injections of anti-Tyrp1 slow the growth of tumors in NSG mice, no
NSG mice were cured (Figure 3.4D) in contrast to the 40% of immunocompetent C57 mice
cured under the same conditions (Figure 3.3A-ii). Mφ's in NSG mice display Fc-receptors
for binding IgG11, and we have shown CD47-knockdown human tumors in NSG mice can
be suppressed with i.v. injections of anti-human mAbs. However, the lack of cures in the
previous study and again here with B16 tumors implicates a role for acquired immunity.
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Serum Ab from cured mice (‘convalescent’ serum) was used to immunoblot B16 lysates,
which revealed an increasing number of bands with progression of the cures and
challenges, in support of our hypothesis of immune responses against B16 antigens
beyond Tyrp1 (Figure 3.4E). To test whether such serum Ab’s are functional to promote
phagocytosis, we added serum from various mice to CD47 KO and DKO B16 cells and
then added this mixture to Mφ's in culture. Most convalescent sera increased phagocytosis
relative to naïve serum (Figure 3.5Ai-ii, Extended Data Figure 3.8B), with similar results
for CD47 KO cells, B16 parental cells, and sub-clones as targets for phagocytosis as well
as for surface binding (Extended Data Figure 3.8A, C, D). As expected, anti-Tyrp1 does
not drive phagocytosis of DKO cells, and neither anti-Tyrp1 nor the serum from cures has
any effect on engulfment of YUMM2.1 melanoma cells that were also derived from C57
mice.38 YUMM2.1 cells generate tumors in mice previously cured of B16 tumors, even
when treated with SIRPα-blocked marrow Mφ’s (Extended Data Figure 3.8E). Cured
serum Ab’s thus target B16-specific antigens beyond Tyrp1 but not antigens expressed
by a syngeneic melanoma or xenogeneic antigens present on cultured cell lines (e.g.,
bovine antigens from media containing fetal bovine serum). Assays of IgG subclasses
confirm the presence of pro-phagocytic IgG2a/c and IgG2b 39 that bind CD47 KO cells and
DKO cells after second and third challenges (Figure 3.5B), with other IgG subtypes also
detected (Extended Data Figure 3.9A-C). Further consistent with a progressive primeboost vaccination and antigenic spread beyond Tyrp1, survivors of the third B16 challenge
(with no anti-Tyrp1 mAb injected) showed higher levels of IgG2a/c compared to nonsurvivors. To test the function of this serum in vivo, CD47 KO B16s were opsonized with
the serum just prior to subcutaneous implantation in naïve mice (Figure 3.5C). Tumor
growth was suppressed by days 11 and 13 similar to anti-Tyrp1 and relative to controls.
However, because any pre-bound IgG will be diluted by B16 proliferation or else lost by
dissociation, we assessed complete elimination of tumor cells by convalescent serum with
tumoroids.
Convalescent serum IgG added to CD47 KOs tumoroids eliminated tumoroids for the most
potent samples (Figure 3.5D-i). Importantly, serum activity against tumoroids correlated
with Mφ clustering at day 2 similar to anti-Tyrp1 (Figure 3.5D-ii), consistent with effects of
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anti-Tyrp1 mAb (Figure 3.2A). Serum alone had no effect (Extended Data Figure 3.9D),
indicating Mφ's are the effector cells for the anti-B16 serum IgG.

3.4 Discussion
Mφ immunotherapy of solid tumors benefits from (1) Mφ number and cooperativity (Figure
3.6), in addition to (2) tumor opsonization with anti-cancer IgG that activates Fc receptors,
and (3) inhibition of the Mφ checkpoint SIRPα that binds CD47. Maximizing all three
factors can cure immunocompetent mice of established syngeneic B16 tumors and initiate
de novo anti-tumor IgG in a vaccine-like response to mAb therapy. There is already
precedent for anti-RBC IgG being induced with CD47 depletion in mouse 40, but this
phenomenon is otherwise understudied. The most promising clinical application of CD47SIRPα blockade to date combines anti-CD47 (magrolimab) and anti-CD20 (rituximab)
against a liquid tumor, non-Hodgkin’s lymphoma15, but B cell depletion by this clinical
treatment limits the capacity of patients to develop any anti-tumor IgG as described here,
which thus prevents a phagocytic feedback.
Anti-cancer IgG have been isolated from cancer patients, including anti-(human Tyrp1)
from a melanoma patient41,42, but a mAb that targets Tyrp1 is not sufficient on its own for
clinical efficacy against melanoma 32. Our analysis of the human metastatic melanoma
cohort in TCGA reveals that high TYRP1 expression is associated with worse survival
than low TYRP1, independent of prior treatment of patients (Extended Data Figure 3.10)
and indicates that TYRP1 remains targetable even in aggressive human melanomas. Low
CD47 expression in the same patients also shows worse survival than high CD47, despite
opposite trends for some other cancers 12,43. Low CD47 can nonetheless be protective as
demonstrated by the failure of Mφ's to eliminate tumoroids at anti-CD47 concentrations <
100 nM (Figure 3.1F-ii).
The important but under-appreciated role for the number and cooperativity of phagocytic
Mφ’s in solid tumors does not contradict the frequent observation that Mφ's are abundant
and provide a poor prognosis in human primary and metastatic tumors including
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melanoma44. Tumor-associated Mφ’s are generally not phagocytic45, although phagocytic
Mφ aggregates have been reported in thyroid cancer and associate with decreased risk
of metastasis46. Moreover, the negative correlation between Mφ abundance and survival
in follicular lymphoma patients receiving chemotherapy was abrogated and potentially
even reversed in patients receiving rituximab and chemotherapy combination 47,48.
Therefore, the role of Mφ’s in tumor progression seems dependent on the physical state
of the Mφ’s and treatment status.
Considerations of the physical properties of the tumor microenvironment including its
immune cell residents4 are critical for success of immunotherapies that rely for efficacy on
(1) IgG permeation, including CD47-blocking mAbs and (2) immune cell infiltration and
segregation into phagocytic clusters. Our SIRPα-blocked monocytes/macrophages take
advantage of the ability of such cells to actively migrate and permeate through very tight
spaces11, overcoming limits of passive permeation. Complete knockout of SIRPα in CIM’s
improved responses beyond those achieved with antibody blockade on adoptively
transferred marrow cells. Further engineering of macrophages and new strategies might
also prove beneficial49,50. Regardless, durability against loss of epitopes, resistance, and
metastasis might thus result from the emergent phagocytic feedback.
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3.5 Materials and Methods
Cell culture
B16-F10 (CRL-6475) cells were obtained from American Type Culture Collection and
cultured at 37 °C, 5% CO2 in either RPMI-1640 (Gibco 11835-030) or Dulbecco’s Modified
Eagle Medium, (DMEM, Corning 10-013-CV) supplemented with 10% (v/v) fetal bovine
serum (FBS, Sigma F2442), 100 U/mL penicillin and 100 µg/mL streptomycin (1% P/S,
Gibco 15140122). B16 KO cell lines were generated as described previously 51 using single
guide RNA (sgRNA) constructs targeting CD47 (5’-TCCCCGTAGAGATTACAATG) and
Tyrp1 (5’- CTTGTGGCAATGACAAATTG) and cultured under the same conditions as the
parental wild-type B16-F10 cell line. YUMM2.1 cells were a gift from Dr. Chi Van Dang at
the Wistar Institute and were cultured under the same conditions in DMEM.

Antibodies
Antibodies used for in vivo treatment and blocking, in vitro phagocytosis, flow cytometry,
and Western blotting are as follows: anti-mouse/human Tyrp1 clone TA99 (BioXCell
BE0151), isotype IgG2a control clone C1.18.4 (BioXCell, BE0085), anti-mouse CD47
clone MIAP301 (BioXCell BE0270), isotype control rat IgG2a (BioXCell, BE0089), antimouse SIRPα clone P84 (BioLegend 144004), isotype control rat IgG1 (BioLegend,
400414). Low-endotoxin and preservative-free antibody preparations were used for in vivo
opsonization and blocking and in vitro phagocytosis experiments. The following
BioLegend antibodies were used for flow cytometry staining: Pacific Blue anti-Ly6C clone
HK1.4 (128013), PE anti-Ly6C clone HK1.4 (128007), PE anti-F4/80 clone BM8 (123109),
APC/Cy7 anti-F4/80 clone BM8 (123118), Brilliant Violet 605 anti-CD11c (117334),
PerCP/Cy5.5 anti-mouse CD45.2 clone 104 (109827), APC anti-mouse CD45.2 clone 104
(109814), PE/Cy7 anti-mouse/human CD11b clone M1/70 (101216), FITC anti-mouse
SIRPα clone P84 (144006), APC/Cy7 anti-mouse IgG1 clone RMG1-1 (406619), APC
anti-mouse IgG2a clone RBG2a-62 (407110), PE/Cy7 anti-mouse IgG2a clone RBG2a62 (407113), APC anti-mouse IgG2b clone RMG2b-1 (406711), PE/Cy7 anti-mouse IgG2b
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clone RMG2b-1 (406714), biotin anti-mouse IgG3 clone RMG3-1 (406803), PE
streptavidin (405203), Alexa Fluor (AF) 647 donkey anti-mouse IgG (ThermoFisher
A31571), AF647 goat anti-rat IgG (ThermoFisher A21247). Primary antibodies used in
Western blotting or immunofluorescence (IF) microscopy were anti-β-actin clone C4
(Santa Cruz sc 47778), mouse anti-lamin A/C clone 4C11 (Cell Signaling Technology
4777) rabbit anti-lamin B1 (Abcam ab16048), mouse anti-N-cadhein clone 13A9
(Biolegend 844701), and mouse anti-α-tubulin (Sigma T9026). Secondary antibodies used
in Western blotting and IF were HRP sheep anti-mouse IgG (GE Life Sciences NA931V),
goat anti-mouse IgG IRDye800CW (LiCoR 926-32210), AF488 donkey anti-mouse IgG
(ThermoFisher A21202), and AF647 donkey anti-rabbit IgG (ThermoFisher A31573).

Mice
C57BL/6J mice (Jackson Laboratory 000664) were 6-12 weeks old at the time of first
challenge unless otherwise specified. Age-matched mice were used as controls in
rechallenge experiments. NOD-scid IL2Rγnul (NSG) mice aged 6-12 weeks old were
obtained from the Stem Cell & Xenograft Core at the University of Pennsylvania. All
experiments were performed in accordance with protocols approved by the Institutional
Animal Care and Use Committee of the University of Pennsylvania.

Bone marrow-derived macrophages (BMDMs)
Bone marrow was harvested from donor mice, lysed with ACK buffer (Gibco A1049201)
to deplete red blood cells, and cultured on Petri dishes for 7 days in Iscove’s Modified
Dulbecco’s Medium (IMDM, Gibco 12440053) supplemented with 10% FBS, 1% P/S, and
20 ng/mL recombinant mouse macrophage colony-stimulating factor (M-CSF, BioLegend,
576406). Successful differentiation was confirmed by flow cytometry staining with
antibodies against macrophage markers. Cytokine-primed BMDMs were cultured in RPMI
growth media + 20 ng/mL M-CSF + 20 ng/mL IFNγ (BioLegend 575302) or 20 ng/mL IL-4
(BioLegend 574302) for 48 h prior to use in tumoroid assays or prior to analysis of protein
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expression

by

immunofluorescence

microscopy

or

flow

cytometry.

For

immunofluorescence microscopy, differentiated BMDMs were detached and re-plated on
bare glass coverslips at a density of ~5.5 x 103 per cm2 in RPMI growth media + 20 ng/mL
M-CSF. Cytokines were added 3 h later when cells were mostly attached to the glass.

Conditionally immortalized macrophage (CIM) progenitors
Macrophage progenitors were generated as previously described 35,36. CIMs were cultured
in suspension in 10 cm Petri dishes in RPMI-1640 (A1049101, ThermoFisher)
supplemented with 10% FBS and 1% P/S as above. Media was also supplemented with
43 µM β-estrogen (Sigma Aldrich, E2758-250MG) and 10 ng/mL recombinant mouse GMCSF (BioLegend, 576302). Cells were passaged every 2 days at sub-confluent
concentration of 1x10 5 cells/mL. To differentiate for phagocytosis assays, cells were
washed twice with 5% FBS/PBS to remove excess β-estrogen and plated in supplemented
DMEM (10% FBS/1%PS) with 20 ng/mL recombinant mouse M-CSF for 7 days.

In vitro phagocytosis
For 2D phagocytosis assays, BMDMs were detached and re-plated in 24 well plates at a
density of 1.8 x104 per cm2 in IMDM supplemented with 10% FBS, 1% P/S, and 20 ng/mL
M-CSF. The next day, BMDMs were labeled with 0.5 µM CellTracker Deep Red dye
(Invitrogen C34565) according to the manufacturer’s protocol. Following staining,
macrophages were washed and incubated in serum-free IMDM (i.e., IMDM supplemented
with 0.1% (w/v) bovine serum albumin and 1% P/S). In some experiments, target B16 cell
lines were labeled with carboxyfluorescein diacetate succinimidyl ester (Invitrogen
V12883) also according the manufacturer’s protocol. B16 were detached and opsonized
with 10-20 µg/mL anti-Tyrp1, with mouse IgG2a isotype control antibody, or with 5% (v/v)
mouse serum collected during the course of tumor challenge as described below in serumfree IMDM for 30 min on ice. For CD47 blockade experiments, 20 µg/mL MIAP301 or rat
IgG2a isotype control antibody was added during opsonization. Opsonized B16
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suspensions were added to BMDMs at a ~2:1 ratio and incubated at 37 °C, 5% CO2 for 2
h. Nonadherent cells were removed by washing with PBS and remaining cells were fixed
with 4% formaldehyde, counterstained with Hoechst 33342 (Invitrogen H3570), and
imaged on an Olympus IX inverted microscope with a 40x/0.6 NA or 20x/0.4 NA objective.
The Olympus IX microscope was equipped with a Prime sCMOS camera (Photometrics)
and a pE-300 LED illuminator (CoolLED) and was controlled with MicroManager software
v1.4 or v252.

Tumoroids
To generate surfaces conducive to B16 tumoroid formation, 96-well plates (Greiner BioOne 650161) were either coated with 70 µL of 2% agarose in water or PBS or treated for
20 min with 100 µL of anti-adherence rinsing solution (StemCell Technologies 07010).
The wells were washed with PBS, and then blocked with RPMI containing 0.5-1% bovine
serum albumin (BSA, Sigma) 37 °C for 1 h. B16 were detached by brief trypsinization,
resuspended in RPMI growth media (RPMI supplemented with 10% FBS, 1x non-essential
amino acid solution [Gibco 11140050], 1 mM sodium pyruvate [Gibco 11360070], and 50
µM β-mercaptoethanol [Gibco 21985023]) at a concentration of 1x10 3 or 1x104 per mL,
and added to passivated wells in a volume of 100 µL. A single aggregate of B16 cells
formed in each well within 12 h. For phagocytosis versus growth studies, CellTracker Deep
Red-labeled BMDMs and antibodies (final concentration 20 µg/mL anti-Tyrp1 and/or 20
µg/mL anti-CD47 or 10 µg/mL anti-SIRPα) or mouse serum (final concentration 1:200
convalescent or naïve) were added 24 h later in a volume of 20 µL RPMI growth media
with 120 ng/mL M-CSF. For myosin II inhibition studies, 20 µM blebbistatin (MilliporeSigma
203389) or an equal volume of DMSO vehicle was added to B16 tumoroids for 1 h prior
to addition of BMDMs. Tumoroids were imaged on the Olympus IX microscope with
10x/0.3 NA or 4x/0.13 NA objectives. Tumoroid areas were measured in ImageJ after
thresholding GFP fluorescence using MaxEntropy or Li algorithms and manually adjusting
the threshold as needed.
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For confocal imaging, clusters were fixed ~20 h after addition of BMDMs and antibodies
by adding an equal volume of 4% formaldehyde directly to the media in each well for 30
min at room temperature. Half of this solution was removed and replaced with an equal
volume of 2% formaldehyde for 30 min. The clusters were washed with PBS to remove
fixative repeating the procedure of removing and replacing half the volume at each step.
The clusters were transferred via a wide-bore pipette tip to an 8-well chambered
coverglass (Lab-Tek) and counterstained with 5 µg/mL Hoechst 33342 (Thermo).
Confocal images were acquired on a Leica TCS SP8 with a 20x/0.75 NA objective. Radial
fluorescence profiles were calculated in ImageJ by thresholding max intensity projections
of GFP and Deep Red fluorescence and calculating the tumoroid centroid, which was used
as the input for r = 0 in the Radial Profile ImageJ plugin applied individually to the GFP
and Deep Red channels. This plugin calculates the average fluorescence intensity I(r) for
a circle of radius r centered at the inputted position of the tumoroid centroid. I(r) values
were normalized by dividing by the total average fluorescence intensity ΣI(r) for all r.

Entropy image analysis
Fluorescence images of CellTracker Deep Red-labeled macrophages were converted to
binary images of black cells on a white background using the Otsu threshold algorithm in
ImageJ. The number of black pixels was determined from the image histogram, and the
image was saved as a PNG file, which is a form of lossless file compression to determine
the compressed file size as a measure of entropy. Random images were generated and
analyzed using the Python NumPy and Pillow packages, respectively.

Transcriptomic analysis
Public microarray data for BMDMs treated with IFNγ for 18 h versus control BMDMs
(GSE6029053) and for BMDMs treated with IL-4 for 24 h versus control BMDMs
(GSE6960754) were accessed and analyzed using the GEO2R interactive web tool
(https://www.ncbi.nlm.nih.gov/geo/geo2r/).

Differential
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expression

was

considered

significant for p < 0.05, where the adjusted p-values were computed by the default method
in GEO2R that uses the false discovery rate method of Benjamini and Hochberg.

Flow cytometry
Phagocytosis of B16 by macrophages in tumoroids was assessed by pooling identically
treated tumoroids from a single 96-well plate, disaggregating them to single cell
suspensions, and analyzing cell suspensions by flow cytometry. Tumoroids were collected
into FACS buffer (PBS plus 1% BSA and 0.1% sodium azide) ~18 h after addition of
BMDMs ± anti-Tyrp1, pelleted by centrifugation and resuspended in FACS buffer + 0.5
mM EDTA for 15-30 min at room temperature. The suspension was pipetted up and down
until the cells were deemed to be disaggregated by inspection on a hematocytometer.
Viable cells were distinguished by staining with Zombie aqua fixable viability dye
(BioLegend 423101) in PBS for 15 min at room temperature. The cells were washed with
FACS buffer, fixed with 4% formaldehyde for 15 min at room temperature, and stored at
4 °C until analysis. Flow cytometry was performed on a BD LSRII (Benton Dickinson) and
data were analyzed with FCS Express 7 software (De Novo Software). Doublets, cell
debris, and nonviable cells were excluded and GFP + DeepRed+ events were considered
to be phagocytic macrophages.
Bone marrow-derived macrophages (BMDMs) were differentiated and primed as
described above. Fc-receptors were blocked with rat anti-mouse CD16/32 (clone 2.4G2,
BD 553149) and rat anti-mouse CD16.2 (clone 9E9, BioLegend 149502) prior to staining
with macrophage marker antibodies.
For serum binding analyses, B16 or YUMM2.1 cells were detached by brief trypsinization,
washed, and resuspended in FACS buffer containing primary antibody or 5% (v/v) mouse
serum collected as described below. Cell suspensions were incubated at 4°C for 30 min
and agitated to prevent cell settling. Cells were washed three times with FACS buffer and
incubated with fluorophore-conjugated secondary antibodies in FACS buffer for 30 min at
4°C and later with PE-streptavidin if required to label biotinylated anti-mouse IgG3. Finally,
cells were washed three times and resuspended in FACS buffer containing 0.2 µg/mL
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DAPI (Cell Signaling Technology). For samples that could not be analyzed on the day of
staining and required fixation, cells were stained with Zombie aqua fixable viability dye in
PBS for 15 min at room temperature prior to staining with antibodies or serum, and DAPI
was omitted from the final fixed cell suspension. Those samples were fixed with FluoroFix
Buffer (Biolegend 422101) or 2-4% paraformaldehyde. For experiments analyzed in the
same plot, the same lots of primary and secondary antibodies and identical staining
conditions were used. When these analyses were performed on different days,
UltraRainbow calibration beads (Spherotech URCP-38-2K) were used to adjust the
photomultiplier tube voltage in each channel to maintain the median fluorescence intensity
of the brightest peak within a tolerance of ± 5%.

Tumor models
B16 and YUMM2.1 cell lines cultured in DMEM growth media were detached by brief
trypsinization, washed with PBS, and resuspended at 2x10 6 per mL in PBS. Cell
suspensions remained on ice until injection. Fur on the injection site (usually the right
flank) was wet slightly with a drop of 70% ethanol and brushed aside to visualize the skin.
A 100 µL bolus (containing 2x10 5 tumor cells) was injected beneath the skin. Treated mice
received i.v. injections of anti-Tyrp1 clone TA99 (250 µg antibody in 100 µl PBS) via the
lateral tail vein on days 4, 5, 7, 11, 13, and 15 post tumor cell inoculation. Where indicated,
mice also received i.v. injections of anti-CD47 clone MIAP301 (83 µg antibody in 100 µl
PBS dosed in the same volume as anti-Tyrp1). Tumors were monitored by palpation and
measured with digital calipers. The projected area was roughly elliptical and calculated as
A = π/4 x L x W where L is the length along the longest axis and W is the width measured
along the perpendicular axis. A projected area of 125 mm2 was considered to be terminal
tumor burden for survival analyses.

Serum collection
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Blood was drawn retro-orbitally and allowed to clot for 30-60 min at room temperature in
a microcentrifuge tube. The serum was separated from the clot by centrifugation at 1500
x g and stored at -20 °C for use in flow cytometry, phagocytosis assays, and Western
blotting.

Immune infiltrate analysis of tumors
For flow cytometry of immune cell markers in tumors, mice were treated with a single dose
of i.v. anti-Tyrp1 at day 4 (96 h) post inoculation and sacrificed 24 h later. Tumors were
photographed, then excised and placed into 5% FBS/PBS. Tumors were then
disaggregated with Dispase (Corning 354235) supplemented with 3 mg/mL Collagenase
Type IV (Gibco 17104019) and DNAseI (Sigma-Aldrich 10104159001) for 30 min at 37
°C, centrifuged for 5 min at 300 x g, and resuspended in 1 mL of ACK lysing buffer for 12
min at RT. Samples were centrifuged for 5 min at 300 x g, washed with FACS buffer, and
incubated in FACS 100 µl FACS buffer containing fluorophore-conjugated antibodies to
immune markers on ice for 30 min. Samples were then washed with FACS buffer and
fixed with FluoroFix Buffer for 30 min at RT prior to analysis on a flow cytometer.
For IF staining of tumor sections, mice were treated in the same manner. Whole tumors
were then excised, fixed in 4% paraformaldehyde overnight at 4 °C, and stored in 70%
ethanol. The Comparative Pathology Core (University of Pennsylvania) embedded the
tissues in paraffin, sectioned, and stained the tumor sections with anti-F4/80 according to
their standardized protocols. Sections were imaged on an Olympus microscope as
described above. Radial profile analysis was conducted with the Radial Profile Plot plugin
for ImageJ. Sectioning and trichrome staining of B16 tumors were performed by the
Molecular Pathology and Imaging Core (University of Pennsylvania). Tile scan images of
the trichrome-stained tumor section were acquired on the EVOS FL Auto Imager with a
10x/0.25 NA objective (Thermo Fisher).

Adoptive cell transfers
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Fresh bone marrow was harvested as above through the RBC lysis step. Marrow cells
were then counted on a hemocytometer and resuspended at 8x10 7 cells/mL in 5%
FBS/PBS. To block SIRPα, cells were then incubated with anti-SIRPα clone P84 (18
µg/mL) for 45 mins at room temperature on a rotator, centrifuged to remove unbound P84,
and re-suspended again at 8x107 cells/mL in 2% FBS/PBS with or without 2.5 mg/mL antiTyrp1 (TA99). Marrow cells (2x10 7 cells in 250 µl 2% FBS/PBS) were injected i.v. into
tumor-bearing mice 4 days after tumor engraftment. SIRPα KO CIM progenitors (4x106
cells in 250 µl 2% FBS/PBS with 2.5 µg/mL anti-Tyrp1) were injected i.v. in the same
manner. YUMM2.1 tumor-bearing mice received a single dose of 2x10 7 SIRPα-blocked
marrow cells i.v. on day 4.

Western blotting
Lysate was prepared from B16 CD47 KO cells using RIPA buffer containing 1x protease
inhibitor cocktail (Sigma P8340) and boiled in 1x NuPage LDS sample buffer (Invitrogen
NP0007) with 2.5% v/v β-mercaptoethanol. For detection of N-cadherin, B16 proteins
were fractionated by ultracentrifugation. Proteins were separated by electrophoresis in
NuPAGE 4-12% Bis-Tris gels run with 1x MOPS buffer (Invitrogen NP0323) and
transferred to an iBlot nitrocellulose membrane (Invitrogen IB301002). The membranes
were blocked with 5% nonfat milk in Tris buffered saline (TBS) plus Tween-20 (TBST) for
1 h and stained with primary antibodies or with 5% (v/v) mouse serum overnight at 4 °C
with agitation. The membranes were washed with TBST and incubated with 1:500
secondary antibody conjugated with horseradish peroxidase (HRP) or with 1:5000
secondary antibody conjugated with IRDye800CW in 5% milk in TBST for 1 h at room
temperature with agitation. The membranes were washed again three times with TBST,
then TBS. Membranes probed with HRP-conjugated secondary were developed with a
3,3’,5,5’-teramethylbenzidine (TMB) substrate (Genscript L0022V or Sigma T0565).
Developed membranes were scanned and analyzed with ImageJ (National Institutes of
Health). Membranes probed with IRDye800CW-conjugated secondary were imaged on
an Odyssey near-infrared scanner (LiCor).
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Pipette aspiration rheology
Tumoroids were formed in non-adhesive well-plates and transferred via wide-bore pipette
to a glass-bottom dish (Mattek). Fresh tumors were harvested and stored in RPMI + 10%
FBS. The tumor was held in a chamber consisting of glass coverslips separated by silicone
spacers on three sides and filled with RPMI + 10% FBS. For aspiration of the tumor
interior, the tumor was sliced with a scalpel or razor blade prior to placement in the
chamber. A glass capillary (1 mm outer diameter/0.75 mm inner diameter, World Precision
Instruments TW100-3) was pulled on a Browning/Flaming type pipette puller (Sutter
Instruments P-97), scored with a ceramic tile, and broken to obtain micropipettes with
diameters 40-100 µm. Only cleanly broken tips were used for aspiration. When required,
micropipettes were bent with a De Fonbrune microforge. The micropipette was backfilled
with 1% (w/v) bovine serum albumin (BSA) in PBS to prevent tissue adhesion and
connected to a dual-stage water manometer. Aspiration was applied manually with a
syringe (0.5-10 mL) and the pressure difference ΔP was measured with a calibrated
pressure transducer (Validyne). Time-lapse brightfield microscopy was performed on a
TE300 microscope (Nikon) with a 20x/0.5 NA objective and images acquired on an Evolve
Delata EMCCD camera (Photometrics) using MicroManager v1.4 software. Tissue
elongation L(t) was determined by image analysis with ImageJ and fit to the standard
linear solid model55 assuming a wall shape parameter Φ ~ 2. Tumor strain typically
reached a plateau value after several seconds that was maintained for the short timescale
of these experiments, allowing the elastic modulus to be approximated as E ~ ΔP (L/RP)-1
as described previously29. Tumoroid flow on longer timescales was modeled by including
a viscosity term in the standard linear model 31.

Statistical analysis and curve fitting
Statistical analyses and curve fitting were performed in Prism 8.4 (GraphPad) and
MATLAB R2020a (MathWorks). Details for each analysis are provided in figure legends.
Symbols indicating statistical significance are used as follows: ns p > 0.05, * p < 0.05, **
97

p < 0.01, *** p < 0.001, **** p < 0.0001. Tumoroid and tumor growth data (projected area
vs. time) were fit to the exponential growth model (A = A0 ekt for tumors and A = A1 ek(t-1)
for tumoroids) using nonlinear least squares regression with prefactors A0 or A1, and k, the
exponential growth rate. Outliers in samples of the fitted parameter k (≤1 per condition,
sample sizes ≥24) were identified by ROUT’s method (maximum false discovery rate, Q
= 1%) in Prism. Cleaned data were fit to mathematical models described in Extended Data
Fig. 3 for the dependence of k on macrophage number.
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3.11 Main Figures & Figure Legends

Figure 3.1 Macrophages (Mφ’s) cooperatively phagocytose IgG-opsonized cancer
cells in engineered tumoroids.
A Engineered ‘immuno-tumoroid’ model for phagocytosis of cohesive tumor cells.
Tumoroids were formed by culturing B16 melanoma cells on non-adhesive surfaces and
subsequent addition of bone marrow-derived Mφ’s with or without opsonizing anti-Tyrp1
IgG. The inset depicts a macrophage-melanoma tumoroid ‘phagocytic synapse’ with FcRIgG signaling that promotes phagocytosis and CD47:SIRPα that inhibits phagocytosis.
B Micropipette aspiration of B16 tumoroids at t = 0 and t = 10 min of constant stress
(aspiration pressure, ΔP). Tumoroid strain or creep is plotted vs. time and fit with a
standard linear model to determine the elastic moduli and viscosity. Scale bar: 50 µm.
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Forces on the order of 100 nN are predicted to be sustained by tumoroids without rupture
based on typical aspiration pressures.
C Phagocytosis of CD47 KO and WT B16 tumoroids ~18 h after addition of Mφ’s at a
nominal 1:1 Mφ:B16 ratio with or without anti-Tyrp1. The % phagocytic Mφ’s corresponds
to GFP+ Mφ’s in cell suspensions from disaggregated tumoroids (mean ± SD, n = 3 where
each replicate consists of cells pooled from the same 96-well plate). Statistical significance
was assessed by two-way ANOVA and Tukey’s multiple comparison test, * p < 0.05, ** p
< 0.01.
D Opsonization with anti-Tyrp1 limits the growth of CD47 KO ‘immuno-tumoroids’, but not
WT immuno-tumoroids.
(i) Representative fluorescence images depict growth or repression of CD47 KO (green)
in immuno-tumoroids from days 1-4 when untreated (top row) or treated with anti-Tyrp1
(bottom row). Mφ’s (magenta, ~1:1 ratio to initial B16 number) and anti-Tyrp1 were added
immediately after the day 1 images were acquired. Scale bar: 0.5 mm. Confocal z-slices
of CD47 immuno-tumoroids on day 2 clearly depict B16s engulfed by Mφ’s (white arrows
indicate engulfed cell).
(ii) Tumoroid growth was measured by calculating the projected GFP+ area at indicated
time points (mean ± SD, n = 6 tumoroids). Statistical significance was assessed by the
Mann-Whitney test (unpaired, two-tailed, * p < 0.05) comparing GFP+ areas with and
without anti-Tyrp1 at each time point. Solid lines are nonlinear regression of the data to a
simple exponential of the form A(t) = A1 exp[k(t-1)]. The doubling time τd or half-life τ1/2 was
calculated from the fitted rate constant k.
E A reaction-kinetic model accounts for division of cancer cells (A) in tumoroids and
phagocytosis by n macrophages (M). Exponential growth or decayof tumoroid area (fitted
curves) depends on the ratio of Mφ’s to B16 cells as well as CD47 on target cells (left)
(mean ± SEM, n = 6-8 tumoroids from a representative of four or more experiments). The
effective growth rate (keff) from fitted exponentials of CD47 KO tumoroids exhibits a Hilllike dependence on Mφ number (Hill parameter = -1.8, IC50 = 3.1, mean ± SEM, n ≥ 24
tumoroids from four independent experiments). A constrained fit of WT tumoroid growth
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with the same Hill parameter indicates much higher Mφ:B16 ratios are required for
tumoroid elimination (IC50 = ~15) (right).
F (i) Effective growth rates of WT tumoroids with anti-CD47 and anti-Tyrp1 also show Hilllike dependence on Mφ number (Hill parameter = -2.7, IC50 ratio = 2.3, mean ± SEM, n ≥
18 tumoroids across three independent experiments). The concentration of anti-CD47
(133nM) used is approximately saturating for CD47 on WT B16 as shown in Fig S2A-ii.
(ii) The effective growth rate of WT tumoroids at a fixed 3:1 Mφ:B16 ratio depends on the
concentration of anti-CD47, but tumoroid elimination is not cooperative with respect to
blocking Ab level (mean ± SEM, n ≥ 16 tumoroids across three independent experiments).
Statistically significant growth repression (keff < 0, one-sample t-test, # p < 0.05) is only
observed at the highest level of blocking (>100 nM anti-CD47 as used in Fig. F-i) that
exceeds by ~4-fold the measured affinity of blocking Ab for CD47 (K ~ 25 nM as shown in
Fig. S2A-ii).
G Proposed cooperative tug-of-war by maximally phagocytic Mφ’s to (i) disrupt target
cancer cell adhesions and subsequently (ii) phagocytose individual cells.
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Figure 3.2: Mφ’s infiltrate, cluster, and repress CD47-depleted syngeneic tumors
in vivo only in combination with therapeutic opsonization by IgG.
A Mφ clusters in tumoroids are consistent with cooperative phagocytosis.
(i) The informational entropy approximated by image file compression analysis
summarizes Mφ clustering within CD47 KO tumoroids across multiple experimental
conditions including anti-Tyrp1 opsonization, kinetic studies, Mφ-priming with interferon-γ
(IFNγ) or interleukin-4 (IL-4), and myosin-II inhibition with blebbistatin, as well as CD47
antibody blockade on WT tumoroids. Corresponding GFP+ tumoroid areas (normalized to
areas on day 1) are shown for the same conditions (mean ± SD, n = 6-8 tumoroids).
Statistical significance of entropy and tumor area differences were assessed by Welch’s
t-test (two-tailed, unpaired) for comparisons between two experimental conditions and
one-way ANOVA with Tukey’s multiple comparison test for the Mφ-priming experiment
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with three conditions. The representative thresholded Mφ images (top left) and
fluorescence images of B16 and Mφ (bottom left) are from CD47 KO tumoroids ~24 h after
addition of 3:1 Mφ:B16 without anti-Tyrp1 (yellow frames) and with anti-Tyrp1 (green
frames), which correspond to the first two bars in the graph. Scale bar: 100 µm.
(ii) Representative max intensity projections of confocal fluorescence images (top) of
CD47 KO (green) and Mφ (magenta) tumoroids one day after addition of Mφ with and
without anti-Tyrp1. Scale bar: 100 µm. Radial profiles (bottom) of Mφ and B16
fluorescence within CD47 KO tumoroids indicate Mφ clustering occurs only when
tumoroids are opsonized with anti-Typr1 (mean ± SD, n = 3).
B (i) Representative photographs of untreated and anti-Tyrp1-treated tumors prior to
disaggregation and analysis by flow cytometry (top). Scale bar: 1 mm. Tumor area as
measured on untreated or anti-Tyrp1-treated mice on day 5 post inoculation, 24 h after
treatment (bottom). ** p < 0.01 by unpaired t-test (n = 3 per group).
(ii) Representative fluorescence images of F4/80 staining in untreated or anti-Tyrp1treated CD47 KO tumors on day 5, 24 h after treatment. Scale bar: 0.5 mm
(iii) CD45 and F4/80 staining of isolated tumors 24 h after a single dose of anti-Tyrp1 on
day 4 after tumor engraftment. Anti-Tyrp1-treatment tumors showed increased infiltrate of
CD45+ cells as a fraction of total nucleated cells relative to untreated control, of which a
~2-fold larger fraction of CD45+ cells were also F4/80+. * p < 0.05 as measured by
unpaired t-test with Welch’s correction (n = 3 per group) and ** p < 0.01 by unpaired t-test.
(iv) Relationship between tumor area and F4/80+ Mφ immune infiltrate, fit with an
exponential curve. F4/80+ cell frequency correlates negatively with tumor area on day 5.
(v) Radial profile analysis of F4/80+ signal in CD47 KO tumors based on 4x images (n =
3 per group). F4/80+ cells infiltrate more highly into the core of anti-Tyrp1-treated tumors
and more highly overall, while control tumors show evenly distributed, lower overall F4/80+
infiltrate.
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Figure 3.3: Increasing macrophages boosts cure rates of CD47-depleted tumors;
engineered macrophages phagocytose cancer cells efficiently and clear WT
tumors in a density-dependent fashion.
A (i) Representative tumor growth curves of projected tumor area versus days after tumor
engraftment. Each symbol represents a separate tumor and is fit with an exponential
growth equation A = A0ekt (solid line). Complete responses in which a tumor was never
palpable are all depicted with the same symbol (filled circle) and solid lines at A = 0. For
KO + anti-Tyrp1, n = 15 across 2 independent experiments are shown; for B16 ctrl + antiTyrp1, n = 5.
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(ii) Survival curves of mice challenged with 2x10 5 WT or CD47 KO cells subcutaneously
(s.c.) and treated i.v. with 250 µg anti-Tyrp1 on days 4, 5, 7, 9, 11, 13, and 15 or left
untreated. Anti-Tyrp1 treatment has no effect on WT tumor survival (treated n = 5,
untreated n = 9), but can eliminate ~40% of CD47 KO tumors (treated n = 82, untreated n
= 60). Donor bone marrow injections combined with i.v. anti-Tyrp1 treatment (n = 11
across 2 independent experiments) increase the fraction of mice cured of CD47 KO
tumors by 2-fold. Significance was determined by the Log-rank (Mantel-Cox) test, * p <
0.05, **** p < 0.0001.
B Scheme of antibody-primed (with anti-Tyrp1, A’), Plus (P) SIRPα-blocked (by antiSIRPα, B) marrow Mo. (monocytes)/Mφ cells (A’PB, left). Conditionally immortalized
macrophage (CIM) progenitors were also used to generate SIRPα KO Mo./Mφ’s as an
improvement of Ab-based blockade. Cells were then injected intravenously into tumorbearing mice on day 4 (right) with indicated antibody i.v. injections on days 4, 5, 7, 9, 11,
13, and 15.
C (i) Phagocytosis of WT B16s by bone marrow-derived Mφ’s. Mφ’s with CD47-SIRPα
signaling disrupted (through anti-CD47 or anti-SIRPα (A’PB)) and target IgG opsonization
effectively engulf cancer cells in vitro. (** p < 0.01, n.s. not significant as measured by oneway ANOVA with Sidak’s test for multiple comparisons, n = 3 per condition)
(ii) Survival curves of WT tumor-bearing mice (non-KO guide ctrl B16) treated i.v. with
anti-CD47 and anti-Tyrp1 combined with either a one (1x) or two (2x) doses of A’PB. The
second A’PB dose was administered on day 7. Significance was determined by the Logrank (Mantel-Cox) test, * p < 0.05, ** p < 0.01 (untreated n = 22, anti-Tyrp1/anti-CD47 n =
6, anti-Tyrp1/anti-CD47/1x A’PB n = 6, anti-Tyrp1/anti-CD47/2x A’PB n = 8).
D (i) Phagocytosis of WT B16s by conditionally immortalized Mφ’s (CIMs). Unedited WT
CIMs (left) engulf opsonized target B16s similar to bone marrow-derived Mφ’s with CD47SIRPα disruption, while SIRPα KO CIMs also engulf target B16s highly with opsonization.
(*** p < 0.001, **** p < 0.0001 as measured by one-way ANOVA with Sidak’s test for
multiple comparisons, n = 3 per condition)
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(ii) Survival curves of WT tumor-bearing mice (parental B16) treated i.v. with anti-Tyrp1
combined with a single dose of SIRPα KO CIM progenitors on day 4 with indicated
antibody i.v. injections on days 4, 5, 7, 9, 11, 13, and 15. Significance was determined by
the Log-rank (Mantel-Cox) test, * p < 0.05 (n = 5 per group).
E Summary of tumor cure data showing that when CD47 is disrupted to maximize Mφ
engulfment, WT B16 tumors can be eradicated in a Mφ number-dependent fashion. High
Mφ transfer counts and permanent ablation of CD47-SIRPα signaling in either engineered
Mφ’s or tumors results in the highest cure rate.
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Figure 3.4: Anti-tumor antibodies in durably cured mice suppress recurrence &
spread beyond the therapeutically targeted antigen, Tyrp1.
A Treatment scheme of B16 tumors with i.v. tail-vein injections of anti-Tyrp1 (top). Survival
curves (bottom) of mice challenged s.c. with 2x10 5 CD47 KO B16 cells and treated with
250 µg anti-Tyrp1 i.v. (n = 82, from Figure 2C-ii) on days 4, 5, 7, 9, 11, 13, and 15 after
engraftment or left untreated (n = 60). Surviving mice challenged with CD47 KO a 2 nd time
and treated with the same anti-Tyrp1 regimen survive at a rate 2.3-fold higher than agematched naïve mice (n = 17 across 4 independent experiments) while 75% of mice
challenged a 3rd time survive without further treatment (n = 12 per group across 3
independent experiments). Significance was determined by the Log-rank (Mantel-Cox)
test, **** p < 0.0001.
B Survival curves of mice bearing experimentally-induced CD47 KO B16 lung metastases.
Anti-Tyrp1 delays survival but fails to cure mice (n = 11 across 2 independent experiments)
unless previously cured of subcutaneous KO tumors (n = 11 across 2 independent
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experiments). Untreated lung metastasis-bearing mice, n = 5. Significance was
determined by the Log-rank (Mantel-Cox) test, **** p < 0.0001
C (i) Flow histograms of Tyrp1, CD47 KO cells (double knockout, DKO) showing complete
depletion of therapeutically mAb-targeted B16 antigen.
(ii) Survival curves of DKO tumor-bearing mice that had previously survived CD47 KO
B16 challenge (+ anti-Tyrp1). 50% of mice survive (n = 4) without additional treatment,
while naïve mice challenged with CD47 KO tumors fail to survive (n = 3). Significance was
determined by the Log-rank (Mantel-Cox) test, * p < 0.05.
D Treatment scheme (top) and survival curves (bottom) of NSG mice engrafted with CD47
KO tumors and treated with anti-Tyrp1 i.v. (n = 5) on days 4, 5, 7, 9 11, 13, and 15 or left
untreated (n = 5). Anti-Tyrp1 treatment modestly delayed tumor progression but failed to
induce cures. Significance was determined by the Log-rank (Mantel-Cox) test, * p < 0.05.
E Anti-B16 IgG emerges after tumor challenge and subsequent re-challenge. Western
blotting of CD47 KO B16 lysate with serum as primary probe followed by anti-mouse IgG
[H+L] secondary staining shows binding to proteins beyond Tyrp1 that increases in the 2 nd
tumor challenge.
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Figure 3.5: Convalescent serum IgG drives B16-specific phagocytosis and
clustering in tumoroids, and suppresses tumor initiation in vivo
A (i) Experimental scheme of phagocytosis assay with serum-opsonized DKO B16s or
wild-type YUMM2.1s. Convalescent serum collected from mice during and after tumor
challenge contains polyclonal anti-B16 that bind and functionally opsonize cells
(ii) Phagocytosis of serum-opsonized CD47 KO B16s, DKO B16s, or wild-type
YUMM2.1s. Convalescent serum IgG from cured mice opsonizes B16s and drives
phagocytosis even when Tyrp1 is deleted, but does not do so against syngeneic YUMM2.1
cells that share a C57 antigen repertoire. ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns not
significant, as measured by one-way ANOVA with Sidak’s test for multiple comparisons
(opsonization conditions: n = 9 convalescent sera each, n = 3 naïve sera, n = 6 anti-Tyrp1
(B16), n = 3 anti-Tyrp1 (YUMM2.1), n = 6 unopsonized).
B Kinetic profiles of anti-B16 IgG levels in convalescent sera across the three tumor
challenges or in naive sera. Binding of IgG2a/c and IgG2b to CD47 KO (filled symbols)
or DKO (open symbols) was measured with subclass-specific secondary antibodies and
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is reported as the median fluorescence intensity (mean ± SEM, n = 4 survivors, n = 3 nonsurvivors, n = 5 naive).
C (i) Schematic of pre-opsonization with serum or anti-Tyrp1 prior to tumor induction.
Convalescent sera are incubated with CD47 KO B16 just prior to s.c. flank injection.
(ii) Tumor growth curves at early timepoints where growth is still in the linear regime.
Linear fits show significant growth suppression by CD47 KO B16 cells pre-opsonized with
either anti-Tyrp1, convalescent serum, isotype IgG2a, or lacking opsonization (ctrl
opsonization n = 9, serum or anti-Tyrp1 opsonization n = 5 per group). * p < 0.05 by twotailed unpaired t-test with Welch’s correction after F test to compare variances.
D (i) Convalescent sera repress KO tumoroid growth and drive Mφ clustering.
Convalescent serum or anti-Tyrp1 can eliminate tumoroids within days whereas naïve
serum or isotype control Ab do not. Solid lines are nonlinear regression of the data to a
simple exponential of the form A(t) = A1 exp[keff(t-1)] (mean ± SEM, n = 3 or 4 tumoroids
per sample for 9 convalescent and 9 naïve sera).
(ii) Entropy measured by image file compression (Fig. 2A) correlated (r = 0.71, p < 0.001)
with the effective growth rate. For simplicity, data are shown for convalescent sera that
produced high (circles), medium (squares), and low (diamonds) entropy clusters (and low,
medium, and high growth repression, respectively) and for a representative naïve serum
sample (n = 3 or 4 tumoroids per serum or Ab condition). Representative fluorescence
images depict high and low entropy Mφ’s, respectively, in tumoroids on day 2, ~24 h after
addition of Mφ’s and naïve (top) or convalescent serum (bottom). Scale bar: 100 µm.
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Figure 3.6: Phagocytic feedback in tumor elimination by cooperative
macrophages.
Proposed mechanism for anti-tumor clearance by macrophages. Phase separating
macrophages cooperatively disrupt tumor cell adhesions and engulf cells when CD47
signaling is disrupted deeply and cancer cells are opsonized with IgG, to maximize
engulfment. Macrophages initiate cell clearance that ultimately leads to the production of
de novo endogenous anti-tumor IgG that provide phagocytic feedback to strengthen the
‘eat me’ signal and enable durable tumor clearance.
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3.12 Extended Data Figures & Legends

Extended Data Figure 3.1: Characterization of B16 tumoroids and subcutaneous
tumors.
A Brightfield and confocal microscopy of B16 tumoroids. (left) Brightfield image of a B16
tumoroid three days after 1000 cells were seeded atop an agarose gel. Large tumoroids
typically have irregular borders and appear dark due to melanin pigments. Scale bar: 0.5
mm. (right) Confocal max intensity projections (xy, xz planes) of a B16 tumoroid GFP
(green) and Hoechst nuclear stain (blue). The tumoroid was fixed ~24 h after 100 cells
were seeded in the non-adhesive well. Scale bar: 100 µm.
B Tumoroid cohesion depends on Ca2+. (i) Transcriptomic analysis of cultured B16 cells
(GSE1621051) indicates N-cadherin and cadherin-19 are possible Ca2+-dependent cellcell adhesion molecules. (ii) Immunoblotting of B16 lysate fractions confirms N-cadherin
protein expression in the membrane fraction and expected lamin-A/C and tubulin
119

distribution in the nuclear and cytoplasmic fractions, respectively. (iii) Treatment of B16
tumoroids with 2 mM EDTA results in a rapid (<1 h) increase in tumoroid projected area
versus untreated tumoroids (n = 7-8 tumoroids, center line, median; box limits, upper and
lower quartiles; whiskers, entire range). Statistical significance was assessed by Welch’s
t-test (unpaired, two-tailed, **** p < 0.0001). Scale bar: 200 µm.
C Tumoroid cohesion depends on the actin cytoskeleton. Treatment of B16 tumoroids with
1 µM Latrunculin A results in a rapid (<1 h) increase in tumoroid projected area versus
treatment with DMSO vehicle (n = 7-8 tumoroids, center line, median; box limits, upper
and lower quartiles; whiskers, entire range). Statistical significance was assessed by
Welch’s t-test (unpaired, two-tailed, ** p < 0.01, **** p < 0.0001). Scale bar: 200 µm.
D Photographs of subcutaneous B16 tumors in mice dissected on day 4, 8, or 12 after
subcutaneous (s.c.) tumor injection. Day 4 tumors were typically elongated compared to
more spherical day 8 and day 12 tumors. Elongation was often observed in the direction
in which the needle was inserted during subcutaneous injection of the cell suspension
(left). Tumor area calculated in ImageJ is reported beneath each photograph. Scale bars:
10 mm (left) and 5 mm (right).
E Trichrome-stained B16 tumor section. The tumor interior (region 1, inset scale bar: 50
µm) is cellular (maroon-stained cytoplasm and blacked-stained nuclei) with some
necrosis. The tumor periphery contains blue-stained ECM fibers (region 2, inset scale bar:
100 µm) and large, round fat droplets. Scale bar: 1 mm.
F Interior regions of tumors typically exhibit large deformation L at low ΔP (top left) while
peripheral regions of tumors typically exhibit small L and require higher ΔP for measurable
deformations (top right). Images depict the extension of tumor into the pipette after 90 s
of aspiration at the indicated ΔP. Scale bar: 50 µm. Tissue strain (L(t)/RP) versus time is
plotted for the constant aspiration pressure creep phase (0-90 s) and after the pressure
was released back to ΔP = 0 for a representative interior region of a tumor. The profile is
typical of a viscoelastic solid and the deformation was recoverable when the pressure was
released. The black line depicts nonlinear regression of L(t)/RP to the standard linear solid
model, which includes the elastic modulus E (as t → ∞) as a fitted parameter. Elastic
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moduli (E) from interior and peripheral regions of an early-stage (day 4) tumor were
calculated from the plateau in the strain vs. time plot. Each symbol represents a separate
aspiration-release measurement. The symbol colors correspond to three different tumors
(15-30 measurements per tumor, center line, median; box limits, upper and lower
quartiles; whiskers, entire range).
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Extended Data Figure 3.2: Analysis of CD47 and Tyrp1 expression and
phagocytosis of B16 tumoroids and cell suspensions.
A Flow cytometry analysis of CD47 and Tyrp1 expression on B16 cell lines. (i)
Representative histograms of anti-CD47 (left) and anti-Tyrp1 (right) binding to CD47 KO
(top) and WT (bottom) B16 cell lines, which were detected with secondary antibodies
conjugated with Alexa Fluor 647. The populations shown in the histograms were gated on
live, single cells using forward/side scatter and DAPI staining. (ii) Median fluorescence
intensity calculated for CD47 KO and WT cells incubated with varying concentrations of
anti-CD47 or anti-Tyrp1 followed by secondary antibody (n = 3 tests per antibody
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concentration, mean ± SD). The data were fit to a hyperbolic binding model of the form y
= A*x/(K+x), which is shown as a solid line.
B Tyrp1 protein expression on B16 melanoma cells. (i) Immunofluorescence image of a
B16 cell surface-stained (fixed, unpermeabilized) with anti-Tyrp1 and anti-mouse IgG
Alexa Fluor 647 (green) and counterstained with Hoechst 33342 (blue). (ii) Brightfield
image of a B16 cell showing pigmented melanosomes. Scale bars: 25 µm (left) and 10 µm
(right).
C Protein expression data from The Human Protein Atlas for CD47 (left) and Tyrp1 (right)
across different normal tissues. CD47 is expressed in all tissues consistent with its role as
a ‘marker of self’. Tyrp1 expression is limited to skin, and specifically to melanocytes.
D Representative flow cytometry analysis of disaggregated tumoroids to measure
phagocytosis. (i) Flow cytometry events were gated on live, single cells using forward/side
scatter and Zombie aqua viability dye. Macrophages were gated based on CellTracker
Deep Red fluorescence. (ii) The % phagocytic macrophages reported in Fig. 1C is
calculated as the number of DeepRed +GFP+ double positive events divided by all
DeepRed+ events multiplied by 100.
E (i) Conventional 2D phagocytosis of WT and CD47 KO B16 cell lines by primary mouse
bone marrow-derived macrophages (BMDMs). (ii) B16 cells (green) were incubated with
opsonizing anti-Tyrp1 or IgG2a isotype control antibody and added to adherent BMDMs
(magenta). Yellow arrows denote phagocytic events, with some BMDMs engulfing multiple
KO cells. Scale bar: 25 µm. (iii) The phagocytic index is calculated as the percentage of
macrophages engulfing a target cell multiplied by the number of engulfed cells per
macrophage (mean ± SD, n = 3 wells). Statistical significance was assessed by two-way
ANOVA and Tukey’s multiple comparison test (* p < 0.05, *** p < 0.001).
F Phagocytic macrophages in tumoroids co-localize with melanin pigments, which is most
easily visualized as a dark shadow in the GFP channel. The signal intensity in this region
is below background light intensity, consistent with light absorbance by pigments. Scale
bar: 100 µm.
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Extended Data Figure 3.3: Modeling cooperative tumoroid phagocytosis and noncooperative phagocytosis in the conventional 2D assay.
A Tumoroid growth is unaffected by anti-Tyrp1 added on day 1 without macrophages,
indicating that anti-Tyrp1 has no direct cytotoxicity and that macrophages are required to
mediate its effects (mean ± SD, n = 6 tumoroids).
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B (i) Macrophages do not significantly repress or eliminate CD47 KO or WT tumoroids in
the absence of anti-Tyrp1 at any Mφ:B16 ratio tested (mean ± SEM, n = 6-8 tumoroids in
a representative experiment).
(ii) The effective growth is greater than 0 and shows little dependence on the Mφ:B16 ratio
for unopsonized tumoroids (mean ± SEM, n ≥ 24 tumoroids across the four independent
experiments shown in Fig 1E).
C Comparison of mathematical models for phagocytosis of tumoroids.
(i) Workflow for fitting keff from tumoroid area (A) growth or decay curves (Fig 1E) and
subsequent model fitting of keff vs. macrophage number (M). Four models (models A-D)
were considered including (model A) a Hill-like sigmoidal response on M, (model B) linear
dependence on M, (model C) a power law dependence on M, and (model D) a sigmoidal
dependence on the number of M.
(ii) The fits of models B-D were compared one-by-one to model A using Akaike’s
Information Criteria (AIC) to determine whether the four-parameter Hill-like model A is
justified rather than comparatively simpler models with two or three parameters. The
comparisons are summarized in the tables and the model fits to keff vs. Mφ:B16 ratio data
(Fig. 1E) are plotted beneath.
D (i) Growth curves for WT tumoroids treated with anti-CD47 and/or anti-Tyrp1 that
correspond to the plot of keff vs Mφ:B16 ratio in Fig 1F-i.
(ii) The fits of models A and D were compared using Akaike’s Information Criteria (AIC).
The comparison is summarized in the tables and the fits are plotted beneath.
E Representative max intensity projection of confocal images of a WT tumoroid one day
after addition of macrophages, anti-Tyrp1, and anti-CD47. Scale bar 100 µm. The
expansion depicts multiple macrophages that have engulfed B16 (denoted by white
arrowheads).
F Conventional 2D phagocytosis assay with adherent macrophages and single-cell
suspensions of WT or CD47 KO B16 cells opsonized with anti-Tyrp1 and treated with
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either anti-CD47 or rIgG2a isotype control antibody (mean ± SD, n = 3 wells per condition)
Statistical significance was assessed by two-way ANOVA and Tukey’s multiple
comparison test. Across all four conditions (2 cell lines x 2 blocking conditions), the
number of macrophages per field of view (FOV) is plotted against the phagocytic index
calculated for that FOV, revealing a weak negative correlation (Pearson’s r = -0.32, p =
0.01)
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Extended Data Figure 3.4: Effects of cytokine priming or the myosin-II inhibitor
blebbistatin on tumoroid growth suppression and macrophage clustering.
A Tumoroid growth or repression following addition of macrophages primed with either 20
ng/mL IFNγ or 20 ng/mL IL-4 for 48 h with (left) or without (right) anti-Tyrp1. (mean ± SEM,
n = 7-8 tumoroids). Statistical significance for each time point was assessed by one-way
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ANOVA and Dunnett’s multiple comparison test between unprimed and IFNγ-primed (##
p < 0.01) or IL-4-primed macrophages (* p < 0.05, ** p < 0.01).
B Transcriptomic microarray analyses of BMDMs treated with IFNγ or IL-4 versus
untreated BMDMs (GSE602902, GSE696073). The heat map depicts log2(fold change) for
selected genes. Proteins encoded by differentially expressed genes are depicted in the
schematic detailing a putative cytoskeleton and nuclear mechanosensing pathway and
membrane receptors involved in phagocytosis and macrophage adhesion. Statistical
significance was assessed by computing an adjusted p-value by the method of Benjamini
and Hochberg (* p < 0.05).
C Measurements of protein expression of selected differentially expressed genes in
BMDMs treated with IFNγ or IL-4 for 48 h. (i) The ratio of lamin-A to lamin-B and the
projected nuclear area were quantified by immunofluorescence microscopy (n > 140 cells
per condition across 8 fields of view). Statistical significance was assessed by one-way
ANOVA followed by Tukey’s multiple comparison test. (ii) Surface expression of MHCII in
IFNγ- or IL-4-treated or untreated BMDMs was measured by flow cytometry. Similar
staining was also performed with antibodies against CD206, CD47, and SIRPα. (iii) The
fold

change

(cytokine-primed

vs.

untreated)

of

indicated

proteins

from

immunofluorescence microscopy and flow cytometry experiments is plotted against the
fold change in gene expression from microarrays.
D Entropy analysis for (i) cytokine-primed and (ii) blebbistatin-treated macrophages
cultured on non-adhesive surfaces at a density of 1000 cells per well (mean ± SD, n = 8
wells). Statistical significance was assessed by one-way ANOVA followed by Tukey’s
multiple comparison test for cytokine priming and Welch’s t-test for blebbistatin treatment.
Cytokines (20 ng/mL) or blebbistatin (20 µM) were added after 6 h and images were
acquired after 48 h. Scale bars: 100 µm.
E Tumoroid growth repression by macrophages was not affected by addition of 20 µM
blebbistatin (mean ± SD, n = 3-4 tumoroids).
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Extended Data Figure 3.5: Isotype IgG2a control or vehicle injections have no
effect on growth relative to untreated CD47 KO B16 tumors.
Growth curves of mice bearing CD47 KO B16 tumors (2x10 5 s.c. flank injection) and
treated i.v. on days 4, 5, 7, 9, 11, 13, and 15 with 250 µg isotype IgG2a control (clone
C1.18.4), 100 µl PBS vehicle, or left untreated. Clone C1.18.4 is the isotype control
antibody for anti-Tyrp1 clone TA99. There are no significant growth differences (mean ±
SEM, n = 6 mice per group).
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Extended Data Figure 3.6: Fc Receptor-primed, SIRPα-blocked (A’PB) marrow
cells cure a fraction of mice bearing WT B16 tumors, while control marrow cells
cannot.
A A’PB macrophages in tumoroids can effectively repress growth at high macrophage:B16
ratios, while anti-SIRPα (B) and anti-Tyrp1 (A’) only conditions fail to control tumoroids.
B Survival curves of mice bearing WT B16-F10 tumors (parental line) and treated with
2x105 A’PB, A’ (Fc-receptor primed only, no SIRPα block), or B (no Fc-receptor priming,
only SIRPα block) marrow cells i.v. on day 4 after tumor engraftment relative to untreated
mice. A’PB and A’ conditions received additional 250 µg anti-Tyrp1 i.v. on days 5, 7, 9,
11, 13, and 15.
C (i) Summary of macrophage number versus therapeutic outcome for tumoroids in vitro
and tumors in vivo. Growth rate is controlled by tumor cell proliferation and macrophage
phagocytosis.
(ii) CD47 signaling dominates pro-phagocytic signaling at low and high macrophage
numbers, but CD47 depletion, IgG opsonization, and macrophage infiltration can
eliminate tumors.
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Extended Data Figure 3.7: Conditional immortalized macrophage (CIM)
progenitors are myeloid committed lineage cells that can be differentiated to
phagocytic macrophage phenotype.
A Schematic for production of CIMs and genetic KOs. CIMs self-renew under estrogen via
the ER-Hoxb8 fusion protein, which is virally transduced and allows for introduction of a
second lentivirus encoding guide RNA for CRISPR-Cas9 genetic KOs. Here, SIRPα is
knocked out to durably ablate CD47-SIRPα signaling in CIMs, which are infused
intravenously into tumor-bearing mice.
B CIM progenitors express myeloid-specific immune markers. Progenitors are GFP+ from
their source marrow from the Rosa26-Cas9 knock-in mouse on the C57BL6/J
background.4,5 Immune marker staining on freshly harvested bone marrow cells is shown
for comparison with lower F4/80 expression due to less lineage commitment compared to
CIM progenitors.
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C Flow histograms showing that SIRPα KO CIM progenitors are depleted of SIRPα relative
to unedited wild-type CIM progenitors.
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Extended Data Figure 3.8: Convalescent serum IgG from CD47 KO tumor cures
binds and opsonizes both CD47 KO and WT CD47 B16s.
A Representative fluorescent image (left) showing serum IgG-opsonized CD47 KO B16s
engulfed by BMDMs. Convalescent serum IgG opsonizes CD47 KO B16s for phagocytosis
by BMDMs as effectively or more highly than anti-Tyrp1 (right). Each serum symbol shape
represents a different mouse sample. Statistical significance was assessed by two-way
ANOVA and Tukey’s multiple comparison test between selected groups (** p < 0.01).
B Convalescent serum IgG from third challenge cured mice opsonizes CD47 KO B16s
and DKO B16s that lack Tyrp1 by BMDMs in 2D phagocytosis assays (same mouse serum
samples from 3D assays in Figure 4D). Statistical significance was assessed by two-way
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ANOVA and Tukey’s multiple comparison test between selected groups (** p < 0.01, *** p
< 0.001).
C Flow histograms of 4 (CD47 KO) third challenged (serum drawn 300 days after tumor
challenge) mice showing that IgG in convalescent serum from cured mice binds to WT
B16s. Anti-B16 IgG2a and IgG2b subclasses bind equivalently to or more highly than antiTyrp1.
D Serum IgG derived from CD47 KO tumor cures retains opsonization and functional
phagocytic ability against WT B16s. Statistical significance was assessed by two-way
ANOVA and Tukey’s multiple comparison test between selected groups (*** p < 0.001).
E Mice thrice cured of CD47 KO B16 tumors also grow YUMM2.1 tumors.
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Extended Data Figure 3.9: Convalescent serum IgG from CD47 KO tumor cures
shows subclass-specific binding to CD47 KO B16s and DKO B16s that lack Tyrp1,
and no binding of IgG1, IgG2a/c, and IgG2b to non-B16 YUMM2.1 cells.
A Flow cytometry analysis of serum IgG binding to B16 cell lines.
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(i) General gating strategy for flow cytometry analysis of IgG binding to B16 cell lines.
Doublet discrimination was performed with pulse height and pulse area parameters in the
forward and side scatter channels (S1 gate, FSC-H vs. FSC-A) and (S2 gate, SSC-H vs.
SSC-A). Cells were distinguished from debris as shown in the G1 gate in the SSC-A vs.
FSC-A plot). Dead cells were excluded from analyses by DAPI or Zombie aqua.
(ii) Representative flow cytometry histograms of KO (solid filled) and DKO (diagonal
hashed) cells incubated with 5% (v/v) serum collected from mice undergoing KO tumor
1st, 2nd, or 3rd challenge on days -1, 15, 30, 45, and 60 after tumor inoculation. Cells were
stained with a panel of monoclonal secondary antibodies specific for mouse IgG1,
IgG2a/c, IgG2b, and IgG3 or with a polyclonal secondary antibody recognizing heavy and
light chains [H+L] of all mouse IgG subclasses. Control samples were stained with either
secondary antibodies only or 10 µg/mL anti-Tyrp1. Binding of anti-Tyrp1 was detected
only with the IgG2a/c and polyclonal IgG [H+L] secondary antibodies.
B Kinetics of de novo IgG generation revealed by flow cytometry analysis of KO (filled
symbols) and DKO cells (open symbols) stained as described in A-ii with serum and with
secondary antibodies specific for mouse IgG1 and IgG3 (rows 1-2) or a polyclonal antimouse IgG [H+L] secondary antibody (row 3). The corresponding data for IgG2a/c and
IgG2b are shown in Fig. 4B. The median fluorescence intensity was corrected by
subtracting the background fluorescence equal to the signal of cells incubated with
secondary antibodies only. Symbols and error bars depict the mean ± SEM of each group.
Staining range with 10 µg/mL anti-Tyrp1 is denoted by the pink boxes or lines.
C Median fluorescence intensity of B16 WT or Yumm2.1 cells incubated with 5% (v/v)
serum collected from a mouse that survived the third challenge, with naïve serum, or with
anti-Tyrp1 followed by staining with a panel of monoclonal secondary antibodies specific
for mouse IgG1, IgG2a/c, IgG2b, and IgG3.
D Convalescent sera do not exhibit direct cytotoxic toward KO tumoroids and require
macrophages to suppress growth and eliminate tumoroids (Fig. 4D). Tumoroids treated
with convalescent serum, naïve serum, anti-Tyrp1, and IgG2a isotype control all grow
similarly. Solid lines are nonlinear regression of the data to a simple exponential of the
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form A(t) = A1 exp[keff(t-1)] (mean ± SEM, n = 3 or 4 tumoroids per sample for 9
convalescent and 9 naïve sera).
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Extended Data Figure 3.10: TCGA analysis of TYRP1 and CD47 in human
melanoma.
A Survival analysis of metastatic melanoma patients in The Cancer Genome Atlas (TCGA)
based on expression of TYRP1 (left) and CD47 (right) above or below the median.
Significance was determined by the Log-rank (Mantel-Cox) test.
B Expression levels of TYRP1 (left, p = 0.68, one-way ANOVA) and CD47 (right, p = 0.36)
were not dependent on treatment reported in TCGA.
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CHAPTER 4: MACROPHAGE CHECKPOINT BLOCKADE:
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4.1 Abstract
The macrophage checkpoint is an anti-phagocytic interaction between signal regulatory
protein alpha (SIRPα) on a macrophage and CD47 on all types of cells – ranging from
blood cells to cancer cells. This interaction has emerged over the last decade as a
potential co-target in cancer when combined with other anti-cancer agents, with antibodies
against CD47 and SIRPα currently in preclinical and clinical development for a variety of
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hematological and solid malignancies. Monotherapy with CD47 blockade is ineffective in
human clinical trials against many tumor types tested to date, except for rare cutaneous
and peripheral lymphomas. In contrast, pre-clinical results show efficacy in multiple
syngeneic mouse models of cancer, suggesting that many of these tumor models are
more immunogenic and likely artificial compared to human tumors. However, combination
therapies in humans of anti-CD47 with agents such as the anti-tumor antibody rituximab
do show efficacy against liquid tumors (lymphoma) and are promising. Here, we review
such trials as well as key interaction and structural features of CD47-SIRPα in order to
inform further potential therapeutic strategies.

4.2 Introduction
Cancer immunotherapy has rapidly expanded into the clinic over the past decade with
significant success for therapies that target functionally suppressed immune cells in tumor
microenvironments.1 T cells have been the primary focus of cancer immunotherapy with
immune checkpoint inhibitors developed to antagonize either CTLA-4 and PD-1 expressed
on T cell membrane proteins, or PD-1’s ligand, PDL-1, which is on the surface of many
cells including cancer cells.2,3 While this receptor-ligand interaction normally inhibits an
activated T cell, inhibiting this paired receptor interaction with blocking antibodies enables
suitably activated T cells to eliminate cancer cells. Dramatic and durable effects are seen
in some patients for some malignancies, with tumors having high mutational loads being
most likely to activate T cells, but most patients do not respond to this type of
immunotherapy, which presents a challenge and an opportunity. 4,5
Macrophages are part of the innate immune response, are often abundant in solid tumors,
and have a general ability to clear foreign cells through the activated process of
phagocytosis.6,7 Phagocytosis is modulated by a checkpoint interaction between the signal
regulatory protein alpha (SIRPα) on macrophages and the surface glycoprotein CD47
found on all cells.8,9 This review focuses on the structure of SIRPα and CD47, the role of
this checkpoint in macrophage function, and therapeutic antibody strategies that target the
SIRPα-CD47 interaction in cancer clinical trials. We also examine the sequence-structurefunction relationships of these paired receptors in efforts to stimulate new therapeutics.
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4.3 The ubiquitous ‘marker of self’ ligand, CD47
CD47 is an integral membrane glycoprotein that is expressed in all normal and diseased
tissues at the RNA and protein levels. This glycoprotein was first discovered as an
overexpressed ovarian carcinoma antigen (OA3). 10 It was also described as associating
with β-integrin proteins and thus named integrin associated protein (IAP).11 The protein
was found on the surface of erythrocytes (which lack integrins) through binding of two
different antibodies and was then designated CD47.12
CD47 belongs to the immunoglobulin superfamily (IgSF) with a single N-terminal
extracellular Ig-like domain, five transmembrane helices, and a C-terminal cytoplasmic
tail. Four cytoplasmic tails range in length from four amino acids (Type 1) to 34 amino
acids (Type 4), but the 16 amino acid tail isoform (Type 2) is the most abundant and is
expressed on the majority of cells in humans and mice.13
An X-ray crystal structure of CD47 reveals an IgV (variable) topology with α-helical as well
as β-sheet secondary structures and a conserved intramolecular disulfide bridge spanning
the middle of the β-sandwich.14 An additional disulfide bridge also forms between the
extracellular domain and one of the transmembrane domains, which is unusual for IgSF
proteins and some evidence suggests it orients the Ig domain for optimal receptor
binding.15 CD47 interacts primarily with three categories of extracellular receptors:
integrins, thrombospondin-1 (TSP-1) protein and SIRPα. Cell adhesion, cell migration, and
regulation of inflammation and phagocytosis are among the reported functions of receptor
interactions with CD47.16
CD47 was first termed a “marker of self” after CD47-deficient red blood cells (RBCs) from
a mouse knockout (C57BL/6 strain) were found to be rapidly cleared from the circulation
of wildtype mice by splenic macrophages.17 The in vitro evidence is compelling that the
CD47 interaction with SIRPα is a “don’t eat me” anti-phagocytic signal when occurring in
parallel with some types of “eat me” signal – most clearly with IgG bound to the phagocytic
target (Figure 4.1). In principle, the expression of CD47 allows all cells, including cancer
cells, to evade macrophage engulfment. Nonetheless, two mysteries continue to persist
since this seminal observation: (i) CD47-knockout mice do not exhibit anemia or any
evident RBC or platelet deficiencies, and (ii) the in vivo “eat me” signal on RBCs in CD47142

knockout mice remains unclear. Some might argue that the clearance cue is the
senescence signal that leads to RBC phagocytosis after circulating weeks (in mouse) or
months (in human), but CD47-knockout RBCs are all cleared within 1-2 days in the
circulation of the wildtype mouse implying that all CD47-knockout RBCs display the
senescence signal.

4.4 The macrophage immune receptor SIRPα
SIRPα is also an IgSF, integral membrane glycoprotein, and although it is expressed on
many if not all cell types, its expression on hematopoietic cells is restricted to myeloid
cells: macrophages, monocytes, dendritic cells, and granulocytes (and not T cells, etc.).18
SIRPα was first identified on rat fibroblasts as PTPNS1 (protein tyrosine phosphatase,
non-receptor type substrate 1) in association with the cytoplasmic tyrosine phosphatase
SHP-2 (Src homology region 2 domain containing phosphatase-2).19 SIRPα was later
found to be expressed on human myeloid cells,20 although expression can vary even within
subtypes of macrophages.21
SIRPα has three IgSF domains, one N-terminal V-like domain (domain-1, D1) and two C1like domains – which is a structure shared by a larger family of SIRPs. 22,23 One
transmembrane helix connects to cytoplasmic tails of varying lengths that govern signaling
in the SIRPs. SIRPα’s cytoplasmic tail has four tyrosine residues that conform to an
immunoreceptor tyrosine-based inhibitory motif (ITIM) which mediates association with
SHP-1 and SHP-2 for inhibitory signaling.19
Two closely related SIRP members are SIRPβ and SIRPγ. SIRPβ has a short cytoplasmic
tail (6 amino acids) and lacks phosphatase binding motifs suggesting it lacks inhibitory
activity. However, SIRPβ associates with DNAX activation protein 12 (DAP12) and can
transmit activating signals.24 SIRPγ has an even shorter cytoplasmic region (4 amino
acids) and is also unlikely to signal. Two uncharacterized members of the SIRP family are
SIRPβ2 and SIRPδ.1,22
The extracellular domains of the SIRP members share highly conserved sequence
homology with very subtle differences.22,23 X-ray crystal structures of D1 for each of
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SIRPα, SIRPβ, SIRPβ2, and SIRPγ closely resemble each other. 14 Additionally, SIRPα is
known to be highly polymorphic.25 Across 10 distinct human SIRPα alleles, 18 amino acids
have been identified as polymorphic residues, all located in the N-terminal IgV domain of
SIRPα.

While CD47 is the main extracellular ligand for SIRPα and might also weakly bind
SIRPγ,8,14,22 additional extracellular ligands that interact with SIRPα include surfactant
proteins A and D (Sp-A and Sp-D), found primarily in the lungs.26,27 Insulin secretion and
muscle formation are among some of the functions that somehow involve SIRPα. 28
However, the best characterized function of SIRPα is its role in inhibiting macrophage
phagocytosis upon binding CD47 on another cell.1,9,29

4.5 Binding of CD47-SIRPα and their other ligands
CD47 is the main ligand for SIRPα across mouse, rat and human, 29 but the interaction is
often weak with only sub-micromolar affinity8,30,31 – as summarized here for various CD47
and SIRPα ligands (Table 4.1). The single N-terminal IgV domain of CD47 interacts with
the D1 of SIRPα. The interaction between these paired receptors is species-specific to an
extent, with limited cross reactivity across species.30 The X-ray crystal structure of the
CD47-SIRPα complex reveals three distinct binding sites with the highest density of
interactions occurring between the β-strands comprising the FG loop of CD47 and a wide
binding pocket made up of SIRPα’s BC, C’D, DE and FG loops. 14 More than 50% of the
interfacial surface between the two proteins occurs at this site. Furthermore, about 45%
of CD47’s contact residues with SIRPα consist of the 8 amino acids that make up the loop
region between strands F and G. Their binding is mediated mainly by charge
complementarity (SIRPα mostly positive and CD47 mostly negative). The FG loop in CD47
is conserved across different species which may explain why human-CD47 binds to some
SIRPα polymorphs from different species – such as SIRPα in non-obese diabetic (NOD)
mice31 and also porcine SIRPα.32
Binding of CD47 to other ligands such as integrins, TSP-1 and TSP-1-derived peptides,
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also involves the IgV domain of CD47.16 While the precise regions of interaction with
integrins have not been determined, binding studies have shown that CD47 can activate
integrins in cis independently as well as while bound to TSP-1 derived peptides or
SIRPα,33-35 indicating that the binding site for integrins on CD47 is not occupied by either
protein. Binding of CD47 to TSP-1, however, inhibits the binding of SIRPα. This finding
was further demonstrated with a monoclonal anti-CD47 antibody, B6H12, that inhibited
binding of both ligands to CD47.36 Although these results suggest that TSP-1 and SIRPα
compete for overlapping binding sites on CD47, mutational and biochemical studies have
also revealed that post-translational modifications of a critical serine residue on CD47
away from the SIRPα binding site is required for TSP-1 binding.37
SIRPα also interacts with ligands other than CD47 such as Sp-A and Sp-D, respectively.
Sp-D has been shown to bind SIRPα in D3, rather than D1. 27 CD47 binding to SIRPα in
D1 is not impaired in the presence of Sp-D. Sp-A binds SIRPα; however, the binding site
is currently unknown. While the binding domain of SIRPα is highly polymorphic, there has
been controversy on whether the polymorphic residues affect CD47 binding. The crystal
structure reveals that the 18 polymorphic amino acids all lie outside of the CD47 interaction
interface,14,38 although this does not preclude an allosteric effect that is common in proteinprotein interactions. Indeed, CD47 affinity to the different SIRPα alleles seems to vary. 39
Separate data suggest SIRPα polymorphism alters post-translational modifications which
could also affect CD47 engagement.25

4.6 CD47-SIRPα as an immune checkpoint
Inhibitory immune signaling occurs upon CD47 binding, with phosphorylation of the ITIM
motifs in SIRPα that then recruit and activate the cytoplasmic phosphatases SHP-1 and
SHP-2.40-42 Downstream targets of dephosphorylation include paxillin and nonmuscle
myosin IIA, decreasing the efficiency of phagocytosis analogous to direct inhibition of
nonmuscle myosin IIA – at least for IgG-opsonized targets.43 Integrin mediated activation
also leads to the recruitment of the phosphatases and enhanced inhibitory
phosphorylation signals.44
When a target for phagocytosis is IgG opsonized, engulfment begins with the activation of
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Fc receptors (FcRs) on the surface of the phagocytic cell. This activation leads to the
formation of a “phagocytic synapse” with rapid cytoskeletal rearrangement and
accumulation of signaling proteins inside the macrophage at its point of contact with the
targeted cell, microbe, or particle. The three main events that occur at the synapse are
adhesion of the cell or particle with the phagocyte, pseudopod extension of the phagocyte
around the target and final internalization. 45 CD47 on the target does not eliminate
adhesion, but tends to impede the pseudopod formation and significantly suppresses the
internalization.
The initial description of elevated CD47 levels in ovarian cancer followed by the
characterization of its role in signaling “don’t eat me” to macrophages eventually inspired
investigation of CD47 as a therapeutic target in cancer – particularly because CD47 tends
to be modestly elevated in many hematologic and solid malignancies. 46-49 Many proof-ofprinciple applications have been developed to target the CD47-SIRPα immune checkpoint
including fully humanized anti-CD47 antibodies, anti-SIRPα antibodies, SIRPα-fusion IgG
proteins, among other protein and peptide antagonists. Table 4.2 summarizes these
antagonists and their in vitro applications against various types of cancer malignancies.
Early preclinical studies demonstrated the efficacy of anti-CD47 treatment of various
malignancies, with many of these indicating activity as a mono-therapy.46,49-51 Importantly,
however, anti-CD47 is an opsonizing IgG, and so it is difficult with monotherapy to identify
the results as (i) the pro-phagocytic effects of opsonizing a cancer cell – which is not novel
but potentially useful, and/or (ii) blocking the anti-phagocytic effects of the “don’t eat me”
signal – which is novel. Antibody-dependent phagocytosis activates the macrophage FcR,
which directs the macrophage towards the target. 52,53 Investigations with FcR-deficient
mice and with Fab blocking antibodies (lacking the Fc chain) has suggested the
mechanism of antibody-dependent macrophage phagocytosis differs depending on the
type of malignancy.54 For a few cancers, it seems sufficient to interrupt the CD47-SIRPα
interaction, but it is ineffective for many cancers, especially solid tumors.55,56
Macrophages also express CD47, and recent evidence suggests this interacts in cis with
SIRPα. As with the trans interaction, the cis interaction leads to relatively high
phosphorylation of SIRPα’s cytoplasmic tail and to relatively low levels of phagocytosis
compared to CD47-knockout macrophages.57 The potency of an anti-CD47 therapy might
thus reflect the cumulative effects of inhibiting trans interactions between a macrophage
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and a cancer cell as well as inhibiting passivating cis interactions on the same
macrophage.

4.7 Clinical targeting CD47-SIRPα in cancer
Decades ago, one anti-CD47 antibody was injected into ovarian cancer patients in order
to image the tumors; the study demonstrated some targetability but provided no insight
into therapeutic effects or safety issues.58 This of course pre-dates by a decade the
description in mouse of CD47 as a ‘Marker of Self’.17 Over the past decade, CD47 has
indeed emerged as a potential therapeutic target for macrophage checkpoint blockade in
clinical trials against cancer, with monoclonal antibodies being the primary antagonists.
Clinical trials up to Phase 2 have rapidly expanded in numbers, diversity of approach, and
targets studied.59-61 Key strategies and current results from trial reports and conference
proceedings are reviewed here (Table 4.3). A main conclusion is that monotherapy with
anti-CD47 shows little to no efficacy across multiple cancer types when administered
systemically, and while it often leads to rapid loss of a large fraction of blood cells
(consistent with rapid loss of CD47-knockout mouse blood cells upon infusion in normal
mice17), anti-CD47 can show efficacy in humans in combination therapies. In reviewing
the clinical trials (below) with this macrophage checkpoint blockade, it seems that some
efforts with anti-CD47 are based on the hope that human tumors would possess
macrophage activating activity that could be unleashed by simply preventing the inhibitory
signaling from CD47-SIRPα (i.e. a monotherapy). As noted earlier, T cell checkpoint
blockade (using antagonists of PD-1’s interaction with PD-L1) succeeds primarily against
human tumors with high mutational loads that tend to activate T cells via their T cell
receptor (TCR).4,5
Magrolimab, previously known as Hu5F9-G4, is the anti-human-CD47 monoclonal that is
most advanced in clinical trials. Two Phase 1 dose escalation trials have been completed
in acute myeloid leukemia (AML) and solid tumors. Magrolimab is a humanized
monoclonal IgG4 antibody that was engineered to not only block CD47 signaling but to
also minimize engagement of FcRs and thereby limit macrophage activation. 49 This is
because the IgG4’s Fc region has weaker affinity for FcRs compared to other IgG
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subtypes; Magrolimab is therefore more likely to work as an inhibitor and less as an
opsonizing antibody. On the other hand, CD47 expression on all cells in the body means
that there is a large sink for infused anti-CD47.
First reports of efficacy required a combination treatment of magrolimab and ritixumab
(anti-CD20) in relapsed/refractory (r/r) non-Hodgkin’s lymphoma (NHL) patients that were
refractory to rituximab alone.62 Phase 1b results showed 36% complete response rate
(CRR) and 50% objective response rate (ORR) for a small cohort of a few dozen patients.
Addition of the tumor-specific antibody to activate macrophage effector functions is a
growing trend in CD47 blockade trials, reflecting the need for pro-phagocytic cues (e.g.
antibody engagement of FcRs) in combination with blockade of ‘don’t eat me’ signals to
drive tumor regression. CD24 was recently proposed as another cell-surface ‘don’t eat
me’ signal and target, although in magrolimab-treated Phase 2 NHL patients, neither
CD24 nor CD47 showed prognostic value.63,64 In another combination Phase 1b trial with
the chemotherapeutic azacitidine, ongoing results reported 92% ORR in untreated higherrisk myelodysplastic syndrome (MDS) and 64% ORR in untreated AML patients. 65,66 A
tentative mechanism for this combination is that azacitidine results in surface display of
pro-phagocytic calreticulin (normally intracellular), which synergizes with CD47 blockade
in cancer cell phagocytosis.67 These latest data contributed to Forty-Seven, Inc’s multibillion dollar acquisition by the much larger firm, Gilead Sciences, announced in March
2020.
TTI-621 and TTI-622 are SIRPα-Fc fusion proteins in trials against hematologic and solid
malignancies.68-71 Both consist of the CD47-binding domain of human SIRPα fused to a
human Fc domain: IgG1 for TTI-621 and IgG4 for TTI-622. The IgG1 domain of TTI-621
contributes to its increased potency, at least in preclinical models.72 The TTI’s were
reported to have no affinity for human RBCs, but a re-analysis of TTI-621 data suggests
otherwise. Magrolimab (5F9) and BRIC126 clearly cause hemagglutination by antibodymediated cross-bridging,72 which is not observed with TTI-621 and other select anti-CD47
agents (Figure 4.2A). On the other hand, addition of ‘saturating concentrations’ (~1

M

based on hemagglutination results) to RBCs and then assayed for binding by flow
cytometry, TTI-621 (and also TTI-622) gives a signal well above several non-specific
antibodies albeit far below several anti-CD47 antibodies; the difference allows one to
estimate a weak sub- M affinity of TTI-621 for RBCs (Figure 4.2B). This is only slightly
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weaker than TTI-621 binding (with ~10 nM to ~1 µM affinities) to fresh white blood cells
and platelets as well as to primary hematopoietic tumor samples, and to various human
tumor cell lines (Figure 4.2C). Curiously, the effective concentrations (EC50) for
phagocytosis of the tumor cell lines was ~10-100 fold stronger (~nM) than the above
binding affinities, which perhaps relates to dominance of the Fc domain, and it is also
curious that RBC phagocytosis results have not been reported. Indeed, tight binding of
~10 nM does not predict efficient phagocytosis (Figure 4.2D). Although TTI-621 showed
some efficacy when administered intratumorally to patients with cutaneous T cell
lymphoma

(mycosis

fungoides),

intravenous

administration

showed

grade

3

thrombocytopenia in 18% of a varied cohort of leukemia, lymphoma, and other solid tumor
patients (25% overall showed some level of thrombocytopenia). It should be noted that
platelet measurements are much noisier than RBC counts, and confident measurements
of cytopenias/anemias also require measurements of any compensating production (e.g.
reticulocytes). Despite potential safety concerns, monotherapies with TTI-621 in B- and Tcell lymphomas produce 18-29% ORR at low doses (0.5 mg/kg) with dose escalation in
progress, which is unlike other anti-CD47 monotherapies under clinical study.73 TTI-622
is being studied in combination with other tumor-specific agents, including rituximab and
a PD-1 inhibitor to engage adaptive immune responses with continued claims of
preferential tumor cell phagocytosis and no RBC binding. 74 For a deeper understanding
of mechanism, future experiments should address RBC phagocytosis effects (i.e. EC50 in
vitro) as well as the effect of bivalent/multivalent protein/peptide binding and blocking of
SIRP

in the absence of a Fc domain.

CC-90002 is a humanized, high affinity (sub-nanomolar) monoclonal IgG4 CD47 antibody
in Phase 1 trials against advanced solid and hematologic malignancies in combination
with rituximab, with an earlier trial terminated due to discouraging safety profiles. In r/r
NHL patients of the combined trial, 13% showed a response rate with 25% showing stable
disease,75 but 50% showed anemia (of any grade) with 33% showing thrombocytopenia.
ALX 148 is a fusion protein that consists of the CD47 binding domains of SIRPα and a
fully inactive Fc domain.76,77 Notably, its molecular mass is 50% that of a typical antibody,
which may enable lower dosing (e.g. 10 mg/kg) to saturate CD47 targets. The most recent
reported data show that just 13.3% and 6.7% of patients (n = 30) show thrombocytopenia
and anemia, respectively, in a combination cohort with ALX148 and trastuzamab (anti149

HER2). Another cohort receiving ALX148 and pembrolizumab (anti-PD1) reported 7.7%
in both of the same measures.78 In a cohort for r/r NHL with rituximab, the maximum
tolerated dose was not reached, similar levels of anemia and thrombocytopenia were
shown, and ongoing preliminary ORRs varied from 31% to 50% depending on tumor type.
Safety concerns with anti-CD47 remain due to the lack of specificity in targeting a
ubiquitously expressed protein. Anemia and thrombocytopenia are widespread in patients
and only partially mitigated by priming and dosing strategies. 59 One fully human
monoclonal antibody, SRF231, caused blood toxicities at such low doses (12 mg/kg)
halting further expansion cohorts in its Phase 1 trial. 79 The addition of tumor-specific
agents alongside anti-CD47 may increase efficacy but does not necessarily address
safety issues, even in the case of bispecific or Fc-inactive antibodies.
Other current candidates in early trials have yet to report results as they monitor patient
safety and dosing profiles such as AO-176, a humanized monoclonal anti-CD47 IgG2
antibody, and HX009, an anti-PD-1/CD47 bispecific antibody.67 IBI-188 is a CD47 IgG4
monoclonal antibody under Phase 1 trials in the US and China against advanced
malignant tumors and lymphomas.80 TJC4 (also known as TJ011133) is another CD47
monoclonal antibody that recently entered Phase 1 trials in the US for solid tumors and
lymphoma in combination with pembrolizumab and rituximab. 81,82 Many other drugs are in
active preclinical development by startups and major pharmaceutical companies. The
expanding field of candidates indicates an exciting but potentially challenging time in the
development of CD47 therapeutics for cancer.
SIRPα is also a target for antibody blockade under preclinical and clinical study in efforts
to address the safety and efficacy concerns of early CD47 drugs, especially given CD47’s
ubiquitous expression.83 Several anti-SIRPα antibodies are in active development in
efforts to augment anti-tumor responses and overcome the significant off-target toxicities
with anti-CD47.84 BI 765063/OSE-172 is a monoclonal SIRPα antagonist in a Phase 1 trial
that dosed its first patient in June 2019 as a monotherapy and in combination with an antiPD-1 monoclonal antibody.85
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4.8 Sequence-function relationships for CD47-SIRPα
Understanding the residues in CD47 and SIRPα that are key to binding and function will
assist in developing new classes of checkpoint blocking proteins and peptides. Antibodies
used for blocking are extremely large, glycoprotein complexes with >1,000 amino acid
residues (~150 kDa). They also possess multiple disulfide bridges that require specialized
eukaryotic machinery to faithfully produce the numerous post-translational modifications.
For these reasons and more monoclonal antibodies with specificity for one protein such
as CD47 are costly to produce in large quantities even though Good Manufacturing
Practice for monoclonals is now a mainstay in biopharma. 86 Indeed, the average annual
cost to a patient for a monoclonal antibody treatment is about $100,000, which adds
greatly to the rapidly rising costs of drugs and healthcare.87,88
The co-crystal structure of CD47-SIRPα shows 13 residues in CD47 that contact 12
residues in SIRPα (polymorphic variants 1 and 2) through hydrogen bonding and salt
bridges.14,38 Cross-species interactions, such as between pig CD47 and human SIRPα 30
or between human CD47 and NOD mouse SIRPα,31 have a potential basis in some critical
contact residues based on sequence alignments (Figure 4.3A). Contact residues in human
CD47 are all conserved in pig CD47 except for Lys-6, which is an Ile in pig. From the
crystal structure, this residue is outside of the CD47 FG binding loop, and Lys is similar in
size to Ile, making it likely that contact is maintained. For similar reasons, monkey CD47
that shares the same contact residues as human CD47, and dog CD47 that shares the
same contact residues as pig CD47, should both bind human SIRPα. Mouse and rat CD47
have two non-conserved mutations at human residues Asp-46 and Glu-106, respectively.
Mutating Asp to a bulky Tyr residue should interfere with the FG loop in SIRPα and remove
an important H-bond. Replacing the negative Glu with a positively charged Lys eliminates
a critical salt bridge with Lys-53 in SIRPα’s binding pocket. Likewise, cow, sheep, and
chicken all have mutations at critical H-bonding sites, which explain the lack of binding to
human SIRPα.
The 12 contact residues in human SIRPα are conserved across its polymorph variants
that all bind human CD47.39 NOD-SIRPα reportedly binds human CD47 65-fold more
tightly than human SIRPα.31 Sequence analysis reveals conserved mutations with
SIRPαV1 except at residues Gln-52 and Lys-53 (Figure 4.3A). From crystal structure
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analysis, the H-bond formed via Lys-53 is potentially maintained with a Thr mutation found
in NOD-SIRPα, a possible explanation for the increased affinity may be due to the
increased hydrophobicity of the Q52F mutation. Phe-52 has the propensity to engage in
hydrophobic interactions with pyroGlu-1 in SIRPα which might compensate for the loss of
the noncritical H-bond. Variance in mouse SIRPα shows that Lys-53 is mutated to aliphatic
Ala, eliminating a critical H-bond with Glu-106 in CD47 and perhaps explaining the lack of
human CD47 binding. Moreover, two residues in mouse SIRPα (Ser-102 & Glu-103) are
absent in NOD-SIRPα and in human SIRPα, which suggests enhanced CD47 affinity for
NOD-SIRPα relative to other mouse SIRPα’s.
Interestingly, human CD47 binding to pig SIRPα inhibits phagocytosis, which indicates
that the sequence variance between pig and human SIRPα does not prevent signaling.32
Two contact residue changes between human and pig, Q52F, which is the same mutation
found in NOD mouse strains, and G97E, a nonconserved mutation that introduces a salt
bridge interaction with Lys37 in CD47 (Figure 4.3A). In NOD-SIRPα, the Q52F mutation
seemingly enhanced CD47 affinity suggesting the same may be true with pig SIRPα,
especially with the addition of a favorable H-bonding interaction at Gly97. However,
phagocytosis is inhibited by the interaction of NOD-SIRPα and human CD47, implying that
the sequence complementarity of the remaining contact residues, namely Lys53, between
the paired receptors is important for signaling regardless of species. When comparing this
to the 10 polymorphs of human SIRPα, which all bind human CD47, 25,38,39 the resultant
“don’t eat me” signal is dependent on which SIRPα variant CD47 interacts with, even
though both are from the same species.89 When comparing monkey and dog SIRPα
sequences, the contact residues are also conserved in the same manner as CD47
(monkey conserved with human sequence and dog conserved with pig sequence except
at Gly97). This becomes significant for preclinical safety and efficacy models and
modulating engraftment of human cells in other species.
Although both CD47 and SIRPα are glycosylated post-translationally, glycosylation is not
a requisite of CD47-SIRPα interaction, with amino acid residues driving the binding. 90,91
Monomeric, recombinant CD47 and SIRPα expressed in E. coli and lacking glycosylation
indeed disrupt the CD47-SIRPα interaction in vitro.92 Glycosylation of SIRPα and of CD47
may sometimes inhibit their binding93 but otherwise seem important for cis dimerization of
SIRPα on the surface of cells.94 An important post-translational modification, however, is
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the N-terminal modification of CD47 by glutaminyl-peptide cyclotransferase-like protein
(QPCTL) to produce pyroglutamate.95 This modification has been demonstrated to
contribute to SIRPα binding as well as signaling, although the earlier results with CD47
expressed in E. coli did not seem to account for this modification.92 Nonetheless, inhibiting
QPCTL enhanced antibody-mediated phagocytosis.95
Major advances have been made in engineering high affinity versions of CD47 and SIRPα
to function as immune checkpoint inhibitors. The most potent protein CD47 inhibitors
developed are FD6 and CV1, which inhibit SIRPα binding at, remarkably, picomolar
concentrations.55 Analysis of the sequence and contact points between wildtype SIRPα
and these engineered variants shows that three contact residues are mutated: K53R
(conserved), E54Q (non-conserved), and L66T (non-conserved compared to SIRPαV1
but conserved compared to V2). The remaining 9 mutations in FD6 (6 mutations in CV1)
appear to contribute to the stability of the engineered variants and add more hydrophobic
contacts with CD47. It is important to note that these engineered variants cross-react with
mouse CD47. Notably, an engineered CD47 variant, Velcro-CD47 N3612, potently
antagonized SIRPα with no changes made to the binding region. 96 Rather, a three amino
acid extension was added (Trp-Gln-Pro) to the N-terminus of CD47 and only a single point
mutation made on Gln-1 (pyroGlu) to a Pro residue. Adding additional N-terminus contact
residues between CD47 and SIRPαV1 and V2 effectively enhanced CD47 affinity to
nanomolar and picomolar concentrations for the SIRPα variants, respectively. A 21-amino
acid ‘Self’ peptide derived from the FG binding loop of CD47 was also shown to bind,
antagonize SIRPα, and inhibit phagocytosis, suggesting that binding and function primarily
converge to this sequence.39
Pan-allelic anti-SIRPα antibodies that interact with more than one polymorph and/or
species of SIRPα have also been engineered in order to overcome limitations that arise
in targeting various polymorphs of SIRPα. One study discovered various classes of panallelic antibodies against SIRPα variants that antagonized human, mouse and monkey
SIRPα.83 Interestingly, some of these anti-SIRPα antibodies promote phagocytosis without
physically blocking the SIRPα binding groove and inhibiting CD47 interaction – although
the mechanism remains unknown. A second study reports on ADU-1805, a humanized
pan-allelic anti-SIRPα antibody that interacts with SIRPα variants 1, 2 and 8. 97 ADU-1805
blocks CD47 binding to SIRPα and SIRPγ, and it does not bind to SIRPβ. Pan-allelic
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agents that bind all SIRPα variants as well as pan-allelic peptides and proteins have yet
to be discovered.

4.9 Structure-function relationship of the CD47-SIRPα axis
In addition to sequence analysis, crystal structures also assist in determining important
structural factors that lead to potent antagonism (Figure 4.3B). For the fully humanized
antibody magrolimab (Hu5F9-G4) that was made to block CD47,98 the crystal structure
reveals a magrolimab-CD47 binding complex like that of the SIRPα-CD47 complex
showing magrolimab competing for the same SIRPα binding site.99 Crystal structures of
the older monoclonal B6H12 as well as hybridoma (C47B161) and phage (C47B222)
derived monoclonal anti-CD47 antibodies also show that SIRPα is inhibited due to
competitive binding to the same CD47 FG loop binding site. 100 2D3 is a monoclonal antiCD47 antibody that binds CD47 but reportedly does not block the interaction with SIRPα
nor the inhibitory signal, indicating it interacts at a site away from the CD47 FG binding
loop.48
SIRPα directed antagonists likewise bind and block CD47 by competing for the ligand
binding groove in SIRPα (Figure 4.3C). KWAR23, an anti-SIRPα blocking antibody,
overlaps the same binding region as CD47, revealing a basis for competitive binding. 101
Most recently, a series of blocking and non-blocking anti-SIRPα antibodies have been
crystalized in complex with SIRPα.83 The blocking antibodies all compete for the same
binding site in SIRPα as CD47; however, one antibody epitope shares only a single
common residue with CD47 in the SIRPα binding groove, but is enough to displace CD47
engagement. These anti-SIRPα blocking and non-blocking antibodies, were potent to
different degrees in promoting phagocytosis of colon and esophageal carcinoma cells in
vitro. These effects were also observed with monoclonal anti-mouse SIRPα, P84, which
does not block CD47 binding, but rather inhibits SIRPα signaling by some other
mechanism to promote macrophage phagocytosis.102
When comparing the crystal structures of bound CD47 and SIRPα, respectively, there are
conserved contact residues in both proteins that interact with the bound ligand. In CD47,
Thr-102 is involved in binding with all the potent antagonists as seen in the crystal
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structures (Figure 4.3B). Likewise, Lys-96 in SIRPα is a conserved contact residue (Figure
4.3C). Considering which residues are conserved in terms of binding can assist in rational
design of protein, peptide, and small molecule inhibitors that are reminiscent of the binding
interface of either CD47 or SIRPα based on the overall fold and positioning of these
conserved contact residues.
It remains unclear whether CD47 binding to SIRPα leads to structural changes in the latter
that somehow promotes cytoplasmic signaling. SIRPα is mobile and accumulates at the
phagocytic synapse.43 Interestingly, “forcing” SIRPα into the phagocytic synapse in the
absence of CD47 also prevents engulfment of opsonized targets indicating the localization
of SIRPα in the synapse is sufficient for signaling “don’t eat me” to the macrophage.103
Accumulation of SIRPα to the synapse is thus driven by the presence of CD47 and
appears to be the main mechanism by which phagocytosis is inhibited.

4.10 Conclusions
A balance of activating and passivating signals in the immune system normally maintains
homeostasis but also allows cancer cells to evade clearance and spread. Immune
checkpoint blockade of the PD-1/PDL-1 axis on T cells has achieved some success
against some cancers as a monotherapy, but current understanding is that T cells in these
patients are being activated by an abundance of mutations that can stimulate only upon
checkpoint blockade. Although monotherapy against CD47-SIRPα seemed promising
based on multiple syngeneic mouse models of cancer that used cancer lines that were
known to be immunogenic, monotherapy also seemed unlikely based on minimally
immunogenic lines such as B16 melanoma in C57 mice. 56 In this model, even PD-1
blockade is relatively ineffective unless the B16 cells are made more immunogenic with
mutations that are also known to favor clinical responses to PD-1 blockade.4,5 Combination
therapies of CD47-SIRPα blockade with tumor-opsonizing antibodies that activate
macrophages through the FcR pathway are thus sensible and promising. They also have
the theoretical potential for antigenic spread within a patient, if engulfment of the cancer
cell by a macrophage or dendritic cell leads to patient-specific antibodies against tumor
mutations that otherwise remain hidden behind the macrophage checkpoint.
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4.14 Main Figures & Legends

Figure 4.1: Phagocytosis is maximized by inhibiting CD47 on ‘self’ cells (the
target) or SIRPα on macrophages in combination with antibodies that opsonize
the target.
CD47 binding to SIRPα signals “don’t eat me” to the macrophage (leftmost). Neither
antibody blockade of CD47-SIRPα nor antibody opsonization of a target is sufficient to
make target engulfment efficient (middle two), whereas the combination maximizes
phagocytosis (rightmost).
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Figure 4.2: Novel re-analysis of TTI-621 binding data from Ref 72.
A. Molecular partition function (ξ) fitting to the hemagglutination data. Schematic of
possible binding states of various CD47 affinity agents is shown for two apposed RBC
membranes. Magrolimab (5F9) and BRIC126 both exhibit high hemagglutination,
whereas TTI-621, B6H12, and 2D3 do not. K1 and K2 are association constants,
inversely related to dissociation constants or EC50.
B. TTI-621 shows non-zero binding to RBCs, which is weaker than anti-CD47 antibodies
but consistent with past reports of sub-µM affinity between CD47 and SIRPα39 Inset: same
data plotted with y-axis on log scale.
C. TTI-621 binding data show sub-µM affinity for white blood cells, primary tumor samples,
and human tumor cell lines. Phagocytosis of the human tumor lines requires less binding
for effective phagocytosis.
D. TTI-621 binding affinities do not predict phagocytic efficiency across various cancer cell
types. BR.C: breast cancer, AML: acute myeloid leukemia, BCL: B cell lymphoma, MM:
multiple myeloma, TCL: T cell lymphoma.
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Figure 4.3: Sequence alignment and crystal structures reveal constant contact
residues critical for cross-species reactivity and ligand binding for both CD47 and
SIRPα.
A. Sequence overlays of CD47 and SIRPα, respectively, reveal conserved residues
across different species. Green highlighted residues are conserved relative to human
172

wildtype sequence. Blue highlighted residues are non-conserved mutations relative to
human wildtype; however, maintain H-bonding. Red highlights are non-conserved
mutations. Porcine CD47 binds human SIRPα and this can be seen from the conservation
of most of the contact residues. Based on this, monkey CD47, which shares the same
contact residues as human CD47, and dog CD47, which shares the same contact residues
as pig CD47, should bind to human SIRPα. Likewise, when comparing SIRPα variants
across different species, the conservation of contact residues among the sequences of
NOD mice and pig SIRPα with human SIRPα provide some rationale as to why human
CD47 interacts with these variants. Based on this, human CD47 should interact with
monkey and dog SIRPα.
Crystal structures of various B) CD47 and C) SIRPα bound inhibitors. For all antibody
bound structures, only the first 100 residues in each of the heavy and light chains are
shown. CD47 and SIRPα contact residues in each complex are highlighted in red. Inset
tables list all contact residues in the respective receptors and how many times each
contact residue is involved in binding across the various complexes.
B) PDB codes 2JJS (CD47/SIRPαV2), 5IWL (CD47/magrolimab), 5TZ4 (CD47/B6H12),
4KJY (CD47/FD6), 5TZ2 (CD47/C47B222), and 5TZT (CD47/C47B161),
C)

PDB

codes

2JJS

(SIRPαV2/CD47),

6NMR

(SIRPαV1/CD47), and 6BIT (SIRPαV1/KWAR23).
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(SIRPαV1/FAB

119),

4CMM

Table 4.1: Known affinities of CD47-SIRPα ligands.
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Table 4.2 CD47-SIRPα immune checkpoint inhibitors used for in vitro
phagocytosis assays against cancer cells.
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Table 4.3 Therapeutic CD47-SIRPα antibodies currently being investigated in the
clinic (through April 2020).
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CHAPTER 5: SUMMARY, CHALLENGES, FUTURE DIRECTIONS

5.1 Summary
The CD47-SIRPα axis is a potent immune checkpoint between macrophages and healthy
‘self’ cells that cancer can co-opt for immune evasion and subsequent metastasis. Despite
emergence as an important clinical target for antibody-based cancer therapeutics, their
development was hindered by CD47’s intrinsic status as a ubiquitous marker of ‘self’.
Here, we have demonstrated the molecular requirements for efficacy of CD47-based
therapies in primary (Chapter 3) and metastatic solid tumors (Chapter 2) that are poorly
immunogenic and tough-to-treat. We showed that the efficacy of these molecular and
cellular therapies targeting this macrophage immune checkpoint requires complete
ablation and an activating, pro-phagocytic signal (e.g. IgG). Analyses of CD47-SIRPα
clinical challenges (Chapters 1 and 4) complemented structural analyses and led to “nanoSelf” peptide designs that showed some activity in vitro with the same tumor model and
caused no acute safety issues in vivo (Chapter 4). We also demonstrated a novel role for
cooperative phagocytosis by macrophages in these tumors and their role in linking innate
and adaptive immunity when macrophages are maximally phagocytic in vitro and in vivo
(Chapter 3). In support of these observations, we provide evidence that macrophages can
eliminate solid tumors in a density-dependent fashion, contrary to thinking in the field
where high macrophage numbers are considered poor for prognosis. Importantly, these
studies move the field forwards in our understanding of macrophage immune checkpoint
blockade for effective anti-cancer strategies and more broadly in oncology and
immunotherapy.

5.2 Challenges and Future Directions
Major challenges to successful immune checkpoint blockade in anti-cancer therapies
remain. Significant barriers include determining conditions (e.g. patient treatment history,
tumor and/or immune status, tumor type, co-morbidities, etc.) under which these
treatments are effective. Recent attention has been given to tumor mutational burden as
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a predictor of response to immune checkpoint blockade (e.g. in anti-PD1/PDL-1), but
complete responses remain low even when stratified by mutational burden. There also
exist considerable biophysical barriers for therapeutics and immune cells to overcome,
especially in solid tumors that require force sensing and generation by immune effectors
to successfully navigate.
Development of effective therapeutics for cancers utilizing CD47 checkpoint blockade
and/or macrophage as effectors will depend upon a deep understanding of the molecular
and

biophysical

mechanistic

underpinning

of

macrophage-tumor

interactions.

Macrophages are highly plastic and migratory cells present in all tissues of the bodies as
tissue-resident macrophages or as infiltrative monocytes produced from the bone marrow
into the bloodstream. They are thus exquisitely primed as effector cells against ‘foreign’,
including cancer, with appropriate spatiotemporal control of phenotypic behavior. It is
increasingly clear the M1-M2 macrophage paradigm is too simplistic to describe
macrophage states across time and tissue, and advances in experimental techniques and
big data -omics will enable a more complete understanding for application to engineered
nano- and cellular therapies.
Additionally, while we have shown macrophages are potent initial effectors in solid tumors,
their causal role and interaction with adaptive immune cells remains unclear. Humoral
immune responses help to feedback and continue providing strengthened tumor-specific
pro-phagocytic cues to macrophages, but long-term immunity almost certainly requires
the contributions of other immune cells, including CD8+ T cells. The intervening immune
interactions between innate immune clearance and durable long-term immunity in
macrophage checkpoint blockade specifically remain of deep interest. We are utilizing
cellular depletions and immunocompromised mouse models to elucidate these
interactions, especially at early times in the context of our adoptive macrophage cell
therapies (Chapter 2 and Chapter 3).
The CD47-SIRPα axis remains an attractive target in this space, as evidenced by the
recent high-profile acquisitions of companies and intellectual property by large,
established pharmaceutical companies (e.g. Forty-Seven, Inc. by Gilead Sciences and
Trillium Therapeutics, Inc. by Pfizer). However, given the challenges discussed above,
significant innovation is required to restrict off-tumor effects and translate to solid tumors
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and metastases. The linear and cyclic nano-Self peptides offer opportunity for such
efficacy in vivo, and intratumoral injections may overcome pharmacokinetic concerns with
the added potential to drive initiating humoral and other adaptive immune responses
beyond the primary tumor. Ongoing work in teratoma and tumor growth in NSG mice that
show evidence of genome instability additionally raises future interesting questions of how
CD47-SIRPα blockade works on evolving tumors with diverse structures (e.g. cysts).
One application of our work offers potential to overcome a long-standing problem in the
field of cancer therapeutics – the identification of tumor-specific antigens for targeted
therapies. Requirements for such targets include specificity to cancer cells (ideally, on the
surface for recognition by immune cells) and expression at null or low levels in normal
tissue. The humoral immune response (Chapter 4) provides evidence for a suite of tumorspecific antigens generated in a mouse model, which can then enable isolation of B cell
clones for identification of de novo tumor targets and, in one application, downstream
generation of therapeutic monoclonal antibodies.
The method can be generalized to any tumor type: 1) obtain engraftable tumor cells by
conventional or novel methods, 2) sufficiently block CD47 signaling either by genetic or
antibody-based methods AND provide a pro-phagocytic stimulus (e.g. monoclonal
antibody, chemotherapeutic, radioablation, convalescent serum transfer, etc.), and 3)
eliminate engrafted tumors and assay serum for tumor-specific IgG binding and activity.
The rate of elimination can be further potentiated by adoptive transfer of macrophages or
marrow to boost steps 2 and 3. We are currently working to show this generalizability
beyond melanoma in several solid tumor and tumoroid models (e.g. A549 lung carcinoma
cells, B6.MYC-CaP prostate cells, TC-1 lung epithelial cells, and CT-2A glioma cells).
Poorly immunogenic solid tumors represent the patients least likely to respond to
conventional immune checkpoint blockade and immunotherapies and are thus an
important, if difficult, step to overcome for translation and improved patient outcomes.
Given the current lack of good (highly expressed and tumor-specific), IgG-targetable
antigens, we are working to develop creative alternative approaches that include folatereceptor targeting and opsonization with allogeneic IgG, amongst others.
In addition to potential as a therapeutic modality, the CIM model also enables pathwayspecific interrogation of causal factors underlying macrophage phagocytosis and
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cooperativity in immunotherapies. We have identified LFA-1 and ICAM1 as possible
mediators of cooperative phagocytosis in the solid tumoroids and tumors (detailed in
Chapter 3), where KOs of these and related gene targets are ongoing.

5.3 Contributions and Team Science
The contents of this chapter include contributions of members of the Discher group past
and present, dissertation committee members, seminar speakers and audiences,
manuscript reviewers, and the entire scientific community – near, far, and across time.
Scientific progress does not happen in a vacuum, rather, it is an ever-evolving
collaborative and team-based process that seeks to answer questions about the workings
of the universe and apply that knowledge. This fact has never been not the case, but it is
increasingly important to highlight in a world that generates near-boundless data, ideas,
collaborations, and hours of intellectual and physical labor towards these collective goals.
It is imperative to enshrine in this dissertation that all of society’s greatest scientific
contributions are built on the exploited.
Specific figure-by-figure contributions and the underlying scientific development are
delineated in Appendix A.3.

180

APPENDIX
APPENDIX A.1: STRUCTURE-FUNCTION RELATIONSHIPS FOR
RATIONALE DESIGN OF CD47 THERAPEUTICS

A.1.0 Contributions and copyright
This appendix supports Chapter 4 and contains content and ideas published in Antibody
Therapeutics, ACS Nano, and ACS Bioconjugate Chemistry:
Jalil, A. R.*, Andrechak, J. C.* & Discher, D. E. Macrophage checkpoint blockade:
results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function.
Antib. Ther. 3, 80–94 (2020).
Jalil, A. R., Hayes, B. H., Andrechak, J. C. et al. Multivalent, Soluble Nano-Self Peptides
Increase Phagocytosis of Antibody-Opsonized Targets while Suppressing “ Self ”
Signaling. (2020). doi:10.1021/acsnano.0c05091
Jalil, A. R., Andrechak, J. C., Hayes, B. H., Chenoweth, D. M. & Discher, D. E. Human
CD47-Derived Cyclic Peptides Enhance Engulfment of mAb-Targeted Melanoma by
Primary Macrophages. Bioconjug. Chem. (2022). doi:10.1021/acs.bioconjchem.2c00020
AbdelAziz R. Jalil contributed significantly to this work through development of minimal
‘self' peptides and structure-function analyses in addition to significant contributions to
scientific discussion, manuscript writing and revisions, and experiments. Jason C.
Andrechak contributed significantly to scientific discussion, manuscript writing and
revisions, and related mouse safety studies and phagocytosis assays. Brandon H.
Hayes contributed significantly to scientific discussion, manuscript writing and revisions,
and phagocytosis assays. Dennis E. Discher and David M. Chenoweth contributed
significantly to ideas, scientific discussion, and analysis that underlie the work.
Specific figure-by-figure contributions are delineated in Appendix A.1.5.
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A.1.1 Abstract
Biologics, including antibodies, small molecules, and peptides, are attractive compounds
for pharmaceutical development due to their manufacturing ease, feature control,
formulation, and scalability. We had previously shown that a 21-mer peptide derived from
native CD47 displayed on viral particles could delay clearance by the immune system and
thus enable longer circulation times for delivery applications. Here, we demonstrate the
development of an 8-mer peptide derived from CD47 as a minimal ‘self’ peptide that
functions as a SIRPα antagonist, enhancing IgG-mediated opsonization and phagocytosis
of blood cells and cancer cells.

A.1.2 Design and implementation of minimal ‘self’ peptides
A.1.2.1 Design of minimal ‘self’ peptides
Based on our previous reports of a 21-mer ‘self’ peptide antagonizing the CD47-SIRPα
interaction, we hypothesized that a minimal, multivalent 8-mer version could achieve this
antagonism and prevent off-target blood cell clearance seen in anti-CD47 clinical trials.
We designed linear and cyclic variants of these nano-Self (nS) peptides with mutations at
critical residues to increase affinity through hydrophobicity and/or aromaticity (Figure
A.1.1). The Thr was mutated with hydrophobic Phe (nS-F) or Val (ns-V), while disulfide
bridges allowed for a cyclic variant to be generated. This central Thr interacts with CD47
and its antagonists in co-crystal structures1, while high-affinity SIRPα binding pocket
mutants had Phe insertions2. Flexible PEG linkers allowed for generation of bivalent nS
peptides.

A.1.2.2 Enhanced phagocytosis of melanoma cancer cells
These nS peptides can act as soluble agonists of macrophage phagocytosis when
combined with IgG-opsonized targets (Figure A.1.2). As proof-of-principle of their CD47
antagonism on red blood cells (RBCs) which are problematic in anti-CD47 clinical trials as
discussed throughout this work, macrophage phagocytosis assays were conducted with
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RBCs as targets. RBCs were opsonized with anti-RBC IgG and added to solutions of nS
peptide at varying concentrations7. B16F10 melanoma cells were similarly opsonized with
anti-Tyrp1 and added to nS peptide solutions. The linear nS-F, F-Cyc, and Cyc peptides
enhanced phagocytosis of target cells by macrophages nearly two-fold over the ‘maximal’
control of anti-CD47/IgG-opsonized conditions. There was also a distinct difference in
phagocytosis of WT B16F10 cells vs. SIRPα KO cells, indicating a role for increased
accessibility of CD47 by inhibition of both trans and cis interactions, which we had
previously shown3. Since these peptides lack an Fc domain unlike anti-CD47, they
efficiently block CD47-SIRPα but only drive eating when combined with a prophagocytic
signal.

A.1.2.3 Safety profile of minimal ‘self’ peptides
Phase 1 clinical trials for safety of anti-CD47 in patients have shown that infusion into the
bloodstream decreases RBC numbers (i.e. hematocrit) and increases reticulocytes (i.e.
new RBCs)4,5, and related blood safety concerns apply to a bivalent CD47-binding protein
made with SIRPα domains fused to a macrophage-binding domain (Fc domain)6. Given
that our nS-F peptide increases phagocytosis of opsonized RBCs and also associates
with mouse macrophages7, we assessed safety of the more potent nS-FF peptide by
intravenous injection into mice. Overall, nS-FF in PBS showed no differences versus PBS
vehicle control in its effects on mouse hematology and body weight after four daily tailvein injections of 1 mg/kg peptide (Figure A.1.3). This corresponds to about 8 µM in the
blood, assuming rapid mixing and no dilution within the ~1.5 mL blood volume of the
mouse. Withdrawal of ~140uL from this blood volume was necessary to obtain a complete
hematology profile, and such a volume is expected to cause slight decreases in hematocrit
and platelets as shown (Figure A.1.3-i, ii). Consistent with this loss, more RBCs should be
produced in each mouse to compensate for the RBC loss, and the ~30% increase in
reticulocytes after the first two blood draws over 11 days (Figure A.1.3-iii) is similar to the
prior amount of blood removed (~300 µl/1500 µl). The mice (~14 weeks) also continued
to gain weight at the same rates (~5% over 11 days) regardless of peptide injections.
These changes are thus expected but, importantly, unaffected by the nS-FF peptide,
which establishes some safety.
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A.1.4 Main Figures and Legends

Figure A.1.1: nano-Self peptides are designed based on the human CD47-SIRPα
interaction with additional cyclic variants not found in nature.
A Derived from CD47, the 8-amino acid nano-Self peptide region in CD47 (blue)
interacts with 3 (red) out of the 4 loops in SIRPα (grey) that make up the binding pocket
which amounts to roughly 40% of all contact residues between the two proteins. PDB:
2JJS
B The critical polar Thr residue in nS-wt (blue) is inserted into a hydrophobic core in the
SIRPα binding pocket (red). Mutating the polar Thr to a hydrophobic Phe, which can also
engage in π-stacking interactions with Phe74 away from the SIRPα binding pocket, may
potentially enhance binding efficiency of the peptide.
C The sequences of the linear nano-Self peptides (including the scrambled nS-X
sequence) are found in natural organisms whereas the cyclic variants are not.
D Chemical structure of the cyclic nano-Self peptide. Synthesis of the cyclic peptide was
characterized using MALDI-TOF mass spectrometry.
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Figure A.1.2 Phagocytosis of IgG-opsonized target B16F10 (WT and SIRPα KO)
cells when combined with linear and cyclic nS peptides.
ns-wt peptides have similar efficacy in driving phagocytosis of IgG-opsonized, CD47blocked target B16 cells, which is enhanced by the modified nS-F, F-Cyc, and Cyc
variants. Differences in phagocytosis of WT and SIRPα KO B16F10s supports the
presence contributions of trans and cis CD47-SIRPα interactions in inhibiting
phagocytosis.
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Figure A.1.3: Safety profile of linear nS-FF peptides in vivo.
Intravenous injections of nS-FF were done for four consecutive days (arrows) followed
by blood withdrawal 24 h after last injection. Blood parameters (i – hematocrit, ii
reticulocytes, iii – platelets) show that nS-FF at 1 mg/kg is safe, with no anemia or
weight loss (iv – normalized body weight).
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A.1.5 Appendix A.1 contributions
AbdelAziz R. Jalil conceived of, designed, and executed generation of the nS peptides
and experiments in Figure A.1.1 and Figure A.1.2.
Jason C. Andrechak supported the assays in Figure A.1.2 and designed and executed
the experiments in Figure A.1.3.
Jason C. Andrechak, Justine Y. Lee Brandon H. Hayes, and Jerome Irianto contributed
to the development of the SIRPα KO B16F10 line used in Figure A.1.2 as also discussed
in Appendix A.3.0.
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APPENDIX A.2: PRELIMINARY SAFETY DATA (SELECTED)

A.2.0 Contributions and copyright
This appendix supports work in Chapter 3.
All worked contained herein was conducted by Jason C Andrechak.

A.2.1 Abstract
Safety is a primary concern in the development of therapeutics and translation from
preclinical studies to clinical trials. Given the significant on-target, off-tumor blood cell
clearance inherent in anti-CD47 approaches1, it is critical to design therapies that restrict
targeting or clearance to tumors and preserve healthy cells. This appendix chapter
presents safety data in support of the work presented in this dissertation, including
representative mouse weight data over time and potential challenges raised by adoptive
marrow/macrophage transfers.

A.2.2 Safety data – combined tumor opsonization and CD47SIRPα ablation
A.2.2.1 Mouse weights in CD47 KO B16F10 tumor experiments
Mice were challenged with 2 x 10 5 CD47 KO B16F10 cells subcutaneously on day 0 and
treated per the standard regimen with TA99 intravenously. Opsonization has no
detrimental effect on mouse weights across tumor challenges (Figure A.2.1). Responding
mice often exhibit vitiligo, which could be an effect of TA99 alone 2 or a response to tumor
clearance3, but it does not appear to cause adverse clinical concerns.
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A.2.2.2 Mouse weights in WT B16F10 tumor experiments in combination with antiCD47
Anti-CD47 administered intravenously (~3 mg/kg) as in Figure 3.3C did cause clinical
safety concerns. Rapid tumor growth obfuscates weight loss, but some mice receiving
anti-CD47 lost weight (Figure A.2.2), became slow-moving and cold to the touch, and had
signs of anemia and thrombocytopenia during blood draws (lighter color blood, less
viscous, poor clotting). Two mice receiving anti-CD47 were found dead spontaneously on
day 24, which is not typically observed even in untreated mice that grow large tumors.
These results underscore the off-tumor blood cell clearance commonly seen in the antiCD47 clinical trials4.

A.2.2.3 Safety profile of SIRPα KO CIMs against WT B16F10 tumors
Male mice bearing WT B16F10 tumors treated with 4 x 10 7 SIRPα KO CIMs intravenously
did not exhibit clinical safety issues. Weight remained stable or increased over the course
of experiments (Figure A.2.3), and no apparent off-tumor cell clearance effects were
observed. In an exceptionally small number of cases, pilot experiments of mice treated
with 2 x 107 SIRPα KO CIMs did show mice that developed a white, solid, gritty-like mass
where the expected B16F10 tumor would be (Figure A.2.4). Given their immortalization
with estrogen-receptor, it is possible that SIRPα KOs localized efficiently to the tumor bed,
but then responded to endogenous estrogen and continued to divide. No such masses
were observed elsewhere at necropsy. We also observed an instance of a solid, white or
de-melanized DKO B16F10 tumor in untreated mice that did not receive any SIRPα KO
CIM treatment, so we cannot conclude positively the CIM identity of these masses
exhibited here. These masses were never observed in experiments where mice received
the lower SIRPα KO cell dose, which comprise the majority of CIM experiments thus far.
However, if the identity of these masses is related to CIMs, that is a factor that is intrinsic
to the ER-Hoxb8 model5,6 and could be engineered for safety in future design iterations.
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A.2.4 Main Figures and Legends
CD47 KO tumors (+ anti-Tyrp1)
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Figure A.2.1: Safety profile of anti-Tyrp1 combined with CD47 KO B16F10 tumors.
Left: Weights of mice challenged with 2 x 10 5 CD47 KO B16F10 cells and treated per
the standard TA99 dosing regimen. Weights shown on day 4 and day 11.
Right: Images showing mild vitiligo on responding mice.
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Figure A.2.2: Blood cell parameters of WT B16F10 (gCtrl) tumor-bearing mice
receiving anti-CD47 intravenously.
Left: Blood cell parameters of mice on the day their tumors measured >125 mm 2 when
measured every other day. Some blood cell loss is observed, especially in those mice
treated with anti-CD47 (MIAP301). Two mice receiving MIAP301/TA99 were found dead
spontaneously, where mice typically do not succumb spontaneously even with large
tumors in control conditions.
Middle: individual RBC counts for each mouse measured (re-plotted from left).
Right: Mouse weights on day 4 and 11 of control (no treatment) and MIAP301/TA99treated.
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Figure A.2.3: Sample images of white or de-melanized tumor masses in B16F10
experiments.

Mouse weights on day 4 and 11 of control (no treatment) and SKO CIM-treated.
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Figure A.2.4: De-melanized B16F10 tumors.
Left: Photograph of white tumor mass of mouse bearing a subcutaneous WT B16F10
treated with 2 x 107 SIRPα KO CIMs.
Right: Photograph of white tumor mass of untreated mouse bearing a subcutaneous
DKO B16F10 tumor.
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A.2.5 Appendix A.2 contributions
Jason C. Andrechak conceived of, designed, and executed the experiments in Appendix
A.2.
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APPENDIX A.3: SPECIFIC CONTRIBUTIONS BY WORK

Innovation in science and engineering relies wholly on team efforts. The author of this
dissertation greatly appreciates the important contributions of many others to the results
in this work. The specific parts of every Figure or Table contributed by the dissertation
author can be identified, but the following is a good-faith effort to document the specific
efforts of contributing authors.

A.3.0 Tools & resources
Jason C. Andrechak, Jerome Irianto, Justine Y. Lee, Hui Zhu, and Brandon H. Hayes
contributed to the development of the CRISPR-based tools used throughout this work (e.g.
CD47 KO, DKO, SIRPα, LMNA KO B16F10 lines, CIM KO lines, etc.). Jerome Irianto
established the KO pipeline for the Discher group, and each subsequently advanced
cloning tools and methods that enable the work. William Zhang supported this
development in CIM lines. These KO models underlie the data and conclusions throughout
the work.
Cory M. Alvey, Kyle R. Spinler, Xiaoling Jin, Brandon H. Hayes, and Manu Tewari
contributed to the development of A’PB and adoptive tumor transfer in A549 tumor models.
Xiaoling Jin and Anthony Secreto developed the implantable A549 liver metastatic model.
Jason C. Andrechak and Lawrence J. Dooling developed A’PB further in the syngeneic
B16F10 and other immunocompetent tumor models.
Jason C. Andrechak and Lawrence J. Dooling contributed to the establishment of the
B16F10 tumor model in C57 mice in the Discher group. Jason C. Andrechak developed
the lung metastasis model and methods for lung tumor burden quantification with the
support of Irena Ivanovska. Jason C. Andrechak established the YUMM2.1, TC-1, and
CT-2A subcutaneous tumor models in C57 mice in the Discher group. These tumor
models underlie the data and conclusions throughout the work.
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Jason C. Andrechak developed the CIM model and its application to in vitro and in vivo
experiments related to phagocytosis and solid tumors. William Zhang supported this
development. Sunny Shin conceived of the original idea to apply the CIM model in
therapeutic development.
Lawrence J. Dooling developed the 2D bone marrow-derived phagocytosis assays in the
Discher group, the 3D in vitro tumoroid model, and analyses for studying macrophagetumor interactions. Ruby Pan and Siddhant Kadu supported this development.
Manasvita Vashisth developed the computational pipeline to analyze TCGA data.
Chi Van Dang (Wistar Institute) supplied YUMM2.1 cells. Igor Brodsky (University of
Pennsylvania) supplied wild-type CIMs. Sunil Singhal (University of Pennsylvania)
supplied TC-1 cells. Leyuan Ma (Children’s Hospital of Philadelphia) supplied CT-2A cells.
Irfan Asangani (University of Pennsylvania) supplied B6.MYC-CaP cells.
The following core facilities supported the work: Stem Cell and Xenograft Core (University
of Pennsylvania), Flow Cytometry & Cell Sorting Facility (University of Pennsylvania),
Molecular Pathology & Imaging Core (University of Pennsylvania), Comparative
Pathology Core (University of Pennsylvania), Cell Center (University of Pennsylvania), the
Translational Research Core (Children’s Hospital of Philadelphia), Cell & Developmental
Biology Microscopy Core (University of Pennsylvania), and the Small Animal Imaging
Facility (University of Pennsylvania). The University Laboratory Animal Resources and the
Office of Animal Welfare supported the work (University of Pennsylvania).
Dennis E. Discher contributed significantly to scientific hypotheses, intellectual ideas,
funding acquisition, project administration, scientific discussion, analysis development and
implementation, and writing and revision of manuscripts. These intellectual contributions
underlie the data and conclusions throughout the work.

A.3.1 Chapter 1 contributions
The contents of this chapter appear in Philosophical Transactions of the Royal Society
B:
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Andrechak, J. C.*, Dooling, L. J.* & Discher, D. E. The macrophage checkpoint CD47 :
SIRPα for recognition of ‘self’ cells: from clinical trials of blocking antibodies to
mechanobiological fundamentals. Philos. Trans. R. Soc. B Biol. Sci. 374, 20180217
(2019).
Jason C. Andrechak is a co-equal author* and contributed significant ideas, writing, and
revision to this work, especially Sections 1.1-1.4.
Lawrence J. Dooling is a co-equal author* and contributed significant ideas, writing, and
revision to this work, especially Sections 1.5-1.8.
Dennis E. Discher contributed intellectually through ideas, writing/revision, scientific
discussion, and analysis.

A.3.2 Chapter 2 contributions
Jason C. Andrechak contributed significantly to development of ideas, execution of
experiments, data analyses, scientific discussion, and writing and revision of the
manuscript. Jason C. Andrechak developed the B16 lung metastatic tumor model for the
Discher group and executed all B16 intravenous injections and treatments. Jason C.
Andrechak conducted experiments for the following Figures and conducted analysis:
Figure 2.1A-B (design, execution, and analysis)
Figure 2.2A-B (design, execution, and analysis)
Figure 2.3A-B (design, execution, and analysis)
Figure 2.4A-D (design, execution, and analysis)
Figure 2.6A-B (design, execution, and analysis)
Figure 2.7 (with support from Dennis E. Discher)
Extended Data Figure 2.1A-B (design, execution, and analysis)

199

Extended Data Figure 2.2A-B (design, execution, and analysis), 2.2C (method
development and application), 2.2D (design, execution, and analysis)
Extended Data Figure 2.3 (design, execution, and analysis)
Extended Data Figure 2.4A (design, execution, and analysis), 2.3B (analysis)
Extended Data Figure 2.5 (design, execution, and analysis)
Extended Data Figure 2.6 (design, execution, and analysis) with analytical
support from Michael P. Tobin)
Extended Data Figure 2.7 (design, execution, and analysis)
Extended Data Figure 2.8 (design, execution, and analysis)
Extended Data Figure 2.9 (design, execution, and analysis, with phagocytosis
assay experimental support from William Zhang)
Xiaoling Jin and Anthony Secreto conducted experiments for Figure 2.5 (design,
execution, and analysis). Cory M. Alvey, Kyle R. Spinler, Xiaoling Jin, and Manu Tewari
contributed to the development of A’PB (e.g. in the form used in Figure 2.4A and Figure
2.5A-B and modified in Figure 2.6A). Brandon H. Hayes developed the CD47 KO and
LMNA KO B16F10 clones used with development support from Jason C. Andrechak,
Justine Y. Lee, and Jerome Irianto as noted in Appendix A.3.0.
Lawrence J. Dooling contributed to phagocytosis assay development (e.g. as shown in
Extended Data Figure 2.9) and significant ideas and discussion that underlie the work.
Dennis E. Discher contributed intellectually through significant ideas, writing/revision,
scientific discussion, and analysis that underlie the work.

A.3.3 Chapter 3 contributions
Jason C. Andrechak* and Lawrence J. Dooling* are co-equal(*) contributors to this work.
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Jason C. Andrechak contributed significantly to development of ideas, execution of
experiments, data analyses, scientific discussion, and writing and revision of the
manuscript. Jason C. Andrechak conducted experiments for the following Figures and
conducted analysis:
Figure 3.2B (design, execution, and analysis)
Figure 3.3A (tumor engraftment, measurement; all treatments), 3.3B (A’PB
development, marrow harvest and engineering; CIM development and
experiments), 3.3Ci (serum & related mouse studies with experimental support
from William Zhang), 3.3Cii (design, execution, and analysis), 3.3D (serum &
related mouse studies with experimental support from William Zhang), 3.3E
Figure 3.4A (tumor engraftment, measurement, all treatments), 3.4B, 3.4C, 3.4D,
3.4E (serum & related mouse studies)
Figure 3.5A, 3.5B, 3.5C, 3.5D
Extended Data Figure 3.5 (design, execution, and analysis)
Extended Data Figure 3.6B (supported tumor engraftment and measurement;
marrow harvest and engineering; all treatments), 3.6C
Extended Data Figure 3.7A, B, C (design, execution, and analysis)
Extended Data Figure 3.8A (serum & related mouse studies), 3.8B (serum &
related mouse studies, phagocytosis assay with experimental support from
William Zhang), 3.8C (binding, serum & related mouse studies), 3.8D serum &
related mouse studies, phagocytosis assay with experimental support from
William Zhang), 3.8E (serum & related mouse studies, marrow harvest and
engineering, tumor engraftment and measurement, all treatments)
Extended Data Figure 3.9A (serum & related mouse studies), 3.9B (serum &
related mouse studies), 3.9C (serum & related mouse studies), 3.9D (serum &
related mouse studies)

201

Lawrence J. Dooling contributed significantly to development of ideas, execution of
experiments, data analyses, scientific discussion, and writing and revision of the
manuscript. Lawrence J. Dooling conducted experiments for the following Figures and
conducted analysis:
Figure 3.1A-G (design, execution, and analysis; with experimental support from
Ruby Pan and Siddhant Kadu)
Figure 3.2A (design, execution, and analysis)
Figure 3.3A (supported tumor engraftment, measurement), 3.3B (A’PB
development, marrow harvest and engineering)
Figure 3.4A (supported tumor engraftment, measurement), 3.4Ci, 3.4E (western
experiment with experimental support from Ruby Pan)
Figure 3.5Ai, 3.5B (binding experiment), 3.5D (phagocytosis assay, imaging,
analysis)
Extended Data Figure 3.1A-F (design, execution, and analysis; with tumor model
development support from Jason C. Andrechak)
Extended Data Figure 3.2A-D, 3.2E-F (with experimental support from Ruby Pan
and Siddhant Kadu)
Extended Data Figure 3.3A-E, 3.3F (with experimental support from Siddhant
Kadu)
Extended Data Figure 3.4A-E (design, execution, and analysis)
Extended Data Figure 3.6A (tumoroid assay, imaging, analysis), 3.6B (supported
tumor engraftment, measurement; marrow harvest and engineering)
Extended Data Figure 3.8A (imaging and phagocytosis assay)
Extended Data Figure 3.9A (binding), 3.9B (binding), 3.9C (binding), 3.9D
(imaging and phagocytosis assay)
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Brandon H. Hayes developed the CD47 KO and Tyrp1 KO B16F10 clones used in the
above experiments, with development support of those KO lines from Jerome Irianto,
Justine Y. Lee, and Jason C. Andrechak as noted in Appendix A.3.0. Brandon H.
Hayes, William Zhang, Ruby Pan, Siddhant Kadu, and Justine Y. Lee contributed to
scientific discussion and development. Manasvita Vashisth contributed data and analysis
from TCGA for Extended Data Figure 3.10. Cory M. Alvey contributed to the
development of A’PB (including in the form shown in Figure 3.3) as noted in Appendix
A.3.0.
Dennis E. Discher contributed intellectually through significant ideas, writing/revision,
scientific discussion, and analysis that underlie the work.

A.3.4 Chapter 4 contributions
This chapter contains content and ideas published in Antibody Therapeutics, ACS Nano,
and ACS Bioconjugate Chemistry:
Jalil, A. R.*, Andrechak, J. C.* & Discher, D. E. Macrophage checkpoint blockade:
results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function.
Antib. Ther. 3, 80–94 (2020).
Jalil, A. R., Hayes, B. H., Andrechak, J. C. et al. Multivalent, Soluble Nano-Self Peptides
Increase Phagocytosis of Antibody-Opsonized Targets while Suppressing “ Self ”
Signaling. (2020). doi:10.1021/acsnano.0c05091
Jalil, A. R., Andrechak, J. C., Hayes, B. H., Chenoweth, D. M. & Discher, D. E. Human
CD47-Derived Cyclic Peptides Enhance Engulfment of mAb-Targeted Melanoma by
Primary Macrophages. Bioconjug. Chem. (2022). doi:10.1021/acs.bioconjchem.2c00020
AbdelAziz R. Jalil contributed significantly to this work through development of minimal
‘self' peptides and structure-function analyses. Jason C. Andrechak* and AbdelAziz R.
Jalil* contributed significantly to development of ideas, data analyses, scientific
discussion, and writing and revision of the manuscript.
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Dennis E. Discher contributed intellectually through significant ideas, writing/revision,
scientific discussion, and analysis that underlie the work.

A.3.5 Chapter 5 contributions
Jason C. Andrechak conceived and wrote Chapter 5 based on Chapters 1-4, scientific
discussions and the scientific literature, and underlying contributions from Discher group
members past, present, and future and the unnamed scientists that stood before us.
Dennis E. Discher contributed intellectually through ideas, writing/revision, scientific
discussion, and analysis resulting from Chapters 1-4 that underlie the work.
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